<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN"
        "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
    <meta charset="utf-8"/>
    <meta name="viewport" content="width=device-width, initial-scale=1"/>

    <link rel="stylesheet" href="http://code.jquery.com/mobile/1.3.0/jquery.mobile-1.3.0.min.css"/>
    <script src="http://code.jquery.com/jquery-1.9.1.min.js"></script>
    <script src="http://code.jquery.com/mobile/1.3.0/jquery.mobile-1.3.0.min.js"></script>

    <link rel="stylesheet" type="text/css" href="../nav.css"/>
    <title>E</title>
</head>

<body>
<div data-role="page" data-back-btn-text="Prev">
    <div data-role="header" data-theme="b" data-id="siteo" data-position="fixed">
        <h1>Site Optimizer - Study More</h1>

        <a href="../s/s.html" data-icon="gear" class="ui-btn-right">Options</a>

        <div data-role="navbar" data-iconpos="top">
            <ul>
                <li><a href="../a/a.html" data-icon="delete">Reflow Table</a></li>
                <li><a href="../b/b.html" data-icon="check">Toggle Table</a></li>
                <li><a href="../c/c.html" id="table" data-icon="custom">Study List Reflow</a></li>
                <li><a href="../d/d.html" id="delta" data-icon="custom">Study List Toggle</a></li>
                <li><a href="../e/e.html" id="star" data-icon="custom" class="ui-btn-active ui-state-persist">Misc.</a></li>
            </ul>
        </div>
    </div>
    <!-- /header -->

    <div data-role="content">
        <p>Study List Toggle</p>

        <table data-role="table" id="myToggle2" data-mode="columntoggle" class="my-custom-class table-stroke">
            <thead>
    <tr>
        <th data-priority="6">Key</th>
        <th>Study ID</th>
        <th data-priority="3">Name</th>
        <th data-priority="1">Thearpeutic Area</th>
        <th data-priority="2">CRO Sponsor</th>
        <th data-priority="2">Project</th>
        <th data-priority="6">Managers</th>
        <th data-priority="1">Status</th>
        <th data-priority="2">Phase</th>
        <th data-priority="2">Plan State</th>
        <th data-priority="2">Priority</th>
        <th data-priority="4">A. Plan</th>
        <th data-priority="4">A. Scenario</th>
        <th data-priority="5">T. Screened</th>
        <th data-priority="4">A. Screened</th>
        <th data-priority="5">T. Enrollment</th>
        <th data-priority="4">A. Enrollment</th>
        <th data-priority="3">AFSFV</th>
        <th data-priority="6">Centers</th>
        <th data-priority="6">PreScreen</th>
        <th data-priority="3">TLSFV</th>
    </tr>
</thead>

<tbody>
    <tr>
        <td>29</td>
        <td>480848/033</td>
        <td>ACS secondary prevention outcome study</td>
        <td>Cardiovascular</td>
        <td>abc</td>
        <td>Source Unavailable</td>
        <td>Elizabeth Lavender,Marie Jarosz,Rachel
            Russell,Terese Womer</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>11500</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
        <td>true</td>
        <td>2011-11-25</td>
    </tr>
    <tr>
        <td>30</td>
        <td>49653/461</td>
        <td>PET AVANDIA IN AD</td>
        <td>Neurology</td>
        <td>efg</td>
        <td>Source Unavailable</td>
        <td>Jeffery Ellis,Ruby Birk,Ruby
            Salazar-Ocampo</td>
        <td>Recruitment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>135</td>
        <td>80</td>
        <td>80</td>
        <td>291.4</td>
        <td>2004-05-18</td>
        <td>2009-11-25</td>
        <td>15</td>
        <td>true</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>31</td>
        <td>497115/003</td>
        <td>PHASE IIA CANCER PTS</td>
        <td>Oncology - PD</td>
        <td>efg</td>
        <td>Source Unavailable</td>
        <td>Jhangir Irani,Sean Keegan,Souria Hasan</td>
        <td>Recruitment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>218</td>
        <td>164</td>
        <td>183</td>
        <td>262.2</td>
        <td>2005-02-07</td>
        <td>2009-11-25</td>
        <td>126</td>
        <td>true</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>32</td>
        <td>683699/003</td>
        <td>MS POC/Dose Ranging Study</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Carla Ball,Narinder Lotay,Ruby
            Salazar-Ocampo</td>
        <td>Recruitment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>304</td>
        <td>260</td>
        <td>261</td>
        <td>275.8</td>
        <td>2004-01-25</td>
        <td>2009-11-25</td>
        <td>57</td>
        <td>true</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>33</td>
        <td>683699/004</td>
        <td>CROHNS POC</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Belinda Hereghty,Darlene Steele-Norwood</td>
        <td>Recruitment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>49</td>
        <td>49</td>
        <td>17</td>
        <td>270.7</td>
        <td>2004-10-12</td>
        <td>2009-11-25</td>
        <td>43</td>
        <td>true</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>34</td>
        <td>714703/005</td>
        <td>Coartem comparator study</td>
        <td>Anti Infectives</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Ammar Qureshi</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>1395</td>
        <td>1334</td>
        <td>183.1</td>
        <td>2004-04-30</td>
        <td>2009-11-25</td>
        <td>12</td>
        <td>true</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>35</td>
        <td>714703/006</td>
        <td>CDA comparator study</td>
        <td>Anti Infectives</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Phyllis Guta</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>900</td>
        <td>902</td>
        <td>199.2</td>
        <td>2006-04-25</td>
        <td>2009-11-25</td>
        <td>8</td>
        <td>true</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>36</td>
        <td>767905/008</td>
        <td>767905 in OBD cancer population</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>John Norris,Wendy Hamon</td>
        <td>Recruitment</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>397</td>
        <td>224</td>
        <td>238</td>
        <td>327.4</td>
        <td>2003-10-08</td>
        <td>2009-11-25</td>
        <td>200</td>
        <td>true</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>37</td>
        <td>767905/011</td>
        <td>OBD DR NONCA PAIN</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Cindy Handelsman,Donna Goldstein,Michael
            Setterfield</td>
        <td>Recruitment</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1107</td>
        <td>625</td>
        <td>540</td>
        <td>335.8</td>
        <td>2003-01-09</td>
        <td>2009-11-25</td>
        <td>155</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>38</td>
        <td>767905/012</td>
        <td>OBD EFFICACY NONCANC</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Lori Hall</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1164</td>
        <td>480</td>
        <td>523</td>
        <td>222.9</td>
        <td>2005-01-12</td>
        <td>2009-11-25</td>
        <td>219</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>39</td>
        <td>767905/013</td>
        <td>OBD EFFICACY NONCANC</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Lori Hall</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1158</td>
        <td>480</td>
        <td>488</td>
        <td>222.9</td>
        <td>2005-08-29</td>
        <td>2009-11-25</td>
        <td>216</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>40</td>
        <td>767905/014</td>
        <td>OBD LTS NONCA</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Lori Hall</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>934</td>
        <td>750</td>
        <td>809</td>
        <td>226.1</td>
        <td>2005-01-05</td>
        <td>2009-11-25</td>
        <td>364</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>41</td>
        <td>767905/015</td>
        <td>Phase 3 Efficacy Study, Alvimopan 0.5mg BID,
            NonCA</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Amy Lee,Cindy Handelsman,Katharine Edmunds,Lori
            Hall,Naomi Briggs</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>1200</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
        <td>2011-11-25</td>
    </tr>
    <tr>
        <td>42</td>
        <td>A4I104392</td>
        <td>Safety &amp; Efficacy SB-683699 in Crohn's
            Disease</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>330</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
        <td>2011-11-25</td>
    </tr>
    <tr>
        <td>43</td>
        <td>A4I104534</td>
        <td>SB-683699 in Ulcerative Colitis Patients</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>350</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
        <td>2011-11-25</td>
    </tr>
    <tr>
        <td>44</td>
        <td>A4M105038</td>
        <td>Relapsing MS Efficacy and safety in SB683699</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Alexia Tolis,Anne Moorat,Claire Wardell,Troy
            Longley,Vimal Thohan</td>
        <td>Recruitment</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>452</td>
        <td>350</td>
        <td>310</td>
        <td>154.4</td>
        <td>2006-12-21</td>
        <td>2009-11-25</td>
        <td>92</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>45</td>
        <td>A4M108119</td>
        <td>CSF Study in relapsing forms of MS with
            SB-683699</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Anne Moorat,Kimberly Sue-Ling,Vibeke Aagaard,Vimal
            Thohan</td>
        <td>Recruitment</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>62</td>
        <td>45</td>
        <td>47</td>
        <td>131.2</td>
        <td>2007-07-18</td>
        <td>2009-11-25</td>
        <td>10</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>46</td>
        <td>ABC107442</td>
        <td>Retrospective PGx study for ABC HSR</td>
        <td>HIV</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Annie Cameron,Steve Chriscoe</td>
        <td>Recruitment</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>223</td>
        <td>80</td>
        <td>213</td>
        <td>172.9</td>
        <td>2006-08-14</td>
        <td>2009-11-25</td>
        <td>70</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>47</td>
        <td>ABD102965</td>
        <td>Dose-Ranging PII: Alvimopan cOBD Cancer Pain
            PhII</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Recruitment</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>37</td>
        <td>280</td>
        <td>21</td>
        <td>192.1</td>
        <td>2006-04-19</td>
        <td>2009-11-25</td>
        <td>83</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>49</td>
        <td>ABD104876</td>
        <td>The Pilot burden of illness study for OBD</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>15</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
        <td>2011-11-25</td>
    </tr>
    <tr>
        <td>50</td>
        <td>ABD106239</td>
        <td>BOI Study (Alvimopan)</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Katharine Edmunds,Margaret Byrne</td>
        <td>Recruitment</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>577</td>
        <td>500</td>
        <td>506</td>
        <td>174.1</td>
        <td>2006-08-23</td>
        <td>2009-11-25</td>
        <td>80</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>51</td>
        <td>ABD106919</td>
        <td>The US Observational study of laxatives in
            patient</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Allison Northcutt,Amy Lee,Jamie Palmer</td>
        <td>Recruitment</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>161</td>
        <td>500</td>
        <td>145</td>
        <td>174.8</td>
        <td>2006-08-07</td>
        <td>2009-11-25</td>
        <td>59</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>53</td>
        <td>ABD107881</td>
        <td>Alvimopan Pharmacodynamic Study</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>74</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
        <td>2011-11-25</td>
    </tr>
    <tr>
        <td>54</td>
        <td>ABD109307</td>
        <td>ABD109307</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>Source Unavailable</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>0</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>55</td>
        <td>ABD109965</td>
        <td>Alvimopan OBD Efficacy and Safety Study</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>1460</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>56</td>
        <td>ABD110657</td>
        <td>Phase 3 Post-Treatment Safety Surveillance Study</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Lori Hall</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>1876</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>57</td>
        <td>AC2105854</td>
        <td>LAMA AC2 IIB study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Christine Barrett,Michelle Verhaeghe</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>600</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>58</td>
        <td>AC2106956</td>
        <td>GSK233705 / GR33343 enabling study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Marie Duggan</td>
        <td>Recruitment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>69</td>
        <td>45</td>
        <td>47</td>
        <td>162.2</td>
        <td>2006-10-26</td>
        <td>2009-11-25</td>
        <td>11</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>59</td>
        <td>AC2110664</td>
        <td>LAMA AC2 IIB once daily study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Aruna Sharma,Candice Blackley,Carol
            Bridges,Christine Barrett,Kathy Russell,Lida Dambrosi,Robin
            Morris</td>
        <td>Recruitment</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>952</td>
        <td>600</td>
        <td>581</td>
        <td>81.1</td>
        <td>2008-05-16</td>
        <td>2009-11-25</td>
        <td>95</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>60</td>
        <td>AC2111509</td>
        <td>GSK233705/GW642444 combo SD in Healthy Subject</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Andrew Preece</td>
        <td>Planned</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>16</td>
        <td>0</td>
        <td>80.8</td>
        <td>2009-11-25</td>
        <td>1</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>61</td>
        <td>ADA103575</td>
        <td>Allergic Asthma Study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Brian Marks,Cesar Cisneros</td>
        <td>Recruitment</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1388</td>
        <td>725</td>
        <td>727</td>
        <td>226.9</td>
        <td>2004-04-03</td>
        <td>2009-11-25</td>
        <td>127</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>62</td>
        <td>ADA103578</td>
        <td>Allergic Asthma Study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Brian Marks,Cesar Cisneros,Sheri
            Seiferheld</td>
        <td>Recruitment</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1181</td>
        <td>650</td>
        <td>665</td>
        <td>226.9</td>
        <td>2005-09-07</td>
        <td>2009-11-25</td>
        <td>84</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>63</td>
        <td>ADA105920</td>
        <td>Advair Asthma Pediatric Exacerbation Study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Jill Wolford,Karen Singletary</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>268</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>64</td>
        <td>ADA105922</td>
        <td>Advair Asthma Pediatric Exacerbation Study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Jill Wolford</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>268</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>65</td>
        <td>ADA111118</td>
        <td>The Adult Asthma Control Test</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>DeAnne Hart</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>3000</td>
        <td>0</td>
        <td>99.2</td>
        <td>2009-11-25</td>
        <td>35</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>66</td>
        <td>ADA111119</td>
        <td>The Peds Asthma Control Test</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>DeAnne Hart</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>3000</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>29</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>67</td>
        <td>ADC105931</td>
        <td>Advair COPD Anti-Inflammatory Effects</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Bettie Thomas,Robert Bartle,Todd
            Hankinson</td>
        <td>Recruitment</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>29</td>
        <td>200</td>
        <td>14</td>
        <td>158.8</td>
        <td>2006-12-15</td>
        <td>2009-11-25</td>
        <td>12</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>68</td>
        <td>ADC109043</td>
        <td>COPD Airway Limitation Study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Eric Lamb</td>
        <td>Recruitment</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>63</td>
        <td>1200</td>
        <td>1274</td>
        <td>139.1</td>
        <td>2007-04-05</td>
        <td>2009-11-25</td>
        <td>51</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>69</td>
        <td>ADC111114</td>
        <td>Advair 250/50 + Tiotropium for COPD [Study 1 of
            2</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Cesar Cisneros</td>
        <td>Recruitment</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>3</td>
        <td>350</td>
        <td>0</td>
        <td>53.2</td>
        <td>2008-12-01</td>
        <td>2009-11-25</td>
        <td>48</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>70</td>
        <td>ADC111115</td>
        <td>Advair 250/50 + Tiotropium for COPD (Study 2 of
            2</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Cesar Cisneros</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>350</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>71</td>
        <td>ADC111117</td>
        <td>Advair HFA COPD Study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Debbie Dukeman</td>
        <td>Recruitment</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>364</td>
        <td>250</td>
        <td>247</td>
        <td>87.9</td>
        <td>2008-03-31</td>
        <td>2009-11-25</td>
        <td>17</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>72</td>
        <td>ADC111891</td>
        <td>Myth of Mild COPD</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Cesar Cisneros</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>1000</td>
        <td>0</td>
        <td>53.2</td>
        <td>2009-11-25</td>
        <td>78</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>73</td>
        <td>ADF105220</td>
        <td>Hepsere Mono Phase III Japan</td>
        <td>Infectious Disease- Anti Viral</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>170</td>
        <td>100</td>
        <td>106</td>
        <td>202.2</td>
        <td>2006-01-12</td>
        <td>2009-11-25</td>
        <td>43</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>74</td>
        <td>ADG103440</td>
        <td>24 Week Study of GW677954 in Dyslipidaemia</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Clara Marr,Jamil Habib,Stephen Coates</td>
        <td>Recruitment</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1220</td>
        <td>290</td>
        <td>275</td>
        <td>208.9</td>
        <td>2005-12-05</td>
        <td>2009-11-25</td>
        <td>56</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>76</td>
        <td>ADG20001</td>
        <td>12 week PoC study</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Martyn Palmer</td>
        <td>Recruitment</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1473</td>
        <td>448</td>
        <td>353</td>
        <td>219.1</td>
        <td>2005-09-23</td>
        <td>2009-11-25</td>
        <td>150</td>
        <td>2011-11-25</td>
        <td>2011-12-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>77</td>
        <td>AK1102364</td>
        <td>Wellbutrin SR Long term study</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Taro Kunitomi</td>
        <td>Recruitment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>267</td>
        <td>250</td>
        <td>234</td>
        <td>261.2</td>
        <td>2004-11-16</td>
        <td>2009-11-25</td>
        <td>44</td>
    </tr>
    <tr>
        <td>78</td>
        <td>AK1102365</td>
        <td>Wellbutrin SR Differenciation study</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Akihiro Fujiwara,Taro Kunitomi</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>418</td>
        <td>300</td>
        <td>323</td>
        <td>209.9</td>
        <td>2006-03-03</td>
        <td>2009-11-25</td>
        <td>76</td>
    </tr>
    <tr>
        <td>79</td>
        <td>AK1102367</td>
        <td>Wellbutrin SR Trazodone study</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>405</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>80</td>
        <td>AK1102369</td>
        <td>Wellbutrin SR Elderly study</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Taro Kunitomi</td>
        <td>Recruitment</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>35</td>
        <td>30</td>
        <td>33</td>
        <td>185.1</td>
        <td>2006-05-18</td>
        <td>2009-11-25</td>
        <td>15</td>
    </tr>
    <tr>
        <td>82</td>
        <td>AMB107816</td>
        <td>Japan Phase II/III study of Ambrisentan</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Akira Wakamatsu,Ryutaro Shimamura,Takayuki
            Iwase</td>
        <td>Recruitment</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>31</td>
        <td>25</td>
        <td>25</td>
        <td>121.8</td>
        <td>2007-08-22</td>
        <td>2009-11-25</td>
        <td>31</td>
    </tr>
    <tr>
        <td>83</td>
        <td>AMB107818</td>
        <td>Japan Ambrisentan Extension study</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Akira Wakamatsu,Ryutaro Shimamura,Takayuki
            Iwase</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>25</td>
        <td>19</td>
        <td>93.1</td>
        <td>2008-02-29</td>
        <td>2009-11-25</td>
        <td>24</td>
    </tr>
    <tr>
        <td>84</td>
        <td>AMB110094</td>
        <td>Ambrisentan post-marketing surveillance program</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Sarah Kensit</td>
        <td>Recruitment</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>15</td>
        <td>800</td>
        <td>33</td>
        <td>74.9</td>
        <td>2008-06-26</td>
        <td>2009-11-25</td>
        <td>45</td>
    </tr>
    <tr>
        <td>85</td>
        <td>AMB111593</td>
        <td>Effect of ambrisentan on testicular function</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>30</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>86</td>
        <td>APV10017</td>
        <td>Hepatic Impairment Study</td>
        <td>HIV</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Martin Curtis,Ruth Braganza,Tamika
            Kelley</td>
        <td>Recruitment</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>93</td>
        <td>60</td>
        <td>53</td>
        <td>266.2</td>
        <td>2004-11-02</td>
        <td>2009-11-25</td>
        <td>25</td>
    </tr>
    <tr>
        <td>87</td>
        <td>APV102002</td>
        <td>908/RTV with other PI for multi PI-experienced
            sub</td>
        <td>Infectious Disease- Anti Viral</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Ross Harding,Ruth Braganza</td>
        <td>Recruitment</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>155</td>
        <td>150</td>
        <td>76</td>
        <td>254.8</td>
        <td>2005-01-25</td>
        <td>2009-11-25</td>
        <td>52</td>
    </tr>
    <tr>
        <td>88</td>
        <td>APV109141</td>
        <td>QD vs BID FPV/r in naives</td>
        <td>HIV</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Ana Martin,Bridin McCaughey,Karen
            Parry-Billings,Peter Tabona,Reine Le-Gall</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>224</td>
        <td>200</td>
        <td>212</td>
        <td>141.2</td>
        <td>2007-03-22</td>
        <td>2009-11-25</td>
        <td>90</td>
    </tr>
    <tr>
        <td>89</td>
        <td>AR1108888</td>
        <td>Safety of UFH for PCI in FX-treated ACS patients</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>2000</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>109</td>
    </tr>
    <tr>
        <td>90</td>
        <td>AR3106116</td>
        <td>Japan Arixtra Abdominal surgety</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Naoko Seki,Takayuki Kawashima</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>133</td>
        <td>120</td>
        <td>127</td>
        <td>188.1</td>
        <td>2006-05-22</td>
        <td>2009-11-25</td>
        <td>22</td>
    </tr>
    <tr>
        <td>91</td>
        <td>AR3106206</td>
        <td>Japan Arixtra PE Treatment</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Hiroshi Tsujimoto,Mika Nariyama,Mio
            Takada,Ryuichiro Okuda</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>43</td>
        <td>40</td>
        <td>41</td>
        <td>127.9</td>
        <td>2007-07-18</td>
        <td>2009-11-25</td>
        <td>32</td>
    </tr>
    <tr>
        <td>92</td>
        <td>AR3106333</td>
        <td>Japan Arixtra THR</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Hiroshi Tsujimoto</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>121</td>
        <td>100</td>
        <td>115</td>
        <td>200.4</td>
        <td>2006-01-30</td>
        <td>2009-11-25</td>
        <td>9</td>
    </tr>
    <tr>
        <td>93</td>
        <td>AR3106335</td>
        <td>Japan Arixtra HF</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>57</td>
        <td>50</td>
        <td>48</td>
        <td>200.2</td>
        <td>2006-02-16</td>
        <td>2009-11-25</td>
        <td>10</td>
    </tr>
    <tr>
        <td>94</td>
        <td>AR3110505</td>
        <td>Japan Arixtra VTE prevention CHF patients</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>500</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>95</td>
        <td>AR3110507</td>
        <td>VTE prevention in ischemic stroke patients</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>130</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>96</td>
        <td>AR3110509</td>
        <td>Japan Arixtra VTE prevention high risk patients</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>60</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>97</td>
        <td>AR3111436</td>
        <td>Japan Arixtra DVT treatment</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Hiroshi Tsujimoto,Mio Takada,Ryuichiro
            Okuda</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>15</td>
        <td>40</td>
        <td>15</td>
        <td>79.4</td>
        <td>2008-06-12</td>
        <td>2009-11-25</td>
        <td>27</td>
    </tr>
    <tr>
        <td>98</td>
        <td>ARI103094</td>
        <td>Two Year Observational Follow-Up Study for
            4-year</td>
        <td>Urogenital</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>2700</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>100</td>
        <td>ARI108888</td>
        <td>ARI108888</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>Source Unavailable</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>0</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>101</td>
        <td>ARI109924</td>
        <td>ARTs</td>
        <td>Urogenital</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Martyn Gilson</td>
        <td>Recruitment</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>350</td>
        <td>276</td>
        <td>296</td>
        <td>110.4</td>
        <td>2006-06-12</td>
        <td>2009-11-25</td>
        <td>81</td>
    </tr>
    <tr>
        <td>102</td>
        <td>ARI40005</td>
        <td>Long term combination with 745 &amp; tamsulosin</td>
        <td>Urogenital</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Cuancha Serrant,Lorraine Martin,Michele
            Gascoigne</td>
        <td>Recruitment</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>14</td>
        <td>4553</td>
        <td>4929</td>
        <td>317.2</td>
        <td>2003-12-22</td>
        <td>2009-11-25</td>
        <td>539</td>
    </tr>
    <tr>
        <td>103</td>
        <td>ARI40006</td>
        <td>A Randomized, Double-blind, Placebo-Controlled,
            Pa</td>
        <td>Urogenital</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Christy Winnell,Denise Fontanilla,Donna
            Goldstein,Karen Anderson,Tammy Butkiewicus</td>
        <td>Recruitment</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>12452</td>
        <td>8000</td>
        <td>8484</td>
        <td>363.2</td>
        <td>2001-11-08</td>
        <td>2009-11-25</td>
        <td>1011</td>
    </tr>
    <tr>
        <td>104</td>
        <td>ART108053</td>
        <td>ARIXTRA vs Placebo in lower limb SVT</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Alice Trelfa,Dave Manning,Else Laursen,Emmanuel
            Neveux,Georgina Spence,Ildiko Kovacs,Isabelle
            Richard-Lordereau,Janet Ball,Karen Lewis,Katie Warren,Patrick
            Mismetti,Pedro Allende Echevarrieta,Rebecca Fitch,Sarah
            Kensit,Vincent Bost</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>2572</td>
        <td>2500</td>
        <td>2393</td>
        <td>144.1</td>
        <td>2004-04-17</td>
        <td>2009-11-25</td>
        <td>276</td>
    </tr>
    <tr>
        <td>105</td>
        <td>AVA102670</td>
        <td>AD Adjunct therapy</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Allison Jack,Amy Lee,Beverly Allen,Carol
            Bridges,Catherine Jones,Christopher Perkins,Claire
            Alderton,Conn Harrington,Daria Dejewska,Fernando de
            Oliveira,Hazel Gorham,Jason Russell,Jennifer Bruce,Joy
            Lewis,Kate Poole,Kerrick Wilson,Kimberly Martin,Lisa
            Hornick,Maria Benetazzo,Maria Kandilogiannaki,Marvin
            Weekes,Mary Castiglia,Michael Irizarry,Michael
            McLaughlin,Monica Gangal,Nikki Lim,Paula Costa,Rahul
            Bhatnagar,Ruth Friedhoff,Sangeeta Sawhney,Tarnjit
            Dehal,Theresa Haughey,Zaza Ebert</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1897</td>
        <td>1450</td>
        <td>1485</td>
        <td>177.9</td>
        <td>2006-07-12</td>
        <td>2009-11-25</td>
        <td>208</td>
    </tr>
    <tr>
        <td>106</td>
        <td>AVA102672</td>
        <td>Adjunct therapy</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Alessandra Giberti,Amy Lee,Anita Treohan,Atsuko
            Shinohara,Beverly Allen,Carol Bridges,Christopher
            Perkins,Claire Alderton,Daria Dejewska,Delphine
            Lepailleur-Enouf,Fernando de Oliveira,Janet Ball,Jennifer
            Bruce,Joy Lewis,Kate Poole,Kenichiro Hiura,Kimberly
            Martin,Lisa Hornick,Maria Benetazzo,Maria
            Kandilogiannaki,Marina Zvartau-Hind,Marvin Weekes,Mary
            Castiglia,Masahiro Shimizu,Megan Vaughan,Michael
            Irizarry,Michael McLaughlin,Monica Gangal,Monika
            Mogilnicka,Narinder Lotay,nathalie Loret,Nikki Lim,Patti
            Owen,Paula Costa,Petra Heine,Rahul Bhatnagar,Sangeeta
            Sawhney,Steve Mangum,Tarnjit Dehal,Theresa Haughey,Zaza
            Ebert</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1901</td>
        <td>1400</td>
        <td>1497</td>
        <td>177.9</td>
        <td>2006-07-13</td>
        <td>2009-11-25</td>
        <td>285</td>
    </tr>
    <tr>
        <td>107</td>
        <td>AVA102675</td>
        <td>AD OL Extension to AVA102670</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Amy Lee,Barbara Jeter,Beverly Allen,Carol
            Bridges,Catherine Jones,Claire Alderton,Conn
            Harrington,Curtis Owens,Guenter Woelfl,Jennifer Bruce,John
            Perryman,Kimberly Martin,Maria Benetazzo,Marvin Weekes,Mary
            Castiglia,Michael Irizarry,Michael McLaughlin,Monica
            Gangal,Narinder Lotay,Paula Costa,Rahul Bhatnagar,Tammy
            Kitaoka,Tarnjit Dehal</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1301</td>
        <td>1800</td>
        <td>1228</td>
        <td>121.2</td>
        <td>2007-07-02</td>
        <td>2009-11-25</td>
        <td>320</td>
    </tr>
    <tr>
        <td>108</td>
        <td>AVA102677</td>
        <td>AD OL Extension to AVA105640</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Anna Rhesa Kallam,Barbara Jeter,Beverly Allen,Carol
            Bridges,Catherine Jones,Claire Alderton,Conn
            Harrington,Connie Randolph,Curtis Owens,Jackie
            Gilbert,Jennifer Bruce,Jennifer Simmons,John
            Perryman,Kimberly Martin,Mary Castiglia,Michael
            Irizarry,Michael McLaughlin,Narinder Lotay,Sagar Patel,Troy
            Longley</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>337</td>
        <td>383</td>
        <td>335</td>
        <td>113.4</td>
        <td>2007-10-01</td>
        <td>2009-11-25</td>
        <td>103</td>
    </tr>
    <tr>
        <td>109</td>
        <td>AVA104617</td>
        <td>PET 49653/461 Extension study</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Curtis Owens,Hazel Gorham,Jeffery Ellis,Lewis
            Millen,Narinder Lotay,Ruby Birk,Ruby Salazar-Ocampo,Tarnjit
            Dehal</td>
        <td>Recruitment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>10</td>
        <td>40</td>
        <td>33</td>
        <td>181.2</td>
        <td>2006-06-20</td>
        <td>2009-11-25</td>
        <td>13</td>
    </tr>
    <tr>
        <td>110</td>
        <td>AVA105640</td>
        <td>AD Monotherapy Active/Placebo Control</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Anna Rhesa Kallam,Barbara Jeter,Beverly Allen,Carol
            Bridges,Catherine Jones,Christopher Perkins,Claire
            Alderton,Conn Harrington,Daria Dejewska,Fernando de
            Oliveira,Hannah Chen,Hazel Gorham,Jackie Gilbert,Janet
            Ball,Jennifer Bruce,Joy Lewis,Kate Poole,Kimberly Martin,Lisa
            Hornick,Mark Rechkemmer,Marvin Weekes,Mary Castiglia,Mary
            Melton,Michael Irizarry,Michael McLaughlin,Nikki Lim,Rahul
            Bhatnagar,Rebecca Fitch,Sagar Patel,Sangeeta Sawhney,Troy
            Longley</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>848</td>
        <td>566</td>
        <td>581</td>
        <td>148.1</td>
        <td>2007-02-13</td>
        <td>2009-11-25</td>
        <td>153</td>
    </tr>
    <tr>
        <td>111</td>
        <td>AVD100521</td>
        <td>Rosiglitazone in patients requiring PCI</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Karita Saarinen</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1150</td>
        <td>672</td>
        <td>676</td>
        <td>255.2</td>
        <td>2004-08-30</td>
        <td>2009-11-25</td>
        <td>170</td>
    </tr>
    <tr>
        <td>112</td>
        <td>AVD104742</td>
        <td>Japan Monotherapy vs Actos</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Daisaku Iwata,Shigeru Yagi</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>458</td>
        <td>350</td>
        <td>372</td>
        <td>205.4</td>
        <td>2005-12-16</td>
        <td>2009-11-25</td>
        <td>46</td>
    </tr>
    <tr>
        <td>113</td>
        <td>AVD105248</td>
        <td>Japan SU-combo vs Placebo</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Shigeru Yagi</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>172</td>
        <td>140</td>
        <td>151</td>
        <td>187.9</td>
        <td>2006-04-24</td>
        <td>2009-11-25</td>
        <td>22</td>
    </tr>
    <tr>
        <td>114</td>
        <td>AVD111179</td>
        <td>52 WK, AVANDIA vs METFORMIN, MoA Study</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Mariana Di Laudo,Rachel James,Robyn
            Widenmaier,Rosemary Fowler,Shanti Melendez</td>
        <td>Recruitment</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>284</td>
        <td>226</td>
        <td>151</td>
        <td>85.1</td>
        <td>2008-04-22</td>
        <td>2009-11-25</td>
        <td>130</td>
    </tr>
    <tr>
        <td>115</td>
        <td>AVD111960</td>
        <td>AVANDIA CV Outomes Study</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Rachel Kozak</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>15560</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>116</td>
        <td>AVL107959</td>
        <td>AVL vs AVA + PBO</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>272</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>117</td>
        <td>AVM107963</td>
        <td>AVM XR vs MET IR BD</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>462</td>
        <td>0</td>
        <td>22.6</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>118</td>
        <td>AVM107965</td>
        <td>AVM vs AVA+PBO</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>272</td>
        <td>0</td>
        <td>39.9</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>119</td>
        <td>AVM110309</td>
        <td>Japanese Phase III of Avandamet</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>300</td>
        <td>0</td>
        <td>43.6</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>120</td>
        <td>AVM110735</td>
        <td>Japan Phase III study of Avandamet XR</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>300</td>
        <td>0</td>
        <td>28.3</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>121</td>
        <td>AVN108292</td>
        <td>FREEDOM 2- REDEEM</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Start-Up</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>180</td>
        <td>0</td>
        <td>19.4</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>122</td>
        <td>AVO105948</td>
        <td>Avodart - Watchful Waiting</td>
        <td>Urogenital</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>John Norris</td>
        <td>Treatment</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>405</td>
        <td>300</td>
        <td>303</td>
        <td>37.1</td>
        <td>35.3</td>
        <td>2006-07-18</td>
        <td>2007-03-06</td>
        <td>2009-11-25</td>
        <td>84</td>
    </tr>
    <tr>
        <td>123</td>
        <td>AVO108943</td>
        <td>A Phase IV study of dutasteride in prostate
            cancer</td>
        <td>Urogenital</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Mariella Bustamante</td>
        <td>Recruitment</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>120</td>
        <td>150</td>
        <td>85</td>
        <td>106.0</td>
        <td>135.2</td>
        <td>2007-05-15</td>
        <td>2009-11-25</td>
        <td>125</td>
    </tr>
    <tr>
        <td>124</td>
        <td>AVO110146</td>
        <td>D-IMPACT</td>
        <td>Urogenital</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Recruitment</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>756</td>
        <td>307</td>
        <td>72.7</td>
        <td>104.4</td>
        <td>2007-12-03</td>
        <td>2009-11-25</td>
        <td>29</td>
    </tr>
    <tr>
        <td>125</td>
        <td>AVR110075</td>
        <td>Japanese Phase III of Avandaryl</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>280</td>
        <td>0</td>
        <td>28.3</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>126</td>
        <td>AVR110134</td>
        <td>Japanese Phase III long term of Avandaryl</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Hiroyuki Hosokawa,Inaha Okuda,Ryutaro
            Ishii</td>
        <td>Start-Up</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>120</td>
        <td>0</td>
        <td>26.6</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>127</td>
        <td>AVS101946</td>
        <td>Avandastat 16 wk lipid lowering study</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Completed</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1602</td>
        <td>360</td>
        <td>372</td>
        <td>49.7</td>
        <td>49.7</td>
        <td>2003-03-10</td>
        <td>2006-07-10</td>
        <td>2009-11-25</td>
        <td>87</td>
    </tr>
    <tr>
        <td>128</td>
        <td>AVT103585</td>
        <td>(AVM XR) in ethnic Minorities</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Martyn Palmer</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>392</td>
        <td>0</td>
        <td>66.3</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>129</td>
        <td>AVT105913</td>
        <td>AVT105913 18 months type 2 diabetes study</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Benny Hui,Lida Dambrosi,Martyn Palmer</td>
        <td>Treatment</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>761</td>
        <td>688</td>
        <td>687</td>
        <td>70.4</td>
        <td>68.3</td>
        <td>2006-11-02</td>
        <td>2008-02-13</td>
        <td>2009-11-25</td>
        <td>124</td>
    </tr>
    <tr>
        <td>130</td>
        <td>AZ3100603</td>
        <td>AD Proof of Concept Study</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Jeni De'ath</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>656</td>
        <td>380</td>
        <td>373</td>
        <td>33.0</td>
        <td>31.7</td>
        <td>2005-09-21</td>
        <td>2006-04-25</td>
        <td>2009-11-25</td>
        <td>58</td>
    </tr>
    <tr>
        <td>131</td>
        <td>AZ3106242</td>
        <td>SB-742457, Aricept and placebo in AD</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Jeni De'ath</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>266</td>
        <td>200</td>
        <td>198</td>
        <td>28.1</td>
        <td>31.9</td>
        <td>2006-05-16</td>
        <td>2006-10-23</td>
        <td>2009-11-25</td>
        <td>29</td>
    </tr>
    <tr>
        <td>133</td>
        <td>AZ3110866</td>
        <td>SB-742457 as adjunct therapy to donepezil in AD</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Alison Emsley,Amy Lee,Beverly Allen,Erica
            Bullock,Gareth Maher-Edwards,Guenter Woelfl,Jeffery
            Ellis,Jeni De'ath,Mark Briggs,Nicola Hall,Sharon
            Sawchak,Sofia Artemenko,Tarnjit Dehal</td>
        <td>Recruitment</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>269</td>
        <td>672</td>
        <td>84</td>
        <td>54.1</td>
        <td>76.4</td>
        <td>2008-07-01</td>
        <td>2009-11-25</td>
        <td>104</td>
    </tr>
    <tr>
        <td>134</td>
        <td>B2C106093</td>
        <td>Mctr 14d RD asthmatics GW642444 &amp; GR33343</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Farshid Valiani,Suus Baggen</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>83</td>
        <td>60</td>
        <td>56</td>
        <td>26.4</td>
        <td>27.1</td>
        <td>2006-05-23</td>
        <td>2006-10-11</td>
        <td>2009-11-25</td>
        <td>7</td>
    </tr>
    <tr>
        <td>1</td>
        <td>ABD109307</td>
        <td>ABD109307</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>Source Unavailable</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>0</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>2</td>
        <td>100414</td>
        <td>Phase 2 Weekly in Endometrial</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Joe Stoebenau</td>
        <td>Recruitment</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>41</td>
        <td>70</td>
        <td>37</td>
        <td>230.9</td>
        <td>2005-10-06</td>
        <td>2009-11-25</td>
        <td>35</td>
    </tr>
    <tr>
        <td>3</td>
        <td>100568</td>
        <td>HAB-155 EXT:084 Y8</td>
        <td>Biologicals Prophylactic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Elisabeth Van Eerdenbrugh</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>210</td>
        <td>0</td>
        <td>192.1</td>
        <td>2009-11-25</td>
        <td>2</td>
    </tr>
    <tr>
        <td>4</td>
        <td>101468/204</td>
        <td>RLS MR VERSUS IR</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Robin Monteith,Sumita Biswas-Baldwin</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>770</td>
        <td>512</td>
        <td>568</td>
        <td>201.1</td>
        <td>2005-07-20</td>
        <td>2009-11-25</td>
        <td>93</td>
    </tr>
    <tr>
        <td>5</td>
        <td>101468/205</td>
        <td>RLS MR SAFETY STUDY</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Michael McLaughlin,Setrina Hunter</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>577</td>
        <td>380</td>
        <td>384</td>
        <td>233.4</td>
        <td>2005-06-14</td>
        <td>2009-11-25</td>
        <td>72</td>
    </tr>
    <tr>
        <td>6</td>
        <td>101468/206</td>
        <td>Year Long Safety Extension Study of Requip XR</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Jeffrey Ellis,Keri Klontz</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>429</td>
        <td>386</td>
        <td>386</td>
        <td>218.4</td>
        <td>2005-10-18</td>
        <td>2009-11-25</td>
        <td>66</td>
    </tr>
    <tr>
        <td>7</td>
        <td>101858</td>
        <td>Hib-MenCY-TT-005</td>
        <td>Biologicals Prophylactic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Renee Sexton</td>
        <td>Recruitment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>750</td>
        <td>762</td>
        <td>277.1</td>
        <td>2004-08-13</td>
        <td>2009-11-25</td>
        <td>32</td>
    </tr>
    <tr>
        <td>8</td>
        <td>102015</td>
        <td>Hib-MenCY-TT-006 BST:005</td>
        <td>Biologicals Prophylactic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Renee Sexton</td>
        <td>Recruitment</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>600</td>
        <td>502</td>
        <td>277.1</td>
        <td>2005-07-01</td>
        <td>2009-11-25</td>
        <td>27</td>
    </tr>
    <tr>
        <td>9</td>
        <td>103813</td>
        <td>HIB-MENCY-TT-009</td>
        <td>Biologicals Prophylactic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Heather Santiago</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>4400</td>
        <td>4442</td>
        <td>198.1</td>
        <td>2006-02-22</td>
        <td>2009-11-25</td>
        <td>103</td>
    </tr>
    <tr>
        <td>10</td>
        <td>104864/902</td>
        <td>Hycamtin IV weekly + Platinum in 1L ovarian
            patie</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Christine Tucker</td>
        <td>Recruitment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>84</td>
        <td>55</td>
        <td>77</td>
        <td>250.4</td>
        <td>2005-03-14</td>
        <td>2009-11-25</td>
        <td>26</td>
    </tr>
    <tr>
        <td>11</td>
        <td>104864/903</td>
        <td>Hycamtin IV weekly + Platinum in 1L SCLC</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Christine Tucker</td>
        <td>Recruitment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>42</td>
        <td>61</td>
        <td>33</td>
        <td>239.4</td>
        <td>2005-06-23</td>
        <td>2009-11-25</td>
        <td>13</td>
    </tr>
    <tr>
        <td>12</td>
        <td>105517/367</td>
        <td>ANTIHTN 2 ARM IR&amp;CR</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Bryan Kosten</td>
        <td>Recruitment</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1017</td>
        <td>284</td>
        <td>340</td>
        <td>275.9</td>
        <td>2004-02-04</td>
        <td>2009-11-25</td>
        <td>77</td>
    </tr>
    <tr>
        <td>13</td>
        <td>105517/369</td>
        <td>EVAL OF MR CV IN HF</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>John Brennan</td>
        <td>Recruitment</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>222</td>
        <td>180</td>
        <td>190</td>
        <td>268.8</td>
        <td>2004-10-10</td>
        <td>2009-11-25</td>
        <td>49</td>
    </tr>
    <tr>
        <td>14</td>
        <td>107062</td>
        <td>IIT0247, Prof. Hoelzer, Frankfurt</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Juergen Dethling</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>160</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>15</td>
        <td>107240</td>
        <td>MAGE3-AS15-NSC-001(ADJ-Chemo)</td>
        <td>Biologicals Therapeutic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Ine Ilsbroux</td>
        <td>Recruitment</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>250</td>
        <td>72</td>
        <td>49</td>
        <td>137.9</td>
        <td>2007-05-31</td>
        <td>2009-11-25</td>
        <td>26</td>
    </tr>
    <tr>
        <td>16</td>
        <td>108509</td>
        <td>Botox PIII for adult spasticity (upper limb)</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Toshio Maeda</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>113</td>
        <td>105</td>
        <td>109</td>
        <td>132.8</td>
        <td>2007-05-22</td>
        <td>2009-11-25</td>
        <td>20</td>
    </tr>
    <tr>
        <td>17</td>
        <td>108512</td>
        <td>Botox P III for adult spasticity (lower limb)</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Toshio Maeda</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>132</td>
        <td>120</td>
        <td>120</td>
        <td>132.8</td>
        <td>2007-05-22</td>
        <td>2009-11-25</td>
        <td>20</td>
    </tr>
    <tr>
        <td>18</td>
        <td>108558</td>
        <td>Metabolic alterations boosted protease</td>
        <td>HIV</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>170</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>19</td>
        <td>108565</td>
        <td>Observational HIV-HCV included FOS</td>
        <td>HIV</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>200</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>20</td>
        <td>109375</td>
        <td>MENACWY-TT-055</td>
        <td>Biologicals Prophylactic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Renee Sexton,Teresa Petree</td>
        <td>Recruitment</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>600</td>
        <td>385</td>
        <td>126.8</td>
        <td>2007-07-05</td>
        <td>2009-11-25</td>
        <td>19</td>
    </tr>
    <tr>
        <td>21</td>
        <td>109377</td>
        <td>MENACWY-TT-052</td>
        <td>Biologicals Prophylactic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Renee Sexton,Teresa Petree</td>
        <td>Recruitment</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>934</td>
        <td>873</td>
        <td>143.2</td>
        <td>2007-04-23</td>
        <td>2009-11-25</td>
        <td>10</td>
    </tr>
    <tr>
        <td>22</td>
        <td>109493</td>
        <td>MAGE3-AS15-NSC-003 (ADJ)</td>
        <td>Biologicals Therapeutic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Alexandra Larbanois Buts,Isabelle Benoot,Pauline
            Nguyen,Scarlett Koninckx,Tamara Noel</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1855</td>
        <td>2270</td>
        <td>226</td>
        <td>113.2</td>
        <td>2007-01-09</td>
        <td>2009-11-25</td>
        <td>431</td>
    </tr>
    <tr>
        <td>23</td>
        <td>110547</td>
        <td>110547</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>Source Unavailable</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>0</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>24</td>
        <td>111482</td>
        <td>MAGE3-AS15-MEL-005 (ADJ)</td>
        <td>Biologicals Therapeutic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Alexandra Larbanois Buts,Genevieve
            Ramaekers,Isabelle Benoot,Lydia Gavrilovic,Pauline
            Nguyen,Scarlett Koninckx,Tamara Noel</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>1300</td>
        <td>0</td>
        <td>55.8</td>
        <td>2009-11-25</td>
        <td>253</td>
    </tr>
    <tr>
        <td>25</td>
        <td>112077</td>
        <td>ZOSTER-010</td>
        <td>Biologicals Prophylactic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Lin Yue</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>396</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>15</td>
    </tr>
    <tr>
        <td>27</td>
        <td>393229/029</td>
        <td>BEXXAR VS. ZEVALIN</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Patricia Haney</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>350</td>
        <td>0</td>
        <td>194.9</td>
        <td>2009-11-25</td>
        <td>6</td>
    </tr>
    <tr>
        <td>135</td>
        <td>B2C107552</td>
        <td>LABA Head to Head study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Suus Baggen</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>46</td>
        <td>0</td>
        <td>11.7</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>136</td>
        <td>B2C108562</td>
        <td>GW642444 Safety Study in Patients with COPD</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Emily Badalamenti,Freddy Byrth,Jennifer
            Gidley</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>146</td>
        <td>65</td>
        <td>71</td>
        <td>28.0</td>
        <td>28.0</td>
        <td>2005-01-25</td>
        <td>2007-04-18</td>
        <td>2009-11-25</td>
        <td>15</td>
    </tr>
    <tr>
        <td>137</td>
        <td>B2C109575</td>
        <td>GW642444 asthma dose ranging study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Farshid Valiani,Robert Bartle,Serge De
            Bartolo</td>
        <td>Reporting</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1238</td>
        <td>625</td>
        <td>614</td>
        <td>29.7</td>
        <td>29.9</td>
        <td>2007-12-29</td>
        <td>2008-07-23</td>
        <td>2009-11-25</td>
        <td>132</td>
    </tr>
    <tr>
        <td>138</td>
        <td>B2C110836</td>
        <td>444 phase III 6-month safety/efficacy study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>300</td>
        <td>0</td>
        <td>49.6</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>139</td>
        <td>B2C110837</td>
        <td>444 phase III 6-month safety/efficacy study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>300</td>
        <td>0</td>
        <td>47.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>140</td>
        <td>B2C111045</td>
        <td>444 Monotherapy dose-ranging study in COPD</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Brian Marks,Carol Bridges,Inderpal Panesar,Nina
            Church,Serge De Bartolo</td>
        <td>Statistical Analysis</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1205</td>
        <td>576</td>
        <td>606</td>
        <td>33.4</td>
        <td>29.1</td>
        <td>2008-02-21</td>
        <td>2008-09-05</td>
        <td>2009-11-25</td>
        <td>149</td>
    </tr>
    <tr>
        <td>141</td>
        <td>B2E100211</td>
        <td>DR797 - Asthma</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>640</td>
        <td>0</td>
        <td>11.9</td>
        <td>2009-11-25</td>
        <td>14</td>
    </tr>
    <tr>
        <td>142</td>
        <td>B2E103041</td>
        <td>797 COPD clinical bridging in Gemini</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>200</td>
        <td>0</td>
        <td>37.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>143</td>
        <td>B2E104863</td>
        <td>GSK159797 Dose ranging study in COPD</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Jennifer Gidley</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>480</td>
        <td>0</td>
        <td>28.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>144</td>
        <td>B2E106202</td>
        <td>Efficacy and safety in females with asthma</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>72</td>
        <td>0</td>
        <td>7.6</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>145</td>
        <td>B2E106359</td>
        <td>M-ctr 7d RD GSK159797 &amp; GR33343 in
            asthmatics</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Antonio Belgrave,Suus Baggen</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>90</td>
        <td>60</td>
        <td>54</td>
        <td>27.1</td>
        <td>27.7</td>
        <td>2006-04-19</td>
        <td>2006-10-20</td>
        <td>2009-11-25</td>
        <td>7</td>
    </tr>
    <tr>
        <td>146</td>
        <td>B2E108560</td>
        <td>GSK159797 Safety Study in Patients with COPD</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>80</td>
        <td>0</td>
        <td>22.4</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>147</td>
        <td>B2E110609</td>
        <td>Low dose 797 indirect comparison study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Karen Singletary</td>
        <td>Start-Up</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>60</td>
        <td>0</td>
        <td>31.3</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>148</td>
        <td>B3A107053</td>
        <td>GW427353 125mg and 250mg bd study in t2dm</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>120</td>
        <td>0</td>
        <td>28.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>149</td>
        <td>B3C109877</td>
        <td>solabegron with oxy vs oxy monotherapy</td>
        <td>Urogenital</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>355</td>
        <td>0</td>
        <td>76.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>150</td>
        <td>B3I108297</td>
        <td>Solabegron Dose-Ranging Study in IBS</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Amy Lee,Lori Hall</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>500</td>
        <td>0</td>
        <td>27.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>151</td>
        <td>B3P102087</td>
        <td>GW427353 vs Placebo for Overactive Bladder</td>
        <td>Urogenital</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Kjellaug Melvik,Marie Jarosz</td>
        <td>Start-Up</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>400</td>
        <td>0</td>
        <td>16.7</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>152</td>
        <td>B3P104833</td>
        <td>Solabegron - Proof of concept</td>
        <td>Urogenital</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Dora Charalambous,Pauline Parkinson,Terese
            Pfister-Peltola</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>506</td>
        <td>240</td>
        <td>258</td>
        <td>27.7</td>
        <td>29.3</td>
        <td>2006-05-18</td>
        <td>2006-11-29</td>
        <td>2009-11-25</td>
        <td>74</td>
    </tr>
    <tr>
        <td>154</td>
        <td>BEL110751</td>
        <td>Phase 3 safety and efficacy study of belimumab</td>
        <td>Inflammation - Pain</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Treatment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>810</td>
        <td>0</td>
        <td>86.6</td>
        <td>2008-07-23</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>155</td>
        <td>BEL110752</td>
        <td>Phase 3 safety and efficacy study of belimumab
            (Ly</td>
        <td>Inflammation - Pain</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Treatment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>810</td>
        <td>0</td>
        <td>62.3</td>
        <td>2008-03-14</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>156</td>
        <td>BEX101662</td>
        <td>QoL Bexxar vs Zevalin</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Amy Fowles</td>
        <td>Start-Up</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>350</td>
        <td>0</td>
        <td>104.9</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>157</td>
        <td>BEX104510</td>
        <td>Relapsed CLL CP-98-018</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Treatment</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>12</td>
        <td>0</td>
        <td>95.1</td>
        <td>2001-04-27</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>158</td>
        <td>BEX104512</td>
        <td>Greater than 25% BM Involvement CP98-028</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Treatment</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>11</td>
        <td>0</td>
        <td>169.0</td>
        <td>2002-08-08</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>159</td>
        <td>BEX104728</td>
        <td>RIT-I-000</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Treatment</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>59</td>
        <td>0</td>
        <td>301.3</td>
        <td>1996-01-17</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>160</td>
        <td>BEX104787</td>
        <td>CCBX0001-055 Vaccine</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Start-Up</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>60</td>
        <td>0</td>
        <td>104.9</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>161</td>
        <td>BEX104788</td>
        <td>CCBX0001-054 Retreatment</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Start-Up</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>50</td>
        <td>0</td>
        <td>104.9</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>270</td>
        <td>EMD20001</td>
        <td>Randomized, Placebo Controlled, Dose Range
            Finding</td>
        <td>Anti Infectives</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Alison Moorat,Chastity Lattanzio,James
            Geib</td>
        <td>Completed</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>1415</td>
        <td>1415</td>
        <td>96.9</td>
        <td>94.0</td>
        <td>2004-09-02</td>
        <td>2006-04-19</td>
        <td>2009-11-25</td>
        <td>433</td>
    </tr>
    <tr>
        <td>271</td>
        <td>EMD30001</td>
        <td>Efficacy and Safety in Sepsis</td>
        <td>Anti Infectives</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>3000</td>
        <td>0</td>
        <td>76.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>272</td>
        <td>ENT108947</td>
        <td>Gynecologic Oncology Study</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>100</td>
        <td>0</td>
        <td>38.9</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>273</td>
        <td>ENT108951</td>
        <td>Entereg SWITCH study - assess preference in
            subjec</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Wendy Hamon</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>150</td>
        <td>0</td>
        <td>16.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>274</td>
        <td>ENT108953</td>
        <td>Entereg decreases opioid-induced GI side effects
            a</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>200</td>
        <td>0</td>
        <td>46.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>275</td>
        <td>ENT108955</td>
        <td>Entereg Efficacy in Palliative Care Patients</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>200</td>
        <td>0</td>
        <td>44.4</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>276</td>
        <td>ENT108958</td>
        <td>Entereg Efficacy in Minorities</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>200</td>
        <td>0</td>
        <td>39.4</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>277</td>
        <td>EPZ104057</td>
        <td>Epzicom vs. Truvada</td>
        <td>HIV</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Annie Cameron</td>
        <td>Completed</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>864</td>
        <td>680</td>
        <td>718</td>
        <td>47.3</td>
        <td>44.9</td>
        <td>2005-01-04</td>
        <td>2006-05-22</td>
        <td>2009-11-25</td>
        <td>89</td>
    </tr>
    <tr>
        <td>278</td>
        <td>EPZ108859</td>
        <td>EPZ-ATV vs EPZ-ATV/r followed by EPZ-ATV</td>
        <td>HIV</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Melinda Bomar,Sheri Skerget</td>
        <td>Treatment</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>740</td>
        <td>419</td>
        <td>431</td>
        <td>40.0</td>
        <td>21.6</td>
        <td>2006-06-11</td>
        <td>2007-08-10</td>
        <td>2009-11-25</td>
        <td>79</td>
    </tr>
    <tr>
        <td>279</td>
        <td>ESZ111503</td>
        <td>Lunivia residual symptom study</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Karen Chalk,Kirsten Wilkinson,Leonie
            Christianson,Sion Jones</td>
        <td>Statistical Analysis</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>72</td>
        <td>0</td>
        <td>11.4</td>
        <td>2008-09-12</td>
        <td>2009-11-25</td>
        <td>1</td>
    </tr>
    <tr>
        <td>280</td>
        <td>FAD108155</td>
        <td>GI262570 as monotherapy in Alzheimer's Disease</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Stephanie Fraczek</td>
        <td>Start-Up</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>210</td>
        <td>0</td>
        <td>28.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>281</td>
        <td>FBX104114</td>
        <td>PPAR 570 Liver Fibrosis, Phase II</td>
        <td>Infectious Disease- Anti Viral</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Irene Miller,Monika Mogilnicka,Richard
            Stroder</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>864</td>
        <td>225</td>
        <td>266</td>
        <td>60.4</td>
        <td>56.7</td>
        <td>2005-01-06</td>
        <td>2006-11-20</td>
        <td>2009-11-25</td>
        <td>126</td>
    </tr>
    <tr>
        <td>282</td>
        <td>FFA100240</td>
        <td>DR 5698 mild asthma</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Karen Singletary</td>
        <td>Start-Up</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>595</td>
        <td>0</td>
        <td>19.1</td>
        <td>2009-11-25</td>
        <td>29</td>
    </tr>
    <tr>
        <td>283</td>
        <td>FFA102714</td>
        <td>GW685698 once vs twice daily study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Elena Craescu,Michelle Verhaeghe,Robin
            Morris</td>
        <td>Start-Up</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>432</td>
        <td>0</td>
        <td>68.0</td>
        <td>220.1</td>
        <td>2009-11-25</td>
        <td>1</td>
    </tr>
    <tr>
        <td>284</td>
        <td>FFA105808</td>
        <td>GW685698X PM Dosing</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Robin Morris</td>
        <td>Start-Up</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>432</td>
        <td>0</td>
        <td>16.3</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>285</td>
        <td>FFA106783</td>
        <td>GW685698X QD morning vs evening vs BID</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Jane Fricker,Mary Bevivino,Michelle
            Verhaeghe,Susannah Hammond,Tanyada Yongchaitrakul</td>
        <td>Completed</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1421</td>
        <td>648</td>
        <td>659</td>
        <td>33.1</td>
        <td>33.0</td>
        <td>2006-11-15</td>
        <td>2007-06-19</td>
        <td>2009-11-25</td>
        <td>89</td>
    </tr>
    <tr>
        <td>286</td>
        <td>FFA109684</td>
        <td>GW685698X Dose Ranging study in Severe asthma</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Alina Goetz,Angela Davis,Candice Blackley,Cindy
            Handelsman,Irene Shupe,Janet Ball,Lavora Mountain,Marie
            Duggan,Niko Pretorius,Susannah Hammond,Tracie
            Pickler</td>
        <td>Reporting</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1238</td>
        <td>625</td>
        <td>629</td>
        <td>31.0</td>
        <td>28.1</td>
        <td>2007-12-20</td>
        <td>2008-06-19</td>
        <td>2009-11-25</td>
        <td>209</td>
    </tr>
    <tr>
        <td>288</td>
        <td>FFA109687</td>
        <td>GW685698X Dose Ranging study in Mild Asthma</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Alina Goetz,Candice Blackley,Cindy
            Handelsman,Hilary Medley,Irene Shupe,Lavora Mountain,Niko
            Pretorius,Susannah Hammond,Tracie Pickler</td>
        <td>Reporting</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1533</td>
        <td>625</td>
        <td>601</td>
        <td>31.0</td>
        <td>29.3</td>
        <td>2007-12-19</td>
        <td>2008-07-02</td>
        <td>2009-11-25</td>
        <td>186</td>
    </tr>
    <tr>
        <td>289</td>
        <td>FFA112202</td>
        <td>Cross over study of QD and BD GW685698X</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Cindy Handelsman,Lavora Mountain</td>
        <td>Treatment</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>336</td>
        <td>180</td>
        <td>190</td>
        <td>10.4</td>
        <td>3.3</td>
        <td>2008-10-09</td>
        <td>2008-10-30</td>
        <td>2009-11-25</td>
        <td>35</td>
    </tr>
    <tr>
        <td>290</td>
        <td>FFA20002</td>
        <td>Dose ranging study (moderate asthma)</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Karen Singletary</td>
        <td>Start-Up</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>510</td>
        <td>0</td>
        <td>17.3</td>
        <td>2009-11-25</td>
        <td>5</td>
    </tr>
    <tr>
        <td>291</td>
        <td>FFA20003</td>
        <td>Dose ranging study (severe asthma)</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Michelle Verhaeghe</td>
        <td>Start-Up</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>425</td>
        <td>0</td>
        <td>71.0</td>
        <td>2009-11-25</td>
        <td>27</td>
    </tr>
    <tr>
        <td>292</td>
        <td>FFR100010</td>
        <td>H5</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>821</td>
        <td>606</td>
        <td>554</td>
        <td>28.7</td>
        <td>28.7</td>
        <td>2005-03-18</td>
        <td>2005-09-30</td>
        <td>2009-11-25</td>
        <td>65</td>
    </tr>
    <tr>
        <td>294</td>
        <td>FFR101747</td>
        <td>Knemometry Study GW685698X Aqueous Nasal Spray</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Rosalind Firth</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>61</td>
        <td>56</td>
        <td>58</td>
        <td>26.0</td>
        <td>25.3</td>
        <td>2005-04-11</td>
        <td>2005-09-22</td>
        <td>2009-11-25</td>
        <td>1</td>
    </tr>
    <tr>
        <td>295</td>
        <td>FFR101782</td>
        <td>Pediatric Long-term Growth Study,GW685698X Aq
            nas</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Aruna Sharma,Inderpal Panesar,Todd
            Hankinson</td>
        <td>Recruitment</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>549</td>
        <td>450</td>
        <td>159</td>
        <td>98.3</td>
        <td>105.4</td>
        <td>2007-11-26</td>
        <td>2009-11-25</td>
        <td>161</td>
    </tr>
    <tr>
        <td>296</td>
        <td>FFR101816</td>
        <td>Allergen Chamber Study, GW685698X AQ nasal spray</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Alina Goetz,Debbie Dukeman</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1228</td>
        <td>380</td>
        <td>381</td>
        <td>16.1</td>
        <td>16.6</td>
        <td>2005-04-04</td>
        <td>2005-07-25</td>
        <td>2009-11-25</td>
        <td>1</td>
    </tr>
    <tr>
        <td>297</td>
        <td>FFR102885</td>
        <td>Adult Allergen Chamber Study GW685698X AQ
            Nas.spra</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Debbie Dukeman,Stephen Mark</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>380</td>
        <td>0</td>
        <td>12.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>298</td>
        <td>FFR103184</td>
        <td>GW685698X AQ Nasal Spray</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Wayne Gibbs</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>425</td>
        <td>288</td>
        <td>284</td>
        <td>15.7</td>
        <td>14.0</td>
        <td>2005-05-30</td>
        <td>2005-07-20</td>
        <td>2009-11-25</td>
        <td>25</td>
    </tr>
    <tr>
        <td>299</td>
        <td>FFR104503</td>
        <td>GW685698X Nasal Biopsy Study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Suus Baggen</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>170</td>
        <td>155</td>
        <td>149</td>
        <td>15.4</td>
        <td>15.4</td>
        <td>2005-09-20</td>
        <td>2005-12-28</td>
        <td>2009-11-25</td>
        <td>4</td>
    </tr>
    <tr>
        <td>300</td>
        <td>FFR104861</td>
        <td>2-week SAR Study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Katie Hanson</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>428</td>
        <td>288</td>
        <td>299</td>
        <td>9.1</td>
        <td>8.0</td>
        <td>2005-08-15</td>
        <td>2005-09-13</td>
        <td>2009-11-25</td>
        <td>20</td>
    </tr>
    <tr>
        <td>301</td>
        <td>FFR105693</td>
        <td>Pilot Preference Validation Study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Robin Morris</td>
        <td>Completed</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>140</td>
        <td>90</td>
        <td>97</td>
        <td>9.0</td>
        <td>9.0</td>
        <td>2006-05-01</td>
        <td>2006-06-01</td>
        <td>2009-11-25</td>
        <td>8</td>
    </tr>
    <tr>
        <td>302</td>
        <td>FFR106080</td>
        <td>GW685698X PAR study in adults and adolescents</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Katie Hanson,Wayne Gibbs</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>570</td>
        <td>288</td>
        <td>301</td>
        <td>12.3</td>
        <td>12.6</td>
        <td>2006-02-07</td>
        <td>2006-05-04</td>
        <td>2009-11-25</td>
        <td>46</td>
    </tr>
    <tr>
        <td>303</td>
        <td>FFR110537</td>
        <td>FFNS Long-Term Ocular Safety Study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Debbie Dukeman,Kimberly Baker,Pamela Pepsin,Yvonne
            Anderson</td>
        <td>Recruitment</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>336</td>
        <td>525</td>
        <td>186</td>
        <td>62.6</td>
        <td>74.4</td>
        <td>2008-06-30</td>
        <td>2009-11-25</td>
        <td>120</td>
    </tr>
    <tr>
        <td>304</td>
        <td>FFR110883</td>
        <td>FFNS 6-Week PAR Efficacy</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Inderpal Panesar</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>288</td>
        <td>0</td>
        <td>17.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>305</td>
        <td>FFR111158</td>
        <td>Fluticasone furoate nasal spray in irritant
            rhinit</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Angela Gibson-White,Tanyada
            Yongchaitrakul</td>
        <td>Recruitment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>79</td>
        <td>100</td>
        <td>43</td>
        <td>43.9</td>
        <td>91.9</td>
        <td>2008-03-12</td>
        <td>2009-11-25</td>
        <td>7</td>
    </tr>
    <tr>
        <td>306</td>
        <td>FFR20002</td>
        <td>Six week adult HPA axis, GW6859698X aq nasal
            spray</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Deborah Young</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>183</td>
        <td>110</td>
        <td>112</td>
        <td>10.0</td>
        <td>9.9</td>
        <td>2005-01-17</td>
        <td>2005-03-14</td>
        <td>2009-11-25</td>
        <td>2</td>
    </tr>
    <tr>
        <td>307</td>
        <td>FFR30002</td>
        <td>Adult 4 week PAR Study, GW685698X AQ Nasal Spray</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Cesar Cisneros,Stephen Mark</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>515</td>
        <td>300</td>
        <td>302</td>
        <td>9.0</td>
        <td>9.1</td>
        <td>2004-02-15</td>
        <td>2005-03-17</td>
        <td>2009-11-25</td>
        <td>49</td>
    </tr>
    <tr>
        <td>308</td>
        <td>FFR30003</td>
        <td>Adult, 2 week SAR Study GW685698X AQ Nasal Spray</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>575</td>
        <td>304</td>
        <td>304</td>
        <td>4.0</td>
        <td>4.1</td>
        <td>2004-12-10</td>
        <td>2004-12-28</td>
        <td>2009-11-25</td>
        <td>7</td>
    </tr>
    <tr>
        <td>309</td>
        <td>FFR30006</td>
        <td>Adult Vasomotor Rhinitis, GW6859698X AQ Nasal
            Spra</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Emily Badalamenti</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>901</td>
        <td>350</td>
        <td>357</td>
        <td>20.9</td>
        <td>25.7</td>
        <td>2005-01-21</td>
        <td>2005-12-26</td>
        <td>2009-11-25</td>
        <td>56</td>
    </tr>
    <tr>
        <td>311</td>
        <td>FFR30008</td>
        <td>Pediatric PAR Study, GW685698X Aq Nasal Spray</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Debbie Dukeman,Jesus Rodriguez</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>809</td>
        <td>576</td>
        <td>558</td>
        <td>28.1</td>
        <td>26.7</td>
        <td>2005-02-23</td>
        <td>2005-08-23</td>
        <td>2009-11-25</td>
        <td>75</td>
    </tr>
    <tr>
        <td>312</td>
        <td>FFU105924</td>
        <td>Allermist Comparator Study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Bettie Thomas,Pamela Pepsin</td>
        <td>Completed</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>524</td>
        <td>360</td>
        <td>377</td>
        <td>7.6</td>
        <td>8.4</td>
        <td>2000-09-28</td>
        <td>2007-10-11</td>
        <td>2009-11-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>313</td>
        <td>FFU105927</td>
        <td>Allermist Comparator Study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Bettie Thomas,Pamela Pepsin</td>
        <td>Completed</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>507</td>
        <td>360</td>
        <td>361</td>
        <td>7.9</td>
        <td>7.7</td>
        <td>2007-08-21</td>
        <td>2007-10-08</td>
        <td>2009-11-25</td>
        <td>29</td>
    </tr>
    <tr>
        <td>314</td>
        <td>FFU108556</td>
        <td>The Single-Dose Preference Evaluation Study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Bettie Thomas,Jennifer Gidley,Todd
            Hankinson</td>
        <td>Completed</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>129</td>
        <td>125</td>
        <td>128</td>
        <td>4.7</td>
        <td>0.4</td>
        <td>2006-12-01</td>
        <td>2006-12-01</td>
        <td>2009-11-25</td>
        <td>14</td>
    </tr>
    <tr>
        <td>315</td>
        <td>FFU108675</td>
        <td>RCAQ Cross-Sectional Health Outcomes Study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Todd Hankinson</td>
        <td>Completed</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>85</td>
        <td>400</td>
        <td>420</td>
        <td>9.1</td>
        <td>6.3</td>
        <td>2006-11-30</td>
        <td>2007-01-04</td>
        <td>2009-11-25</td>
        <td>28</td>
    </tr>
    <tr>
        <td>317</td>
        <td>FFU109049</td>
        <td>RCAQ - Longitudinal</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Todd Hankinson</td>
        <td>Completed</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>71</td>
        <td>400</td>
        <td>409</td>
        <td>14.1</td>
        <td>3.7</td>
        <td>2008-03-03</td>
        <td>2008-04-04</td>
        <td>2009-11-25</td>
        <td>32</td>
    </tr>
    <tr>
        <td>318</td>
        <td>FFU109409</td>
        <td>FFU109409</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>Source Unavailable</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>0</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>319</td>
        <td>FFU111120</td>
        <td>Veramyst Sleep Quality- 1 of 2</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>354</td>
        <td>0</td>
        <td>22.7</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>320</td>
        <td>FFU111121</td>
        <td>Veramyst Sleep Quality 2 of 2</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>354</td>
        <td>0</td>
        <td>22.7</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>321</td>
        <td>FFU111439</td>
        <td>FFNS for the Treatment PAR</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Alina Goetz,Candice Blackley,Inderpal
            Panesar</td>
        <td>Completed</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>509</td>
        <td>300</td>
        <td>315</td>
        <td>17.7</td>
        <td>17.0</td>
        <td>2008-01-25</td>
        <td>2008-05-21</td>
        <td>2009-11-25</td>
        <td>37</td>
    </tr>
    <tr>
        <td>322</td>
        <td>FLN109153</td>
        <td>Epoproxenol switch study</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>53</td>
        <td>0</td>
        <td>28.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>323</td>
        <td>FRX106365</td>
        <td>INPACT</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Else Laursen</td>
        <td>Treatment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>520</td>
        <td>500</td>
        <td>503</td>
        <td>143.0</td>
        <td>128.3</td>
        <td>2006-05-02</td>
        <td>2008-08-19</td>
        <td>2009-11-25</td>
        <td>100</td>
    </tr>
    <tr>
        <td>324</td>
        <td>FTI102595</td>
        <td>GW813893 for VTE Px in TKR</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Pedro Allende Echevarrieta,Samantha Wright,Talya
            Smeyatsky,Terese Womer</td>
        <td>Start-Up</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>930</td>
        <td>0</td>
        <td>54.7</td>
        <td>2009-11-25</td>
        <td>8</td>
    </tr>
    <tr>
        <td>325</td>
        <td>FTI110547</td>
        <td>Factor Xa study in TKR Patients</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Brendt Stier</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>200</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>326</td>
        <td>GEP110525</td>
        <td>Gepirone ER in the prevention of relapse</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>1200</td>
        <td>0</td>
        <td>53.4</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>327</td>
        <td>GEP110533</td>
        <td>Gepirone ER for GAD in Adults</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>400</td>
        <td>0</td>
        <td>46.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>328</td>
        <td>GEP110535</td>
        <td>Gepirone ER for GAD in adults</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>400</td>
        <td>0</td>
        <td>46.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>329</td>
        <td>GEP110539</td>
        <td>Gepirone ER for GAD in adults</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>800</td>
        <td>0</td>
        <td>90.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>330</td>
        <td>GLP107294</td>
        <td>GSK716155 Dose Range</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Corinne Terchek</td>
        <td>Start-Up</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>222</td>
        <td>0</td>
        <td>27.1</td>
        <td>2009-11-25</td>
        <td>103</td>
    </tr>
    <tr>
        <td>331</td>
        <td>GLP107306</td>
        <td>Byetta Comparison Study</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>123</td>
        <td>0</td>
        <td>-33.4</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>332</td>
        <td>GLP107865</td>
        <td>Japanese Phase1of GSK716155</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Hajime Miyahara</td>
        <td>Reporting</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>76</td>
        <td>40</td>
        <td>40</td>
        <td>24.1</td>
        <td>27.3</td>
        <td>2007-08-01</td>
        <td>2008-02-06</td>
        <td>2009-11-25</td>
        <td>6</td>
    </tr>
    <tr>
        <td>333</td>
        <td>GLP108470</td>
        <td>Add on to Met</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Rhona Scott</td>
        <td>Start-Up</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE3</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>700</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>334</td>
        <td>GLP108472</td>
        <td>Add on to TZD</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>360</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>335</td>
        <td>GLP108474</td>
        <td>Comparison to insulin</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Rhona Scott</td>
        <td>Start-Up</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE3</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>750</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>336</td>
        <td>GLP108476</td>
        <td>Add on to Met + TZD</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Rhona Scott</td>
        <td>Start-Up</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE3</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>450</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>337</td>
        <td>GLP108478</td>
        <td>Monotherapy</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Rhona Scott</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>315</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>338</td>
        <td>GLP108486</td>
        <td>Add on to insulin</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Rhona Scott</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>252</td>
        <td>0</td>
        <td>106.7</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>339</td>
        <td>GLP108488</td>
        <td>Add on to met + SU</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Rhona Scott</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>252</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>340</td>
        <td>GLP108489</td>
        <td>Head to head v Byetta (scenario one only)</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Rhona Scott</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>420</td>
        <td>0</td>
        <td>106.7</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>341</td>
        <td>GLP108492</td>
        <td>Weight Loss dose range</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>500</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>342</td>
        <td>GLP110125</td>
        <td>Weekly, Bi-weekly, &amp; Monthly Dosing Study</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Rhona Scott</td>
        <td>Reporting</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>330</td>
        <td>0</td>
        <td>34.6</td>
        <td>2007-11-16</td>
        <td>2009-11-25</td>
        <td>217</td>
    </tr>
    <tr>
        <td>343</td>
        <td>GLP110932</td>
        <td>Japan-Asia Phase IIb monotherapy</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>200</td>
        <td>0</td>
        <td>26.3</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>344</td>
        <td>GRZ109613</td>
        <td>Phase 2b 735 Therapy in HIV-1 Infected Adults</td>
        <td>HIV</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>100</td>
        <td>0</td>
        <td>17.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>345</td>
        <td>GRZ109789</td>
        <td>GSK364735 vs Merck-0518 in patients with HIV</td>
        <td>HIV</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>600</td>
        <td>0</td>
        <td>102.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>346</td>
        <td>H3A105520</td>
        <td>GSK189254 PoC</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>350</td>
        <td>0</td>
        <td>16.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>347</td>
        <td>H3A110594</td>
        <td>Dose range finding study of GSK189254</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>500</td>
        <td>0</td>
        <td>53.4</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>348</td>
        <td>H3A110596</td>
        <td>Dose Range Finding Study of GSK189254</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>500</td>
        <td>0</td>
        <td>53.4</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>349</td>
        <td>HCT100414</td>
        <td>HCT100414</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>Source Unavailable</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>0</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>350</td>
        <td>HPR101244</td>
        <td>Salvage Study of GW640385 in HIV Subjects</td>
        <td>HIV</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>104</td>
        <td>0</td>
        <td>27.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>162</td>
        <td>BGS108496</td>
        <td>'568 IN DR</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>600</td>
        <td>0</td>
        <td>14.6</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>163</td>
        <td>BKB108451</td>
        <td>GSK366074 vs placebo in overactive bladder</td>
        <td>Urogenital</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Lori DeMauro</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>160</td>
        <td>0</td>
        <td>27.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>164</td>
        <td>BON103593</td>
        <td>Bone Quality</td>
        <td>Musculoskeletal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Laurel Watts</td>
        <td>Completed</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>305</td>
        <td>100</td>
        <td>98</td>
        <td>40.1</td>
        <td>77.4</td>
        <td>2005-08-02</td>
        <td>2007-01-25</td>
        <td>2009-11-25</td>
        <td>15</td>
    </tr>
    <tr>
        <td>165</td>
        <td>BON105960</td>
        <td>Oral Boniva for Patients with Male Osteoporosis</td>
        <td>Musculoskeletal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Laurel Watts</td>
        <td>Statistical Analysis</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>723</td>
        <td>126</td>
        <td>136</td>
        <td>34.7</td>
        <td>34.6</td>
        <td>2007-01-27</td>
        <td>2007-09-17</td>
        <td>2009-11-25</td>
        <td>53</td>
    </tr>
    <tr>
        <td>166</td>
        <td>CBA109389</td>
        <td>GW842166 Analgesic efficacy in OA of the knee</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Karen Ryan,Marlene Jordan</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>640</td>
        <td>308</td>
        <td>313</td>
        <td>18.3</td>
        <td>13.7</td>
        <td>2007-04-04</td>
        <td>2007-06-22</td>
        <td>2009-11-25</td>
        <td>22</td>
    </tr>
    <tr>
        <td>167</td>
        <td>CBA110729</td>
        <td>CB2, OA DRF, Ph2b</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>520</td>
        <td>0</td>
        <td>20.6</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>168</td>
        <td>CBA110730</td>
        <td>CB2, RA DRF, 2b</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>650</td>
        <td>0</td>
        <td>28.6</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>169</td>
        <td>CBA1107730</td>
        <td>CBA1107730</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>Source Unavailable</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>0</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>170</td>
        <td>CCA107487</td>
        <td>Eff and Saf GW679769/Citalopram Adjunc Therapy</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>400</td>
        <td>0</td>
        <td>98.6</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>171</td>
        <td>CCR100136</td>
        <td>Phase IIb Dose Selection study for CCR5</td>
        <td>HIV</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Christopher Hair,David Thorpe,Karen Shields,Nancy
            Flack,Sandy Fox</td>
        <td>Completed</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>396</td>
        <td>175</td>
        <td>195</td>
        <td>34.7</td>
        <td>30.1</td>
        <td>2004-12-13</td>
        <td>2005-07-06</td>
        <td>2009-11-25</td>
        <td>80</td>
    </tr>
    <tr>
        <td>172</td>
        <td>CCR102408</td>
        <td>CCR5 antagonist in salvage therapy.</td>
        <td>HIV</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Sangeeta Sedani</td>
        <td>Start-Up</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>72</td>
        <td>0</td>
        <td>20.9</td>
        <td>2009-11-25</td>
        <td>3</td>
    </tr>
    <tr>
        <td>173</td>
        <td>CCR102709</td>
        <td>GW873140 R5 Tropic in NA/LatinA</td>
        <td>HIV</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Christopher Hair</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>29</td>
        <td>406</td>
        <td>25</td>
        <td>39.7</td>
        <td>12.7</td>
        <td>2005-07-21</td>
        <td>2005-09-13</td>
        <td>2009-11-25</td>
        <td>60</td>
    </tr>
    <tr>
        <td>174</td>
        <td>CCR102711</td>
        <td>Phase III GW873140 Treatment Na&#239;ve</td>
        <td>HIV</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Nancy Flack</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>900</td>
        <td>0</td>
        <td>43.6</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>175</td>
        <td>CCR102881</td>
        <td>Phase IIB GW873140 Dose Ranging with Combivir</td>
        <td>HIV</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Christopher Hair,Nancy Flack,Sangeeta
            Sedani</td>
        <td>Completed</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>272</td>
        <td>125</td>
        <td>148</td>
        <td>22.0</td>
        <td>24.3</td>
        <td>2005-01-14</td>
        <td>2005-06-27</td>
        <td>2009-11-25</td>
        <td>63</td>
    </tr>
    <tr>
        <td>176</td>
        <td>CCR104401</td>
        <td>Hepatic Impairment</td>
        <td>HIV</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Anne Shachoy-Clark,Julie Borland</td>
        <td>Planned</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>12</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>177</td>
        <td>CCR104456</td>
        <td>GW873140 R5 Tropic in EU/RoW</td>
        <td>HIV</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Ana Martin,Peter Tabona</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1</td>
        <td>406</td>
        <td>1</td>
        <td>38.0</td>
        <td>10.9</td>
        <td>2005-09-05</td>
        <td>2005-09-06</td>
        <td>2009-11-25</td>
        <td>23</td>
    </tr>
    <tr>
        <td>178</td>
        <td>CCR104458</td>
        <td>Phase III GW873140 R5/X4 Tropic</td>
        <td>HIV</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Christopher Hair</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>21</td>
        <td>240</td>
        <td>19</td>
        <td>39.7</td>
        <td>12.7</td>
        <td>2005-07-28</td>
        <td>2005-09-13</td>
        <td>2009-11-25</td>
        <td>80</td>
    </tr>
    <tr>
        <td>179</td>
        <td>CCR104627</td>
        <td>CCR phase 3 Screening Protocol</td>
        <td>HIV</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Christopher Hair</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>231</td>
        <td>1700</td>
        <td>0</td>
        <td>34.7</td>
        <td>12.7</td>
        <td>2005-06-22</td>
        <td>2005-09-13</td>
        <td>2009-11-25</td>
        <td>91</td>
    </tr>
    <tr>
        <td>180</td>
        <td>CCR104629</td>
        <td>CCR X4 Observational Study</td>
        <td>HIV</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Christopher Hair</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>100</td>
        <td>2</td>
        <td>22.1</td>
        <td>10.7</td>
        <td>2005-08-24</td>
        <td>2005-08-30</td>
        <td>2009-11-25</td>
        <td>73</td>
    </tr>
    <tr>
        <td>181</td>
        <td>CDA102514</td>
        <td>Longitudinal study of CDA vs LapDap</td>
        <td>Anti Infectives</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>500</td>
        <td>0</td>
        <td>56.6</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>182</td>
        <td>CDA107210</td>
        <td>CDA phase IIIB infant study</td>
        <td>Anti Infectives</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Phyllis Guta</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>238</td>
        <td>0</td>
        <td>53.7</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>183</td>
        <td>CDA108534</td>
        <td>CDA G6PD study</td>
        <td>Anti Infectives</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>5000</td>
        <td>0</td>
        <td>106.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>184</td>
        <td>CFD105453</td>
        <td>Carvedilol CR in Combination with Lisinopril</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Bryan Kosten</td>
        <td>Reporting</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>2858</td>
        <td>643</td>
        <td>655</td>
        <td>67.6</td>
        <td>82.1</td>
        <td>2004-04-13</td>
        <td>2008-01-31</td>
        <td>2009-11-25</td>
        <td>178</td>
    </tr>
    <tr>
        <td>186</td>
        <td>CFD110733</td>
        <td>SS PK of FDC compared to CR</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Brendt Stier</td>
        <td>Completed</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>24</td>
        <td>0</td>
        <td>113.4</td>
        <td>2009-11-25</td>
        <td>2</td>
    </tr>
    <tr>
        <td>187</td>
        <td>CIL106062</td>
        <td>Japan Ariflo COPD</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>50</td>
        <td>0</td>
        <td>74.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>188</td>
        <td>CNA106030</td>
        <td>Abacavir HSR study</td>
        <td>HIV</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Dmitry Zamoryakhin,Karen Parry-Billings</td>
        <td>Completed</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1998</td>
        <td>1806</td>
        <td>1956</td>
        <td>28.1</td>
        <td>25.4</td>
        <td>2006-04-12</td>
        <td>2006-09-29</td>
        <td>2009-11-25</td>
        <td>316</td>
    </tr>
    <tr>
        <td>189</td>
        <td>CNA108223</td>
        <td>ABC-naive observational study</td>
        <td>HIV</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Dmitry Zamoryakhin</td>
        <td>Completed</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>32</td>
        <td>3</td>
        <td>13.4</td>
        <td>13.4</td>
        <td>2007-03-22</td>
        <td>2007-05-30</td>
        <td>2009-11-25</td>
        <td>26</td>
    </tr>
    <tr>
        <td>190</td>
        <td>CNA109586</td>
        <td>Kivexa versus Truvada</td>
        <td>HIV</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Bridin McCaughey,Helen Pearce,Reine
            Le-Gall</td>
        <td>Treatment</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>505</td>
        <td>380</td>
        <td>395</td>
        <td>18.1</td>
        <td>19.9</td>
        <td>2007-06-22</td>
        <td>2007-10-30</td>
        <td>2009-11-25</td>
        <td>96</td>
    </tr>
    <tr>
        <td>191</td>
        <td>COR100216</td>
        <td>Carv CR vs Atenolol in Pts with LVH &amp; HTN</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Bryan Kosten</td>
        <td>Statistical Analysis</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>510</td>
        <td>255</td>
        <td>287</td>
        <td>129.7</td>
        <td>131.7</td>
        <td>2004-08-26</td>
        <td>2007-06-25</td>
        <td>2009-11-25</td>
        <td>121</td>
    </tr>
    <tr>
        <td>192</td>
        <td>COR103560</td>
        <td>Carv CR vs Toprol XL in Pts w/ MAU &amp; HTN</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Bryan Kosten</td>
        <td>Completed</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>322</td>
        <td>1292</td>
        <td>107</td>
        <td>41.3</td>
        <td>44.7</td>
        <td>2005-08-10</td>
        <td>2006-05-09</td>
        <td>2009-11-25</td>
        <td>98</td>
    </tr>
    <tr>
        <td>193</td>
        <td>COR103561</td>
        <td>Carv CR vs Metoprolol in Pts w/ Dyslipid. &amp;
            HTN</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Lida Dambrosi,Michelle Vettese-Dadey</td>
        <td>Completed</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1327</td>
        <td>554</td>
        <td>577</td>
        <td>66.7</td>
        <td>64.7</td>
        <td>2005-12-30</td>
        <td>2007-03-16</td>
        <td>2009-11-25</td>
        <td>123</td>
    </tr>
    <tr>
        <td>194</td>
        <td>COR105957</td>
        <td>Coreg Vascular Biomarker Study</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>John Brennan</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>150</td>
        <td>0</td>
        <td>41.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>195</td>
        <td>COR111096</td>
        <td>Coreg CR+ lisinopril compared to lisinopril
            monoth</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Bryan Kosten,Nancy Sendecki,Ruth
            Mininger</td>
        <td>Statistical Analysis</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>600</td>
        <td>348</td>
        <td>432</td>
        <td>52.0</td>
        <td>10.3</td>
        <td>2007-04-15</td>
        <td>2008-06-05</td>
        <td>2009-11-25</td>
        <td>135</td>
    </tr>
    <tr>
        <td>196</td>
        <td>CR9108815</td>
        <td>Fracture Healing of Ankle</td>
        <td>Musculoskeletal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Philippa Smith</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>800</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>197</td>
        <td>CR9108914</td>
        <td>Fracture Healing of Distal Radius</td>
        <td>Musculoskeletal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Lori DeMauro,Myong-Joo Byun,Philippa Smith,Trish
            McBride</td>
        <td>Data Management</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>130</td>
        <td>219</td>
        <td>86</td>
        <td>59.0</td>
        <td>59.3</td>
        <td>2007-09-20</td>
        <td>2008-10-07</td>
        <td>2009-11-25</td>
        <td>37</td>
    </tr>
    <tr>
        <td>198</td>
        <td>CR9108963</td>
        <td>Phase II Dose Finding</td>
        <td>Musculoskeletal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Christine Dabrowski,Kathryn Briggs,Laurel Watts,Mia
            Martins,Myong-Joo Byun,Phillip Ertel,Shaista
            Hussain</td>
        <td>Treatment</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1595</td>
        <td>520</td>
        <td>570</td>
        <td>22.6</td>
        <td>30.3</td>
        <td>2007-05-14</td>
        <td>2007-11-29</td>
        <td>2009-11-25</td>
        <td>51</td>
    </tr>
    <tr>
        <td>199</td>
        <td>CR9109111</td>
        <td>Japanese Phase ll of SB751689</td>
        <td>Musculoskeletal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>150</td>
        <td>0</td>
        <td>15.6</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>200</td>
        <td>CRH103004</td>
        <td>Drug Drug interaction</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Marika Vousden</td>
        <td>Completed</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>40</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>1</td>
    </tr>
    <tr>
        <td>201</td>
        <td>CRH103152</td>
        <td>Drug drug interaction</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Hiba Tappouni</td>
        <td>Completed</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>30</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>1</td>
    </tr>
    <tr>
        <td>202</td>
        <td>CRH103390</td>
        <td>Social Phobia POC</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Alison Emsley,Joanne Cedrone,Sookti Bhangu,Vimal
            Thohan</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>483</td>
        <td>280</td>
        <td>299</td>
        <td>30.3</td>
        <td>26.1</td>
        <td>2006-11-09</td>
        <td>2007-04-27</td>
        <td>2009-11-25</td>
        <td>36</td>
    </tr>
    <tr>
        <td>203</td>
        <td>CRH104708</td>
        <td>MDD POC</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Joanne Cedrone,Karen Frusciante,Monica
            Lopez</td>
        <td>Start-Up</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>250</td>
        <td>0</td>
        <td>78.9</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>204</td>
        <td>CRI108299</td>
        <td>CRF-1 Dose-Ranging Study in IBS</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>500</td>
        <td>0</td>
        <td>31.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>205</td>
        <td>CRS106139</td>
        <td>MDD PoC</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Sara Harward,Sheila Perry,Steve Chriscoe</td>
        <td>Recruitment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>47</td>
        <td>150</td>
        <td>5</td>
        <td>80.1</td>
        <td>62.1</td>
        <td>2008-10-02</td>
        <td>2009-11-25</td>
        <td>16</td>
    </tr>
    <tr>
        <td>206</td>
        <td>CRV110734</td>
        <td>Japan Phase I/II study of Coreg CR</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Hirohiko Murayama,Yuki Fujii</td>
        <td>Recruitment</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>16</td>
        <td>60</td>
        <td>10</td>
        <td>30.7</td>
        <td>69.8</td>
        <td>2008-08-28</td>
        <td>2009-11-25</td>
        <td>21</td>
    </tr>
    <tr>
        <td>207</td>
        <td>CRV110823</td>
        <td>Japan Phase III study of Coreg CR_Switching</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>156</td>
        <td>0</td>
        <td>15.3</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>208</td>
        <td>CXA30007</td>
        <td>Phase 3: Knee Osteoarthritis efficacy and safety</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Barbara Jeter,Charlotte Rustioni,Conn
            Harrington,Fiona O'Neill,Lisa Howard,Neville
            Harkin</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>2298</td>
        <td>1120</td>
        <td>1340</td>
        <td>15.6</td>
        <td>15.7</td>
        <td>2005-01-22</td>
        <td>2005-08-12</td>
        <td>2009-11-25</td>
        <td>260</td>
    </tr>
    <tr>
        <td>210</td>
        <td>DAN106587</td>
        <td>Repeat Dose Study</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Joanne Ratcliffe,Sharon Bullman</td>
        <td>Reporting</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>88</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>2</td>
    </tr>
    <tr>
        <td>211</td>
        <td>DAN108428</td>
        <td>POC in Smokers</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Connie Orander,Dana Tielemans,Frances
            Kinrade,Jennifer Park</td>
        <td>Recruitment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1</td>
        <td>170</td>
        <td>0</td>
        <td>20.1</td>
        <td>53.9</td>
        <td>2008-12-01</td>
        <td>2009-11-25</td>
        <td>17</td>
    </tr>
    <tr>
        <td>212</td>
        <td>DB1111581</td>
        <td>Repeat Dose COPD Study with Combination 444/705</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Karen Singletary</td>
        <td>Recruitment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>57</td>
        <td>60</td>
        <td>20</td>
        <td>11.7</td>
        <td>55.2</td>
        <td>2008-11-13</td>
        <td>2009-11-25</td>
        <td>17</td>
    </tr>
    <tr>
        <td>213</td>
        <td>DEM100175</td>
        <td>Dose-ranging BMD study to select dose for Phase
            II</td>
        <td>Inflammation - Dermatology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Erin Brown,Hayley Crouch,Laurel Watts,Mia
            Martins,Philippa Smith,Serge De Bartolo,Ute
            Lichtenfeld</td>
        <td>Start-Up</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>330</td>
        <td>0</td>
        <td>32.1</td>
        <td>2009-11-25</td>
        <td>8</td>
    </tr>
    <tr>
        <td>214</td>
        <td>DIX109177</td>
        <td>FTIH in GSK376501</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Nancy Herje</td>
        <td>Completed</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>72</td>
        <td>0</td>
        <td>22.7</td>
        <td>2007-04-13</td>
        <td>2009-11-25</td>
        <td>1</td>
    </tr>
    <tr>
        <td>215</td>
        <td>DPB100925</td>
        <td>12 Wk Double-Blind, Pbo-Control with 12 Wk Ext</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Rachel Kozak</td>
        <td>Completed</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1254</td>
        <td>366</td>
        <td>367</td>
        <td>34.4</td>
        <td>37.7</td>
        <td>2005-05-03</td>
        <td>2005-12-23</td>
        <td>2009-11-25</td>
        <td>114</td>
    </tr>
    <tr>
        <td>216</td>
        <td>DPB105351</td>
        <td>AVD XR + 093 vs AVD XR + PBO</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Cindy Lehner</td>
        <td>Start-Up</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>240</td>
        <td>0</td>
        <td>21.6</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>217</td>
        <td>DPB105355</td>
        <td>Met + 093 vs Met + PBO vs 093 + PBO</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>852</td>
        <td>0</td>
        <td>26.6</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>218</td>
        <td>DPB105357</td>
        <td>Met IR + 093 vs Met IR + PBO</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Cindy Lehner</td>
        <td>Start-Up</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>306</td>
        <td>0</td>
        <td>22.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>219</td>
        <td>DPB105359</td>
        <td>Met IR+093 vs Met IR +SU</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Cindy Lehner</td>
        <td>Start-Up</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>634</td>
        <td>0</td>
        <td>21.6</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>220</td>
        <td>DPB105361</td>
        <td>Met XR + 093 vs Met XR + PBO</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>240</td>
        <td>0</td>
        <td>25.6</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>221</td>
        <td>DPB105365</td>
        <td>093 vs AGI</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Takashi Kurita</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>240</td>
        <td>0</td>
        <td>19.9</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>222</td>
        <td>DPB105367</td>
        <td>093 vs MetIR</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Cindy Lehner</td>
        <td>Start-Up</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>544</td>
        <td>0</td>
        <td>21.6</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>223</td>
        <td>DPB105385</td>
        <td>093 + Insulin vs PBO + Insulin</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>240</td>
        <td>0</td>
        <td>26.9</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>224</td>
        <td>DPB105475</td>
        <td>Outcomes Study 1</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>5000</td>
        <td>0</td>
        <td>39.4</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>225</td>
        <td>DPB106652</td>
        <td>Japan Phase IIa Mono of GW823093</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Completed</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>312</td>
        <td>200</td>
        <td>159</td>
        <td>21.9</td>
        <td>21.6</td>
        <td>2006-04-25</td>
        <td>2006-10-14</td>
        <td>2009-11-25</td>
        <td>25</td>
    </tr>
    <tr>
        <td>226</td>
        <td>DPB106655</td>
        <td>Japan PhaseIIb Mono of GW823093</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>240</td>
        <td>0</td>
        <td>30.4</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>227</td>
        <td>DPB107246</td>
        <td>52-Week Dose Ranging Study</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Cindy Lehner</td>
        <td>Start-Up</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>852</td>
        <td>0</td>
        <td>21.7</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>228</td>
        <td>EGF100151</td>
        <td>Comparison of GW572016 and Capecitabine</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Anne Connor</td>
        <td>Treatment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>524</td>
        <td>407</td>
        <td>411</td>
        <td>143.0</td>
        <td>124.9</td>
        <td>2004-03-03</td>
        <td>2006-04-05</td>
        <td>2009-11-25</td>
        <td>307</td>
    </tr>
    <tr>
        <td>229</td>
        <td>EGF100161</td>
        <td>Taxotere + Herceptin +/- Lapatinib in ErbB2 +
            ABC</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Abdellatif Ezzaher,Danielle Ledger,Jennifer
            Carver</td>
        <td>Recruitment</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>46</td>
        <td>120</td>
        <td>36</td>
        <td>226.8</td>
        <td>2005-10-07</td>
        <td>2009-11-25</td>
        <td>5</td>
    </tr>
    <tr>
        <td>230</td>
        <td>EGF100644</td>
        <td>GW572016, Ph II extension</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>15</td>
        <td>0</td>
        <td>17.9</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>231</td>
        <td>EGF102988</td>
        <td>Maintenance study in H&amp;N patients</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>AiJun Ding,Barbara Ibarguchi,Dora
            Charalambous,Edward Edson,Jennifer Carver,Kathleen
            DeRose,Shirley Young,Sophie Gardiner,Souria Hasan</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>367</td>
        <td>680</td>
        <td>250</td>
        <td>160.6</td>
        <td>155.1</td>
        <td>2006-12-21</td>
        <td>2009-11-25</td>
        <td>133</td>
    </tr>
    <tr>
        <td>232</td>
        <td>EGF103165</td>
        <td>Lapatinib in Patients with Head &amp; Neck
            Cancer</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>600</td>
        <td>0</td>
        <td>54.3</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>233</td>
        <td>EGF103659</td>
        <td>EAP Lapatinib plus Capecitabine in MBC</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Start-Up</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>3390</td>
        <td>0</td>
        <td>145.7</td>
        <td>2009-11-25</td>
        <td>462</td>
    </tr>
    <tr>
        <td>234</td>
        <td>EGF103890</td>
        <td>Phase II Combination with Avastin</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>John Brennan,Michael Gress</td>
        <td>Reporting</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>55</td>
        <td>50</td>
        <td>53</td>
        <td>64.4</td>
        <td>60.9</td>
        <td>2007-02-27</td>
        <td>2008-04-22</td>
        <td>2009-11-25</td>
        <td>9</td>
    </tr>
    <tr>
        <td>235</td>
        <td>EGF104334</td>
        <td>Ph II Neoadjuvant Lapatinib Head and Neck cancer</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Muhammad Shoaib,Sonja Phillips,Sophie
            Gardiner</td>
        <td>Reporting</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>128</td>
        <td>100</td>
        <td>106</td>
        <td>78.1</td>
        <td>79.4</td>
        <td>2006-03-02</td>
        <td>2007-06-28</td>
        <td>2009-11-25</td>
        <td>13</td>
    </tr>
    <tr>
        <td>236</td>
        <td>EGF104383</td>
        <td>Tra + Pac + Lap vs Tra + Pac in ErBb2+ MBC</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Bridgette White,Chris Holland,Constantina
            Papageorgiou,Sarah Taylor</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>65</td>
        <td>720</td>
        <td>51</td>
        <td>254.7</td>
        <td>213.1</td>
        <td>2005-12-13</td>
        <td>2009-11-25</td>
        <td>76</td>
    </tr>
    <tr>
        <td>237</td>
        <td>EGF104535</td>
        <td>PIII of taxol/lapatinib in ErbB2+</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Anna Rhesa Kallam</td>
        <td>Treatment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>978</td>
        <td>430</td>
        <td>430</td>
        <td>156.6</td>
        <td>151.3</td>
        <td>2004-04-18</td>
        <td>2008-11-13</td>
        <td>2009-11-25</td>
        <td>57</td>
    </tr>
    <tr>
        <td>238</td>
        <td>EGF104578</td>
        <td>Lapatinib w/paclitaxel, Gastric cancer study</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Akihira Mukaiyama,Masayuki Kanezaki,Mikiro
            Kobayashi,Talya Smeyatsky,Yoshinobu Tanaka</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>158</td>
        <td>272</td>
        <td>41</td>
        <td>131.0</td>
        <td>125.9</td>
        <td>2007-07-05</td>
        <td>2009-11-25</td>
        <td>50</td>
    </tr>
    <tr>
        <td>240</td>
        <td>EGF104900</td>
        <td>Lapatinib +/- Herceptin in refractory metastatic</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Bridgette White,Lissa Macintyre</td>
        <td>Treatment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>397</td>
        <td>270</td>
        <td>296</td>
        <td>57.0</td>
        <td>53.6</td>
        <td>2005-11-03</td>
        <td>2006-10-27</td>
        <td>2009-11-25</td>
        <td>153</td>
    </tr>
    <tr>
        <td>241</td>
        <td>EGF105084</td>
        <td>016 in breast cancer patients with brain mets</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Monika Mogilnicka,Natalie Jones,Sarah Catlow,Sherri
            Smithson,Yuhui Xu</td>
        <td>Treatment</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>277</td>
        <td>220</td>
        <td>245</td>
        <td>49.7</td>
        <td>58.7</td>
        <td>2005-12-02</td>
        <td>2007-01-12</td>
        <td>2009-11-25</td>
        <td>74</td>
    </tr>
    <tr>
        <td>242</td>
        <td>EGF105485</td>
        <td>Adjuvant Lapatinib in Women with Early-Stage</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Joan Curran,Lynn Nicolodi,Megan Vaughan,Shanti
            Melendez,Victoria Bush</td>
        <td>Treatment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>4687</td>
        <td>3300</td>
        <td>3200</td>
        <td>106.6</td>
        <td>173.9</td>
        <td>2001-09-19</td>
        <td>2008-04-04</td>
        <td>2009-11-25</td>
        <td>465</td>
    </tr>
    <tr>
        <td>243</td>
        <td>EGF105635</td>
        <td>Phase I study of lapatinib with trastuzumab</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Toshinao Wakamatsu</td>
        <td>Data Management</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>12</td>
        <td>22</td>
        <td>11</td>
        <td>39.1</td>
        <td>49.0</td>
        <td>2006-04-06</td>
        <td>2007-03-05</td>
        <td>2009-11-25</td>
        <td>6</td>
    </tr>
    <tr>
        <td>244</td>
        <td>EGF105637</td>
        <td>Phase III study of lapatinib with trastuzumab</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>400</td>
        <td>0</td>
        <td>104.7</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>245</td>
        <td>EGF105764</td>
        <td>PhII of Lapatinib + Taxol in 1st line MBC</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Nicola Jackson</td>
        <td>Treatment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>95</td>
        <td>56</td>
        <td>57</td>
        <td>57.3</td>
        <td>63.0</td>
        <td>2006-05-13</td>
        <td>2007-05-16</td>
        <td>2009-11-25</td>
        <td>15</td>
    </tr>
    <tr>
        <td>246</td>
        <td>EGF105884</td>
        <td>A phase II trial of lapatinib in combination
            with</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Amel Ouettar,Anne Connor,Barbara Ibarguchi,Sonja
            Phillips</td>
        <td>Recruitment</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>178</td>
        <td>74</td>
        <td>66</td>
        <td>118.4</td>
        <td>164.2</td>
        <td>2006-11-27</td>
        <td>2009-11-25</td>
        <td>31</td>
    </tr>
    <tr>
        <td>247</td>
        <td>EGF106708</td>
        <td>BIG Adjuvant Study</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Alessandra Pranzo,James Bao,Kate Norman,Mariana Di
            Laudo,Matthew Scullion,Naomi Briggs,Patricia Tosi,Rowena
            Abbey,Tanyada Yongchaitrakul</td>
        <td>Recruitment</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>2633</td>
        <td>8000</td>
        <td>3306</td>
        <td>198.1</td>
        <td>139.2</td>
        <td>2004-04-02</td>
        <td>2009-11-25</td>
        <td>1366</td>
    </tr>
    <tr>
        <td>248</td>
        <td>EGF106903</td>
        <td>Big Neoadjuvant Study</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Ute Lichtenfeld</td>
        <td>Start-Up</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>450</td>
        <td>0</td>
        <td>93.0</td>
        <td>107.8</td>
        <td>2009-11-25</td>
        <td>122</td>
    </tr>
    <tr>
        <td>249</td>
        <td>EGF107521</td>
        <td>Tykerb + oral topotecan phase 1 combo</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>30</td>
        <td>0</td>
        <td>63.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>250</td>
        <td>EGF107566</td>
        <td>Neoadjuvant USON FEC preoperative study</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>90</td>
        <td>0</td>
        <td>49.6</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>251</td>
        <td>EGF107671</td>
        <td>Lap+Topo or Lap + Capecitabine for Brain Mets</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Megan Vaughan,Sarah Catlow,Sean Keegan,Sejal
            Patel,Silvia Neumeier</td>
        <td>Treatment</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>25</td>
        <td>55</td>
        <td>22</td>
        <td>115.0</td>
        <td>69.9</td>
        <td>2007-05-01</td>
        <td>2008-08-11</td>
        <td>2009-11-25</td>
        <td>48</td>
    </tr>
    <tr>
        <td>252</td>
        <td>EGF107673</td>
        <td>EAP IBC</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>1270</td>
        <td>0</td>
        <td>49.7</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>253</td>
        <td>EGF107674</td>
        <td>EAP Brain Mets</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>1270</td>
        <td>0</td>
        <td>50.9</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>254</td>
        <td>EGF107675</td>
        <td>EAP Lapatinib plus Trastuzumab in MBC</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>4690</td>
        <td>0</td>
        <td>36.7</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>255</td>
        <td>EGF108618</td>
        <td>Multicentre randomised phase II study of Tykerb
            mo</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>AiJun Ding,Barbara Ibarguchi,Shane
            McLoughlin</td>
        <td>Start-Up</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>156</td>
        <td>0</td>
        <td>37.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>256</td>
        <td>EGF108916</td>
        <td>PhII tykerb + chemo in herceptin adjuvant
            failures</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Anne Connor,Christopher Cunnane</td>
        <td>Treatment</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>11</td>
        <td>9</td>
        <td>9</td>
        <td>96.9</td>
        <td>63.3</td>
        <td>2007-11-06</td>
        <td>2008-08-08</td>
        <td>2009-11-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>257</td>
        <td>EGF108919</td>
        <td>PhIII tykerb + chemo vs. herceptin + chemo</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Danielle Ledger,Sean Keegan</td>
        <td>Start-Up</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>600</td>
        <td>0</td>
        <td>119.1</td>
        <td>63.1</td>
        <td>2009-11-25</td>
        <td>139</td>
    </tr>
    <tr>
        <td>258</td>
        <td>EGF108923</td>
        <td>Multicentre randomised study of Pazopanib vs
            Tyker</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>450</td>
        <td>0</td>
        <td>79.6</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>259</td>
        <td>EGF109462</td>
        <td>PhI adaptive PhII Lap/Alimta vs Alimta in 2L
            NSCL</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Catherine Matonti,Christoph Geiger,Donatella
            Albanesi,Iwona Chwesiuk,Saba Khan-Wasti,Sondra
            Druker</td>
        <td>Treatment</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>19</td>
        <td>30</td>
        <td>18</td>
        <td>27.6</td>
        <td>26.4</td>
        <td>2007-09-20</td>
        <td>2008-03-06</td>
        <td>2009-11-25</td>
        <td>5</td>
    </tr>
    <tr>
        <td>260</td>
        <td>EGF109749</td>
        <td>combination with capecitabine</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Hisami Shimizu,Kenji Ishizuka,Toshinao
            Wakamatsu</td>
        <td>Recruitment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>58</td>
        <td>51</td>
        <td>51</td>
        <td>67.0</td>
        <td>132.8</td>
        <td>2007-06-19</td>
        <td>2009-11-25</td>
        <td>16</td>
    </tr>
    <tr>
        <td>262</td>
        <td>EGF110500</td>
        <td>Tykerb phase II head to head</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>80</td>
        <td>0</td>
        <td>66.6</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>263</td>
        <td>EGF110656</td>
        <td>PhII/PhIII TyXELOX in AGC</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Benny Hui,Edward Edson,Nicola Jackson,Shane
            McLoughlin,Stephanie Smith</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>14</td>
        <td>410</td>
        <td>12</td>
        <td>99.9</td>
        <td>82.8</td>
        <td>2008-09-03</td>
        <td>2009-11-25</td>
        <td>82</td>
    </tr>
    <tr>
        <td>264</td>
        <td>EGF111438</td>
        <td>L+C or T+C in ErB2+ MBC following A or T
            exposure</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Dipak Kothari</td>
        <td>Start-Up</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>650</td>
        <td>0</td>
        <td>167.3</td>
        <td>2009-11-25</td>
        <td>43</td>
    </tr>
    <tr>
        <td>265</td>
        <td>EGF20009</td>
        <td>Phase II Trial with GW572016 monotherapy in
            first</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Anna Rhesa Kallam</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>330</td>
        <td>130</td>
        <td>138</td>
        <td>78.4</td>
        <td>78.4</td>
        <td>2004-06-28</td>
        <td>2005-12-16</td>
        <td>2009-11-25</td>
        <td>32</td>
    </tr>
    <tr>
        <td>267</td>
        <td>EGF30001</td>
        <td>Randomized 2 arm phase III study</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Anne Connor,Dipak Kothari,Kathy Piliouras,Michelle
            Norman,Ryan Macri</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>739</td>
        <td>570</td>
        <td>580</td>
        <td>58.4</td>
        <td>82.9</td>
        <td>2004-01-19</td>
        <td>2005-06-13</td>
        <td>2009-11-25</td>
        <td>210</td>
    </tr>
    <tr>
        <td>268</td>
        <td>EGF30008</td>
        <td>Letrozole +/- 016</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Andrea Afinec,Meggan Leigh,Sejal Patel,Sophia
            Paul</td>
        <td>Treatment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1516</td>
        <td>1280</td>
        <td>1291</td>
        <td>164.6</td>
        <td>160.7</td>
        <td>2003-12-09</td>
        <td>2006-12-18</td>
        <td>2009-11-25</td>
        <td>313</td>
    </tr>
    <tr>
        <td>269</td>
        <td>EL110006</td>
        <td>COPD efficacy PoC</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>257</td>
        <td>200</td>
        <td>206</td>
        <td>28.0</td>
        <td>27.6</td>
        <td>2005-01-25</td>
        <td>2005-05-23</td>
        <td>2009-11-25</td>
        <td>38</td>
    </tr>
    <tr>
        <td>459</td>
        <td>NAP108394</td>
        <td>GW273225 for Relapse Prevention of BP Mood
            Episode</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Mary Flood</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>860</td>
        <td>0</td>
        <td>77.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>460</td>
        <td>NAP108396</td>
        <td>GW273225 for acute treatment of BP Depression</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Connie Orander,Kunal Merchant,Mary Flood</td>
        <td>Start-Up</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>592</td>
        <td>0</td>
        <td>76.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>461</td>
        <td>NAP108398</td>
        <td>GW273225 for acute treatment of Bipolar
            Depression</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Start-Up</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>592</td>
        <td>0</td>
        <td>76.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>462</td>
        <td>NAP108400</td>
        <td>GW273225 for acute treatment of bipolar mania</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Connie Orander,Kunal Merchant,Mary Elkins,Mary
            Flood</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>200</td>
        <td>0</td>
        <td>54.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>463</td>
        <td>NEC107055</td>
        <td>GW273225 Safety Study</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Mary Elkins</td>
        <td>Start-Up</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>50</td>
        <td>0</td>
        <td>22.1</td>
        <td>77.9</td>
        <td>2009-11-25</td>
        <td>1</td>
    </tr>
    <tr>
        <td>464</td>
        <td>NEC107333</td>
        <td>273225 epilepsy continuation study</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Mary Elkins,Tonya Peele</td>
        <td>Start-Up</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>2000</td>
        <td>0</td>
        <td>110.1</td>
        <td>2009-11-25</td>
        <td>1</td>
    </tr>
    <tr>
        <td>465</td>
        <td>NEC108538</td>
        <td>GW273225 Dose Rising study</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>300</td>
        <td>0</td>
        <td>63.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>466</td>
        <td>NKB105022</td>
        <td>NK1 For OAB</td>
        <td>Urogenital</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Lori DeMauro</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>478</td>
        <td>160</td>
        <td>170</td>
        <td>47.3</td>
        <td>47.9</td>
        <td>2005-12-16</td>
        <td>2006-10-28</td>
        <td>2009-11-25</td>
        <td>66</td>
    </tr>
    <tr>
        <td>467</td>
        <td>NKB106007</td>
        <td>Dose ranging study of NK1 for OAB</td>
        <td>Urogenital</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>642</td>
        <td>0</td>
        <td>55.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>468</td>
        <td>NKF100092</td>
        <td>MDD Fixed Dose Study</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Angela Mcwhorter,Jennifer Bruce,Karen
            Frusciante,Megan Vaughan</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1693</td>
        <td>348</td>
        <td>356</td>
        <td>84.4</td>
        <td>85.3</td>
        <td>2004-10-22</td>
        <td>2006-06-02</td>
        <td>2009-11-25</td>
        <td>39</td>
    </tr>
    <tr>
        <td>469</td>
        <td>NKF100096</td>
        <td>MDD Fixed Dose Comparator Study</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Joanne Cedrone</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>547</td>
        <td>360</td>
        <td>362</td>
        <td>70.7</td>
        <td>54.4</td>
        <td>2005-06-02</td>
        <td>2006-05-24</td>
        <td>2009-11-25</td>
        <td>47</td>
    </tr>
    <tr>
        <td>470</td>
        <td>NKF100110</td>
        <td>SAD Fixed Dose Study</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Monica Lopez</td>
        <td>Completed</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>402</td>
        <td>227</td>
        <td>242</td>
        <td>37.0</td>
        <td>37.4</td>
        <td>2005-08-25</td>
        <td>2006-05-04</td>
        <td>2009-11-25</td>
        <td>29</td>
    </tr>
    <tr>
        <td>471</td>
        <td>NKG110733</td>
        <td>NKG110733</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>Source Unavailable</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>0</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>472</td>
        <td>NKG110833</td>
        <td>GW823296: Efficacy and Safety DR Study #1</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Erica Lawson,Leonie Christianson,Monica
            Lopez,Sookti Bhangu</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>464</td>
        <td>0</td>
        <td>66.9</td>
        <td>2009-11-25</td>
        <td>62</td>
    </tr>
    <tr>
        <td>473</td>
        <td>NKG111733</td>
        <td>GW823296: Efficacy and Safety in MDD</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Erica Lawson,Leonie Christianson,Monica
            Lopez</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>464</td>
        <td>0</td>
        <td>84.0</td>
        <td>2009-11-25</td>
        <td>21</td>
    </tr>
    <tr>
        <td>474</td>
        <td>NKG111833</td>
        <td>NKG111833</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>Source Unavailable</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>0</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>475</td>
        <td>NKI111364</td>
        <td>Vestipitant and Vofopitant 28day PSG study</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Monica Fiore</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>150</td>
        <td>0</td>
        <td>54.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>476</td>
        <td>NKO101287</td>
        <td>GW597599 1-Day IV Dose Ranging in Female
            Subjects</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Trisha Piontek</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>667</td>
        <td>630</td>
        <td>624</td>
        <td>70.6</td>
        <td>70.4</td>
        <td>2004-12-17</td>
        <td>2006-04-07</td>
        <td>2009-11-25</td>
        <td>67</td>
    </tr>
    <tr>
        <td>477</td>
        <td>NKP102847</td>
        <td>Eff and Saf GW679769/Citalopram Adjunct Therapy</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Jane St Lambert</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>400</td>
        <td>0</td>
        <td>106.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>478</td>
        <td>NKP103401</td>
        <td>SAD Fixed Dose 12-Wk Study of
            GW597599/Paroxetine</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Jane St Lambert,Martien Reddingius</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>260</td>
        <td>204</td>
        <td>202</td>
        <td>29.4</td>
        <td>29.9</td>
        <td>2004-11-15</td>
        <td>2005-05-21</td>
        <td>2009-11-25</td>
        <td>17</td>
    </tr>
    <tr>
        <td>480</td>
        <td>NKT102260</td>
        <td>Phase II One Day Dosing of GW679769 in PONV</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Tessa Creasy</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>789</td>
        <td>665</td>
        <td>701</td>
        <td>43.4</td>
        <td>41.3</td>
        <td>2002-03-15</td>
        <td>2005-07-29</td>
        <td>2009-11-25</td>
        <td>72</td>
    </tr>
    <tr>
        <td>481</td>
        <td>NKT102552</td>
        <td>Phase III GW679769 Study in PONV/PDNV</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Stephanie Derbyshire,Trisha Piontek</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>548</td>
        <td>462</td>
        <td>516</td>
        <td>26.1</td>
        <td>14.3</td>
        <td>2006-03-22</td>
        <td>2006-06-20</td>
        <td>2009-11-25</td>
        <td>70</td>
    </tr>
    <tr>
        <td>482</td>
        <td>NKT102553</td>
        <td>Phase III GW679769 Study in PONV</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Christopher Cunnane,Maura Watmuff,Stephanie
            Derbyshire,Trisha Piontek</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>525</td>
        <td>462</td>
        <td>482</td>
        <td>26.1</td>
        <td>15.0</td>
        <td>2006-03-21</td>
        <td>2006-06-27</td>
        <td>2009-11-25</td>
        <td>58</td>
    </tr>
    <tr>
        <td>483</td>
        <td>NKT107060</td>
        <td>Low Dose IV Push or Infusion</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>470</td>
        <td>0</td>
        <td>28.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>484</td>
        <td>NKV101983</td>
        <td>GW679769 for the Prevention of CINV in MEC</td>
        <td>Oncology - Supportive</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Judith Schnyder,Leah Lilienfeld</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>768</td>
        <td>708</td>
        <td>722</td>
        <td>32.0</td>
        <td>37.9</td>
        <td>2004-12-27</td>
        <td>2005-08-31</td>
        <td>2009-11-25</td>
        <td>130</td>
    </tr>
    <tr>
        <td>486</td>
        <td>NKV102551</td>
        <td>Phase III GW679769 in HEC</td>
        <td>Oncology - Supportive</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Eric Parks,Ina Camlett,Leah Lilienfeld,Lynne
            Coetzee,Muhammad Shoaib,Nellie Hudson,Oliver Wright,Sanjeev
            Shoor</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>854</td>
        <td>810</td>
        <td>811</td>
        <td>41.7</td>
        <td>32.4</td>
        <td>2006-11-06</td>
        <td>2007-05-11</td>
        <td>2009-11-25</td>
        <td>83</td>
    </tr>
    <tr>
        <td>487</td>
        <td>NKV110721</td>
        <td>1 Day IV casopitant for oxaliplatin induced
            nausea</td>
        <td>Oncology - Supportive</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Jaime Pecsi,Judith Bushong</td>
        <td>Treatment</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>748</td>
        <td>700</td>
        <td>712</td>
        <td>35.9</td>
        <td>39.0</td>
        <td>2008-03-10</td>
        <td>2008-11-11</td>
        <td>2009-11-25</td>
        <td>99</td>
    </tr>
    <tr>
        <td>488</td>
        <td>NKV20001</td>
        <td>GW679769 NK-1 Receptor Antagonist for CINV in
            HEC</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Sarah Taylor,Simon Thorn</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>532</td>
        <td>492</td>
        <td>495</td>
        <td>26.3</td>
        <td>28.7</td>
        <td>2005-02-08</td>
        <td>2005-08-12</td>
        <td>2009-11-25</td>
        <td>58</td>
    </tr>
    <tr>
        <td>489</td>
        <td>NN2100245</td>
        <td>nNRTI Experienced Study (Dose-defining)</td>
        <td>HIV</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>450</td>
        <td>0</td>
        <td>26.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>490</td>
        <td>NOA102777</td>
        <td>Acute Migraine POC SB823387</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>244</td>
        <td>0</td>
        <td>16.6</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>491</td>
        <td>NOS103325</td>
        <td>Migraine prophylaxis 2 part study</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>David Morrison,Frances Kinrade,Mark
            Briggs</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>615</td>
        <td>326</td>
        <td>422</td>
        <td>18.1</td>
        <td>78.7</td>
        <td>2005-10-27</td>
        <td>2007-04-23</td>
        <td>2009-11-25</td>
        <td>64</td>
    </tr>
    <tr>
        <td>492</td>
        <td>NPP100023</td>
        <td>Double-Blind , placebo-controlled study</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Irene Miller,Mark Khan,Setrina Hunter</td>
        <td>Start-Up</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>398</td>
        <td>0</td>
        <td>33.1</td>
        <td>245.1</td>
        <td>2009-11-25</td>
        <td>1</td>
    </tr>
    <tr>
        <td>493</td>
        <td>NPP101982</td>
        <td>PDN LTG XR-EU</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Irene Miller,Mark Khan,Setrina Hunter</td>
        <td>Start-Up</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>398</td>
        <td>0</td>
        <td>16.3</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>494</td>
        <td>NSB102852</td>
        <td>MDD Efficacy and Safety of GSK206136</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>372</td>
        <td>0</td>
        <td>54.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>495</td>
        <td>ODS100207</td>
        <td>DE943 - Mild/moderate asthma</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Andrew Sykes,Chris Holland,Susannah
            Hammond</td>
        <td>Start-Up</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>600</td>
        <td>0</td>
        <td>29.3</td>
        <td>2009-11-25</td>
        <td>7</td>
    </tr>
    <tr>
        <td>496</td>
        <td>OFA110631</td>
        <td>ofatumumab: Mthx failure+ structual damage</td>
        <td>Inflammation - RA</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>200</td>
        <td>0</td>
        <td>76.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>497</td>
        <td>OFA110632</td>
        <td>ofatumumab: TNF failure+ structual damage</td>
        <td>Inflammation - RA</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>522</td>
        <td>0</td>
        <td>88.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>498</td>
        <td>OFA110633</td>
        <td>ofatumumab in RA patients on DMARD therapy</td>
        <td>Inflammation - RA</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>alessandra perna,Amy Lee,Bettina Bruun,Carrie-Ann
            Anderson,Emer Doherty,Kjellaug Melvik,Lorraine Martin,Mette
            Kielsholm,Peter Critchley,Vladislav Kurtev</td>
        <td>Start-Up</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>1000</td>
        <td>0</td>
        <td>67.1</td>
        <td>72.9</td>
        <td>2009-11-25</td>
        <td>1</td>
    </tr>
    <tr>
        <td>499</td>
        <td>OFA110634</td>
        <td>ofatumumab in RA pts who failed &gt;1 TNF
            therapy</td>
        <td>Inflammation - RA</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>alessandra perna,Carrie-Ann Anderson,Christine
            Walsh,Khalid Amin,Kimiko Marshall,Kjellaug Melvik,Lesley
            Kahl,Steven Wolfe</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>77</td>
        <td>236</td>
        <td>49</td>
        <td>64.1</td>
        <td>102.9</td>
        <td>2008-01-03</td>
        <td>2009-11-25</td>
        <td>48</td>
    </tr>
    <tr>
        <td>500</td>
        <td>OFA110635</td>
        <td>ofatumumab in RA pts who have failed Mthx
            therapy</td>
        <td>Inflammation - RA</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>alessandra perna,Bettina Bruun,Carrie-Ann
            Anderson,Christine Walsh,Khalid Amin,Kimiko Marshall,Mette
            Kielsholm</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>277</td>
        <td>248</td>
        <td>163</td>
        <td>59.0</td>
        <td>102.9</td>
        <td>2008-01-02</td>
        <td>2009-11-25</td>
        <td>48</td>
    </tr>
    <tr>
        <td>501</td>
        <td>OFA110867</td>
        <td>Ofatumumab Subcutaneous PK/PD and bridging trial</td>
        <td>Inflammation - RA</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Steven Wolfe</td>
        <td>Recruitment</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>63</td>
        <td>70</td>
        <td>12</td>
        <td>55.1</td>
        <td>79.2</td>
        <td>2008-05-26</td>
        <td>2009-11-25</td>
        <td>31</td>
    </tr>
    <tr>
        <td>503</td>
        <td>OFA111537</td>
        <td>Phase III Study of Ofatumumab in Adult RA</td>
        <td>Inflammation - RA</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>alessandra perna,Shaista Hussain</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>1500</td>
        <td>0</td>
        <td>106.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>504</td>
        <td>OHB100637</td>
        <td>GW353162 in FMS</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Mary Elkins,Robin Monteith,Sarah Jarman</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>234</td>
        <td>0</td>
        <td>23.3</td>
        <td>2009-11-25</td>
        <td>2</td>
    </tr>
    <tr>
        <td>505</td>
        <td>OHB100775</td>
        <td>GW-353162 RLS Proof Of Concept</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Megan Vaughan,Narinder Lotay</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>140</td>
        <td>75</td>
        <td>76</td>
        <td>26.3</td>
        <td>29.9</td>
        <td>2004-04-27</td>
        <td>2004-09-27</td>
        <td>2009-11-25</td>
        <td>14</td>
    </tr>
    <tr>
        <td>506</td>
        <td>OHB103753</td>
        <td>MDD Flex Dose</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>364</td>
        <td>0</td>
        <td>47.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>507</td>
        <td>OHB103755</td>
        <td>MDD Flex Dose</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Denise Fontanilla</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>364</td>
        <td>0</td>
        <td>54.0</td>
        <td>2009-11-25</td>
        <td>3</td>
    </tr>
    <tr>
        <td>508</td>
        <td>OHB104406</td>
        <td>Radafaxine in Adult ADHD</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>240</td>
        <td>0</td>
        <td>42.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>509</td>
        <td>OHB105459</td>
        <td>MDD ABPM</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>250</td>
        <td>0</td>
        <td>41.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>510</td>
        <td>OHB105517</td>
        <td>Female Orgasm Disorder</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>80</td>
        <td>0</td>
        <td>44.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>511</td>
        <td>OHB105929</td>
        <td>FOD Mechanistic Study</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Joanne Cedrone</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>44</td>
        <td>0</td>
        <td>44.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>512</td>
        <td>OHB20004</td>
        <td>MDD Fixed Dose</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Denise Fontanilla,Janette Daves,Megan
            Vaughan,Michelle Gee</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>548</td>
        <td>0</td>
        <td>47.0</td>
        <td>2009-11-25</td>
        <td>7</td>
    </tr>
    <tr>
        <td>513</td>
        <td>OMB110911</td>
        <td>Phase III O-chlor vs. chlor IL CLL</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Allison Moore,Debra Pearson,Doug Fecteau,Kathleen
            DeRose,Oliver Wright</td>
        <td>Start-Up</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>444</td>
        <td>0</td>
        <td>158.1</td>
        <td>56.1</td>
        <td>2009-11-25</td>
        <td>62</td>
    </tr>
    <tr>
        <td>514</td>
        <td>OMB110913</td>
        <td>Phase III OFC vs. FC in relapsed CLL</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Allison Moore,Andrew Chilelli,Debra Pearson,Doug
            Fecteau,Kathleen DeRose,Nima Sonpal,Oliver Wright</td>
        <td>Start-Up</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>352</td>
        <td>0</td>
        <td>99.3</td>
        <td>2009-11-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>515</td>
        <td>OMB110914</td>
        <td>O retx + O mtn in CLL O responders who have
            relaps</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>80</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>516</td>
        <td>OMB110918</td>
        <td>ofa/bendamustine combo vs bendamustine mono-RRIL</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Allison Moore</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>338</td>
        <td>0</td>
        <td>163.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>517</td>
        <td>OMB110920</td>
        <td>PII ofa+chemo comb + maint for those who relapse</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>80</td>
        <td>0</td>
        <td>78.3</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>518</td>
        <td>OMB110921</td>
        <td>PhsII O in Waldenstroms</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Julie Switzky</td>
        <td>Start-Up</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>36</td>
        <td>0</td>
        <td>107.1</td>
        <td>2009-11-25</td>
        <td>6</td>
    </tr>
    <tr>
        <td>519</td>
        <td>OMB110923</td>
        <td>PhsII single agent in 2L Mantle Cell - GSK184115</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>26</td>
        <td>0</td>
        <td>81.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>520</td>
        <td>OMB110927</td>
        <td>PhII O + ICE or DHAP in relapsed DLBCL</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Doug Fecteau</td>
        <td>Start-Up</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>48</td>
        <td>0</td>
        <td>53.7</td>
        <td>2009-11-25</td>
        <td>7</td>
    </tr>
    <tr>
        <td>521</td>
        <td>OMB111148</td>
        <td>Ofatumumab Japan PhaseI study for NHL</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Akira Miyazato,Hisami Shimizu,Shigeomi
            Iimura</td>
        <td>Recruitment</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>3</td>
        <td>12</td>
        <td>3</td>
        <td>29.1</td>
        <td>64.1</td>
        <td>2008-09-18</td>
        <td>2009-11-25</td>
        <td>3</td>
    </tr>
    <tr>
        <td>522</td>
        <td>OPL104072</td>
        <td>AECOPD PILOT</td>
        <td>Anti Infectives</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>3000</td>
        <td>0</td>
        <td>82.4</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>523</td>
        <td>OPL104226</td>
        <td>AECOPD Stage II - Psychometric Validation Study</td>
        <td>Anti Infectives</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Irene Miller</td>
        <td>Completed</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>800</td>
        <td>222</td>
        <td>259</td>
        <td>53.7</td>
        <td>49.9</td>
        <td>2005-01-19</td>
        <td>2006-10-03</td>
        <td>2009-11-25</td>
        <td>129</td>
    </tr>
    <tr>
        <td>524</td>
        <td>OSM104972</td>
        <td>Single dose GSK315234 in RA patients</td>
        <td>BioPharm</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Andrea Campanile</td>
        <td>Start-Up</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>112</td>
        <td>0</td>
        <td>69.4</td>
        <td>93.9</td>
        <td>2009-11-25</td>
        <td>32</td>
    </tr>
    <tr>
        <td>525</td>
        <td>OTA105101</td>
        <td>ADME</td>
        <td>Urogenital</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Eilis O'Driscoll</td>
        <td>Completed</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>6</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>3</td>
    </tr>
    <tr>
        <td>526</td>
        <td>OTA105256</td>
        <td>Oxytocin PoC</td>
        <td>Urogenital</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Brendt Stier,Lisa Giancaterino,Marcella Tucci,Sarah
            Gross,Thomas Atkins</td>
        <td>Recruitment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>32</td>
        <td>75</td>
        <td>32</td>
        <td>142.7</td>
        <td>142.9</td>
        <td>2007-10-12</td>
        <td>2009-11-25</td>
        <td>35</td>
    </tr>
    <tr>
        <td>527</td>
        <td>OTA106034</td>
        <td>GSK221149 for PTL (dose-ranging, maintenance)</td>
        <td>Urogenital</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>415</td>
        <td>0</td>
        <td>78.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>528</td>
        <td>OTA111003</td>
        <td>Dose ranging study of GSK221149 in pre-term
            labor</td>
        <td>Urogenital</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Sharon Baptiste-Brown</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>125</td>
        <td>0</td>
        <td>50.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>529</td>
        <td>OXS104094</td>
        <td>Single Dose Sleep Model in healthy Volunteers</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Alessandro Pinna,Lesley Clement</td>
        <td>Completed</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>52</td>
        <td>0</td>
        <td>21.9</td>
        <td>24.3</td>
        <td>2007-05-30</td>
        <td>2009-11-25</td>
        <td>1</td>
    </tr>
    <tr>
        <td>530</td>
        <td>OXS109137</td>
        <td>Phase II DR Insomnia, 28D PSG</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Alessandro Pinna,Erica Bullock,Martien
            Reddingius</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>342</td>
        <td>0</td>
        <td>50.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>531</td>
        <td>OXS110722</td>
        <td>Long-term safety study</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Leonie Christianson</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>1500</td>
        <td>0</td>
        <td>41.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>532</td>
        <td>OXS110845</td>
        <td>Elderly PSG</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Leonie Christianson</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>50</td>
        <td>0</td>
        <td>50.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>533</td>
        <td>OXS111165</td>
        <td>Acute effect of SB649868 in adult primary
            insomnia</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Leonie Christianson</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>50</td>
        <td>0</td>
        <td>28.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>534</td>
        <td>PAD107271</td>
        <td>PPARdelta plus statin in hypercholesterolaemia</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Gail Kemp,Karita Saarinen</td>
        <td>Start-Up</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>192</td>
        <td>0</td>
        <td>30.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>535</td>
        <td>PGA105446</td>
        <td>Phase I Study of Nelarabine in Japan</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Masayuki Kanezaki</td>
        <td>Recruitment</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>13</td>
        <td>12</td>
        <td>11</td>
        <td>149.7</td>
        <td>177.9</td>
        <td>2006-08-30</td>
        <td>2009-11-25</td>
        <td>2</td>
    </tr>
    <tr>
        <td>537</td>
        <td>PIR105770</td>
        <td>Paroxetine for GAD in Children and Adolescents</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>265</td>
        <td>0</td>
        <td>98.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>538</td>
        <td>PIR109164</td>
        <td>PTSD Phase III study of Paroxetine</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Hirotaka Inoue,Risako Ito,Takeshi Kimura</td>
        <td>Treatment</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>5</td>
        <td>30</td>
        <td>4</td>
        <td>56.1</td>
        <td>31.4</td>
        <td>2008-02-07</td>
        <td>2008-08-27</td>
        <td>2009-11-25</td>
        <td>13</td>
    </tr>
    <tr>
        <td>539</td>
        <td>PKI108574</td>
        <td>GW856553X 15mg compared to placebo in subj w/
            MDD</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Elvira Ivanova,Heli Paat,Marcin Budzinski,Monica
            Lopez,Peeter Looke,Rabia Anselm,Stephanie Fraczek,Svetlana
            Udotova</td>
        <td>Statistical Analysis</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>78</td>
        <td>60</td>
        <td>30</td>
        <td>88.0</td>
        <td>77.1</td>
        <td>2007-09-12</td>
        <td>2008-05-28</td>
        <td>2009-11-25</td>
        <td>15</td>
    </tr>
    <tr>
        <td>351</td>
        <td>HPR105184</td>
        <td>385 in hepatically-impaired HIV patients</td>
        <td>HIV</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>40</td>
        <td>0</td>
        <td>80.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>352</td>
        <td>HPR20001</td>
        <td>Phase IIB Study of HIV-infected, PI-experienced
            su</td>
        <td>HIV</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Ines Barbosa,Jennifer Wilson,Paulina
            Tymkewycz,Steven Lauder,Tameika Stringfield</td>
        <td>Completed</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>289</td>
        <td>130</td>
        <td>147</td>
        <td>32.4</td>
        <td>28.4</td>
        <td>2005-03-23</td>
        <td>2006-01-25</td>
        <td>2009-11-25</td>
        <td>91</td>
    </tr>
    <tr>
        <td>353</td>
        <td>HPR30001</td>
        <td>385/r vs Std of Care in experienced pts</td>
        <td>HIV</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>804</td>
        <td>0</td>
        <td>55.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>354</td>
        <td>HPR30002</td>
        <td>385/r in experienced pts compared to Kaletra</td>
        <td>HIV</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>716</td>
        <td>0</td>
        <td>38.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>355</td>
        <td>HS2100275</td>
        <td>GH Suppression with &lt;=1 Year History</td>
        <td>Infectious Disease- Anti Viral</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Completed</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>955</td>
        <td>384</td>
        <td>384</td>
        <td>90.7</td>
        <td>87.0</td>
        <td>2004-06-16</td>
        <td>2006-01-25</td>
        <td>2009-11-25</td>
        <td>75</td>
    </tr>
    <tr>
        <td>356</td>
        <td>HS2108575</td>
        <td>An EU Pediatric PK Study</td>
        <td>Infectious Disease- Anti Viral</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>26</td>
        <td>0</td>
        <td>51.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>357</td>
        <td>HSP110035</td>
        <td>A PHASE IIA CLINICAL TRIAL OF GSK625433</td>
        <td>Infectious Disease- Anti Viral</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>165</td>
        <td>0</td>
        <td>19.4</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>358</td>
        <td>HTP109035</td>
        <td>Phase IIa Depression study</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Simone Chimeura</td>
        <td>Start-Up</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>150</td>
        <td>0</td>
        <td>44.7</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>359</td>
        <td>HYT104152</td>
        <td>Phase I Topotecan PK Characterization</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Reporting</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>16</td>
        <td>0</td>
        <td>34.6</td>
        <td>49.7</td>
        <td>2007-05-07</td>
        <td>2009-11-25</td>
        <td>1</td>
    </tr>
    <tr>
        <td>360</td>
        <td>HYT105962</td>
        <td>Oral or IV Topotecan plus Radiotherapy NSCLC</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Colleen Briner,Tracey Sessa</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE1</td>
        <td>NOSOURCE</td>
        <td>true</td>
        <td>false</td>
        <td>508</td>
        <td>242</td>
        <td>500</td>
        <td>221</td>
        <td>242.9</td>
        <td>164.1</td>
        <td>2006-12-06</td>
        <td>2009-11-25</td>
        <td>95</td>
    </tr>
    <tr>
        <td>361</td>
        <td>HYT105964</td>
        <td>Hycamtin (Dx5) +/- Avastin 2L Trtmt Ovarian
            Cancer</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>120</td>
        <td>0</td>
        <td>68.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>362</td>
        <td>HYT109091</td>
        <td>Safety, Tolera, &amp; pK of oral topotecan &amp;
            pazopani</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>January Baron,Joe Stoebenau</td>
        <td>Start-Up</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>40</td>
        <td>0</td>
        <td>130.6</td>
        <td>64.8</td>
        <td>2009-11-25</td>
        <td>3</td>
    </tr>
    <tr>
        <td>363</td>
        <td>HYT111127</td>
        <td>Oral Topotecan daily x5 combined with Avastin</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Christine Tucker,Kamalnayan Bhatt</td>
        <td>Recruitment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>20</td>
        <td>50</td>
        <td>12</td>
        <td>54.1</td>
        <td>73.4</td>
        <td>2008-07-01</td>
        <td>2009-11-25</td>
        <td>29</td>
    </tr>
    <tr>
        <td>364</td>
        <td>HZA106831</td>
        <td>Horizon vs GW685698 vs ICS comparator vs plac -
            EU</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>1000</td>
        <td>0</td>
        <td>28.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>365</td>
        <td>HZA106833</td>
        <td>Horizon vs GW685698 vs ICS comparator 24 wks -
            EU</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>1000</td>
        <td>0</td>
        <td>28.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>367</td>
        <td>HZA106849</td>
        <td>GSK159797 vs LABA vs placebo - EU</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>500</td>
        <td>0</td>
        <td>28.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>368</td>
        <td>HZA109895</td>
        <td>Pilot viral inoculation study with Advair and FP</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Brian Marks</td>
        <td>Data Management</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>187</td>
        <td>45</td>
        <td>16</td>
        <td>60.7</td>
        <td>47.4</td>
        <td>2007-10-16</td>
        <td>2008-07-24</td>
        <td>2009-11-25</td>
        <td>1</td>
    </tr>
    <tr>
        <td>369</td>
        <td>HZA109912</td>
        <td>Pilot allergen challenge study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Robert Bartle,Robin Morris</td>
        <td>Reporting</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>54</td>
        <td>30</td>
        <td>23</td>
        <td>37.0</td>
        <td>21.7</td>
        <td>2007-08-24</td>
        <td>2008-01-22</td>
        <td>2009-11-25</td>
        <td>2</td>
    </tr>
    <tr>
        <td>370</td>
        <td>HZC109634</td>
        <td>444 COPD dose ranging study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>1240</td>
        <td>0</td>
        <td>22.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>371</td>
        <td>HZC110945</td>
        <td>Exploratory COPD viral exacerbation study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>45</td>
        <td>0</td>
        <td>2.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>372</td>
        <td>HZC110946</td>
        <td>4wk 24hr serial spirometry 444 &amp; GW685698X in
            COPD</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>60</td>
        <td>0</td>
        <td>32.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>374</td>
        <td>I13106870</td>
        <td>PoC study study for GSK679586</td>
        <td>BioPharm</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Adrian Serone,Inderpal Panesar,Isabelle
            Drouet,Kevin Jenkins</td>
        <td>Start-Up</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>160</td>
        <td>0</td>
        <td>54.1</td>
        <td>53.1</td>
        <td>2009-11-25</td>
        <td>4</td>
    </tr>
    <tr>
        <td>375</td>
        <td>ING111521</td>
        <td>GSK1349572 POC Study in HIV Positive</td>
        <td>HIV</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Richard Stroder</td>
        <td>Reporting</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>53</td>
        <td>50</td>
        <td>35</td>
        <td>10.7</td>
        <td>2.3</td>
        <td>2008-06-25</td>
        <td>2008-07-08</td>
        <td>2009-11-25</td>
        <td>34</td>
    </tr>
    <tr>
        <td>376</td>
        <td>IPC101939</td>
        <td>Inhaled RD in COPD patients with G</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Christine Barrett,John Ackrill</td>
        <td>Treatment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>173</td>
        <td>105</td>
        <td>104</td>
        <td>54.0</td>
        <td>67.9</td>
        <td>2007-10-04</td>
        <td>2008-11-04</td>
        <td>2009-11-25</td>
        <td>19</td>
    </tr>
    <tr>
        <td>377</td>
        <td>IPR109129</td>
        <td>Dose-ranging study for intranasal GSK256066</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>640</td>
        <td>0</td>
        <td>5.9</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>378</td>
        <td>ITI101711</td>
        <td>TOPVENT</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Completed</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1217</td>
        <td>960</td>
        <td>961</td>
        <td>46.1</td>
        <td>52.4</td>
        <td>2005-09-28</td>
        <td>2006-07-14</td>
        <td>2009-11-25</td>
        <td>113</td>
    </tr>
    <tr>
        <td>379</td>
        <td>ITI101724</td>
        <td>Study in Low Risk Atrial Fibrillation Patients</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Completed</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>574</td>
        <td>470</td>
        <td>458</td>
        <td>43.1</td>
        <td>43.9</td>
        <td>2005-11-24</td>
        <td>2006-07-31</td>
        <td>2009-11-25</td>
        <td>154</td>
    </tr>
    <tr>
        <td>380</td>
        <td>ITI105668</td>
        <td>Japan Odiparcil Phase II</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Takayuki Iwase</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>70</td>
        <td>0</td>
        <td>17.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>381</td>
        <td>ITI106650</td>
        <td>Japan Phase II DB study for DVT preventiom</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Takayuki Iwase</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>270</td>
        <td>0</td>
        <td>72.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>382</td>
        <td>KG2105255</td>
        <td>12-week study in treatment naive T2DM subjects</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Gonzalo Simon,Jamie Lorimer,Karunakar Reddy,Leslie
            Nash,Rachel Kozak,Surya Nakkella</td>
        <td>Completed</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>929</td>
        <td>336</td>
        <td>336</td>
        <td>42.4</td>
        <td>40.3</td>
        <td>2007-01-23</td>
        <td>2007-10-18</td>
        <td>2009-11-25</td>
        <td>144</td>
    </tr>
    <tr>
        <td>383</td>
        <td>KG2107735</td>
        <td>12-week study in T2DM subjects taking metformin</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Gail Kemp,Linda Earland</td>
        <td>Start-Up</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>392</td>
        <td>0</td>
        <td>25.1</td>
        <td>2009-11-25</td>
        <td>1</td>
    </tr>
    <tr>
        <td>384</td>
        <td>KG2109954</td>
        <td>Pre-Screening Initiative KG2PsI01</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Completed</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>100</td>
        <td>2</td>
        <td>28.3</td>
        <td>1.0</td>
        <td>2007-02-05</td>
        <td>2007-02-05</td>
        <td>2009-11-25</td>
        <td>1</td>
    </tr>
    <tr>
        <td>385</td>
        <td>KG2110375</td>
        <td>QD Dosing Study in Treatment Naive T2DM Subjects</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Darlene Steele-Norwood,Gail Kemp,Karl
            Thorpe,Karunakar Reddy,Linda Earland,Rachel Kozak,Talya
            Smeyatsky</td>
        <td>Reporting</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>799</td>
        <td>252</td>
        <td>252</td>
        <td>35.3</td>
        <td>27.6</td>
        <td>2006-02-26</td>
        <td>2008-02-15</td>
        <td>2009-11-25</td>
        <td>173</td>
    </tr>
    <tr>
        <td>386</td>
        <td>KG2111186</td>
        <td>075 vs placebo</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Clara Marr</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>480</td>
        <td>0</td>
        <td>36.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>387</td>
        <td>KG2111218</td>
        <td>Met +075 vs Met + Pbo</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Clara Marr</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>408</td>
        <td>0</td>
        <td>36.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>388</td>
        <td>KGW108331</td>
        <td>Dose ranging study of GSK189075 in obesity</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>450</td>
        <td>0</td>
        <td>49.4</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>389</td>
        <td>KIN110732</td>
        <td>p38i, GW856553, PDN, 2b</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>500</td>
        <td>0</td>
        <td>28.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>390</td>
        <td>KOA105341</td>
        <td>SB-462795 for OA Phase II</td>
        <td>Musculoskeletal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Anna Rhesa Kallam,Erin Brown,Mia Martins</td>
        <td>Start-Up</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>1000</td>
        <td>0</td>
        <td>47.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>391</td>
        <td>KOA108731</td>
        <td>A study of Relacatib for OA</td>
        <td>Musculoskeletal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Hayley Crouch,Laurel Watts</td>
        <td>Start-Up</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>54</td>
        <td>0</td>
        <td>37.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>392</td>
        <td>LAM100034</td>
        <td>Epilepsy Partial Seizures Adjun therapy Lamictal
            X</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Connie Orander,Jenna McNeill,Mariana Di
            Laudo,Stephanie Fraczek</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>277</td>
        <td>191</td>
        <td>244</td>
        <td>67.1</td>
        <td>67.0</td>
        <td>2004-10-19</td>
        <td>2005-12-01</td>
        <td>2009-11-25</td>
        <td>157</td>
    </tr>
    <tr>
        <td>393</td>
        <td>LAM100036</td>
        <td>Epilepsy PGTC Adjun therapy LTG-XR in patient</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Connie Orander,Jenna McNeill,Mariana Di
            Laudo,Stephanie Fraczek</td>
        <td>Statistical Analysis</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>181</td>
        <td>140</td>
        <td>153</td>
        <td>123.3</td>
        <td>123.0</td>
        <td>2005-01-10</td>
        <td>2006-12-27</td>
        <td>2009-11-25</td>
        <td>159</td>
    </tr>
    <tr>
        <td>394</td>
        <td>LAM100118</td>
        <td>LTG for absence seizures</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Curtis Owens</td>
        <td>Completed</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>62</td>
        <td>53</td>
        <td>54</td>
        <td>60.9</td>
        <td>58.0</td>
        <td>2004-11-01</td>
        <td>2005-10-19</td>
        <td>2009-11-25</td>
        <td>23</td>
    </tr>
    <tr>
        <td>395</td>
        <td>LAM107844</td>
        <td>Japan Phase III study of BW430C</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Completed</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>102</td>
        <td>96</td>
        <td>102</td>
        <td>39.7</td>
        <td>33.3</td>
        <td>2006-08-07</td>
        <td>2007-03-16</td>
        <td>2009-11-25</td>
        <td>12</td>
    </tr>
    <tr>
        <td>396</td>
        <td>LAM20007</td>
        <td>Epilepsy in Infants (1mos-24mos)</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Robin Monteith</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>166</td>
        <td>225</td>
        <td>197</td>
        <td>255.0</td>
        <td>253.1</td>
        <td>2000-09-05</td>
        <td>2005-04-08</td>
        <td>2009-11-25</td>
        <td>74</td>
    </tr>
    <tr>
        <td>398</td>
        <td>LAM40124</td>
        <td>An Assessment of Behavioral Changes Associated
            wit</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Rachel Ballard,Rochelle Suffern</td>
        <td>Completed</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>312</td>
        <td>270</td>
        <td>274</td>
        <td>142.1</td>
        <td>150.7</td>
        <td>2003-09-19</td>
        <td>2006-04-21</td>
        <td>2009-11-25</td>
        <td>111</td>
    </tr>
    <tr>
        <td>399</td>
        <td>LAV108550</td>
        <td>Lavoltidine Clinical Pilot Study</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>212</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>400</td>
        <td>LBI108884</td>
        <td>Lamictal ODT &amp; Tx Satisfaction</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Christopher Henry</td>
        <td>Completed</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>16</td>
        <td>75</td>
        <td>99</td>
        <td>17.3</td>
        <td>4.3</td>
        <td>2000-01-04</td>
        <td>2008-01-10</td>
        <td>2009-11-25</td>
        <td>26</td>
    </tr>
    <tr>
        <td>401</td>
        <td>LEP103944</td>
        <td>IR to XR Switch (Publication)</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Robin Monteith</td>
        <td>Completed</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>10</td>
        <td>45</td>
        <td>44</td>
        <td>43.4</td>
        <td>33.1</td>
        <td>2005-10-21</td>
        <td>2006-05-09</td>
        <td>2009-11-25</td>
        <td>13</td>
    </tr>
    <tr>
        <td>402</td>
        <td>LEP105972</td>
        <td>LAM-XR PK in the Elderly</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Kathleen Harding,Rosemarie Pladna</td>
        <td>Recruitment</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>87</td>
        <td>170</td>
        <td>73</td>
        <td>94.4</td>
        <td>124.4</td>
        <td>2007-08-27</td>
        <td>2009-11-25</td>
        <td>64</td>
    </tr>
    <tr>
        <td>404</td>
        <td>LEP105976</td>
        <td>Co-Morbid Depression</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>332</td>
        <td>0</td>
        <td>84.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>405</td>
        <td>LEP108937</td>
        <td>LAM XR AED Interactions with Atorvastatin</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Kathleen Harding</td>
        <td>Reporting</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>119</td>
        <td>0</td>
        <td>23.4</td>
        <td>20.1</td>
        <td>2008-06-10</td>
        <td>2009-11-25</td>
        <td>1</td>
    </tr>
    <tr>
        <td>406</td>
        <td>LEV106718</td>
        <td>Dyslipidemia and vardenafil</td>
        <td>Urogenital</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Belinda Hereghty</td>
        <td>Completed</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>714</td>
        <td>366</td>
        <td>395</td>
        <td>37.1</td>
        <td>31.1</td>
        <td>2006-05-22</td>
        <td>2006-12-19</td>
        <td>2009-11-25</td>
        <td>65</td>
    </tr>
    <tr>
        <td>407</td>
        <td>LEV108959</td>
        <td>ED &amp; Metabolic Syndrome</td>
        <td>Urogenital</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Belinda Cao</td>
        <td>Start-Up</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>212</td>
        <td>0</td>
        <td>28.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>408</td>
        <td>LEV112511</td>
        <td>Endurance II Levitra Study</td>
        <td>Urogenital</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>510</td>
        <td>0</td>
        <td>38.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>409</td>
        <td>LEX106430</td>
        <td>Lexiva/r BID to Lexiva/r QD</td>
        <td>HIV</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Janice Royall</td>
        <td>Reporting</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>291</td>
        <td>214</td>
        <td>210</td>
        <td>89.1</td>
        <td>90.4</td>
        <td>2006-05-15</td>
        <td>2008-02-01</td>
        <td>2009-11-25</td>
        <td>67</td>
    </tr>
    <tr>
        <td>410</td>
        <td>LOV112742</td>
        <td>Outcomes Study of Lovaza 4gr/day - GSK2212836</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>8500</td>
        <td>0</td>
        <td>80.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>411</td>
        <td>LP2105521</td>
        <td>SB-659032 POC Study</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Lois Wentzell</td>
        <td>Start-Up</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>60</td>
        <td>0</td>
        <td>48.6</td>
        <td>2009-11-25</td>
        <td>12</td>
    </tr>
    <tr>
        <td>412</td>
        <td>LPL100601</td>
        <td>CHD+ Outcome Study</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Claes Held,Hisami Shimizu,Margareta Forsman,Marie
            Jarosz,Mary Bevivino,Matts Hogberg,Monica Gangal,Oliver-Kai
            Kante,Patricia Connolly,Rachel Lunn,Rachel Russell,Shigeru
            Yagi,Taeko Yonekawa,Takayuki Iwase,Talya Smeyatsky,Terese
            Womer,Ulrika Boden,Viviana Garay</td>
        <td>Start-Up</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>15500</td>
        <td>0</td>
        <td>78.7</td>
        <td>2009-11-25</td>
        <td>393</td>
    </tr>
    <tr>
        <td>413</td>
        <td>LPL104884</td>
        <td>12 week dose-ranging study with three 480848
            doses</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Completed</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1315</td>
        <td>920</td>
        <td>969</td>
        <td>28.6</td>
        <td>27.7</td>
        <td>2005-01-09</td>
        <td>2006-03-31</td>
        <td>2009-11-25</td>
        <td>144</td>
    </tr>
    <tr>
        <td>414</td>
        <td>LPL110118</td>
        <td>Japan Phase II study of SB-480848</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Hisami Shimizu,Shigeru Yagi,Taeko Yonekawa,Takayuki
            Iwase</td>
        <td>Recruitment</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>116</td>
        <td>120</td>
        <td>108</td>
        <td>27.1</td>
        <td>66.4</td>
        <td>2008-08-26</td>
        <td>2009-11-25</td>
        <td>9</td>
    </tr>
    <tr>
        <td>415</td>
        <td>LPL110736</td>
        <td>SB480848 Japan Phase I repeat</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Shigeru Nohda</td>
        <td>Completed</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>18</td>
        <td>0</td>
        <td>-1.4</td>
        <td>1.4</td>
        <td>2008-01-24</td>
        <td>2009-11-25</td>
        <td>2</td>
    </tr>
    <tr>
        <td>416</td>
        <td>LPT108741</td>
        <td>Discontinuation Sudy of Tykerb w/ ErbB2 + cancer</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Tracey Sessa</td>
        <td>Treatment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>32</td>
        <td>0</td>
        <td>49.0</td>
        <td>49.0</td>
        <td>2008-04-02</td>
        <td>2009-11-25</td>
        <td>20</td>
    </tr>
    <tr>
        <td>417</td>
        <td>LPT109096</td>
        <td>A Randomized Trial of Preoperative Tykerb (T)
            plus</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>January Baron,Tracey Sessa</td>
        <td>Recruitment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>42</td>
        <td>99</td>
        <td>39</td>
        <td>101.3</td>
        <td>123.9</td>
        <td>2007-08-07</td>
        <td>2009-11-25</td>
        <td>36</td>
    </tr>
    <tr>
        <td>418</td>
        <td>LPT109098</td>
        <td>Lapatinib w/ Oral Topotecan subj w/ adv sol
            tumors</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Colleen Briner,Suzanne Strayhorn</td>
        <td>Start-Up</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>30</td>
        <td>0</td>
        <td>116.7</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>419</td>
        <td>LPT109747</td>
        <td>correlation of lapatinib induced
            flouropyrimidine</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Colleen Briner,Dawn Weeks,Natalia Dralova,Patricia
            Haney,Stephanie Smith</td>
        <td>Recruitment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>29</td>
        <td>64</td>
        <td>19</td>
        <td>98.4</td>
        <td>95.2</td>
        <td>2007-03-17</td>
        <td>2009-11-25</td>
        <td>22</td>
    </tr>
    <tr>
        <td>420</td>
        <td>LPT109795</td>
        <td>P1 study of ACL followed by THL followed by HL</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>100</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>421</td>
        <td>LPT111110</td>
        <td>comb vinorelbine + lapa 2nd line breast</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Amy Kline</td>
        <td>Recruitment</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>8</td>
        <td>60</td>
        <td>7</td>
        <td>71.1</td>
        <td>75.9</td>
        <td>2008-06-23</td>
        <td>2009-11-25</td>
        <td>54</td>
    </tr>
    <tr>
        <td>422</td>
        <td>LPT111111</td>
        <td>Combo nab-paclitaxel + lapa 1st line breast</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Amy Kline</td>
        <td>Recruitment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>5</td>
        <td>60</td>
        <td>4</td>
        <td>71.3</td>
        <td>74.8</td>
        <td>2008-07-02</td>
        <td>2009-11-25</td>
        <td>99</td>
    </tr>
    <tr>
        <td>424</td>
        <td>MAD103894</td>
        <td>Insomnia 28-day PSG Tolerance Study</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Erica Bullock,Lisa Durham,Michelle Gee</td>
        <td>Completed</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>2476</td>
        <td>321</td>
        <td>342</td>
        <td>49.0</td>
        <td>55.6</td>
        <td>2006-01-02</td>
        <td>2006-12-15</td>
        <td>2009-11-25</td>
        <td>104</td>
    </tr>
    <tr>
        <td>425</td>
        <td>MAD105514</td>
        <td>Insomnia Dose Ranging Study</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Michelle Gee,Rochelle Suffern</td>
        <td>Completed</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>696</td>
        <td>120</td>
        <td>122</td>
        <td>52.4</td>
        <td>55.1</td>
        <td>2006-01-23</td>
        <td>2006-12-15</td>
        <td>2009-11-25</td>
        <td>35</td>
    </tr>
    <tr>
        <td>426</td>
        <td>MAD105516</td>
        <td>Time of Administration Study</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Althea Wilson,Andrea Schmid,Brandy Isaacks,Dave
            Fewell,Ellen Holloway,Eva Matejka,Jeffrey Beckman,Linda
            Harris,Melinda Millard,Michelle Gee,Rochelle
            Suffern,Stephanie Phillips</td>
        <td>Completed</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>268</td>
        <td>58</td>
        <td>68</td>
        <td>51.1</td>
        <td>51.0</td>
        <td>2006-05-19</td>
        <td>2007-03-22</td>
        <td>2009-11-25</td>
        <td>37</td>
    </tr>
    <tr>
        <td>427</td>
        <td>MAD106599</td>
        <td>Comparative Cognition Study</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Marika Vousden</td>
        <td>Completed</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>75</td>
        <td>0</td>
        <td>23.7</td>
        <td>2006-12-09</td>
        <td>2009-11-25</td>
        <td>2</td>
    </tr>
    <tr>
        <td>428</td>
        <td>MAD107448</td>
        <td>Elderly long-term efficacy</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Michelle Gee</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>450</td>
        <td>0</td>
        <td>39.9</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>429</td>
        <td>MAD108068</td>
        <td>Casopitant Nocturnal Awakening Protocol (CNAP)</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Hiba Tappouni</td>
        <td>Start-Up</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>40</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>1</td>
    </tr>
    <tr>
        <td>430</td>
        <td>MAD110850</td>
        <td>Casopitant 28-Day Tolerance Study</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>322</td>
        <td>0</td>
        <td>51.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>432</td>
        <td>MD7110852</td>
        <td>Pazopanib eye drop dose finding wet AMD
            treatment</td>
        <td>Musculoskeletal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>John Norris</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>500</td>
        <td>0</td>
        <td>25.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>433</td>
        <td>MEA104531</td>
        <td>Mepolizumab in Severe Asthma</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Christina Tyren,Delphine Lepailleur-Enouf,Eun Soon
            Park,Jennifer Gidley,Kay-Uwe Heuer,Marie Duggan,Min-Jung
            Lim,Niek Vermue,Sarah Walmsley-McCarthy,Sebastian
            DiNatale,Viviana Garay</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>272</td>
        <td>0</td>
        <td>19.4</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>434</td>
        <td>MEE103219</td>
        <td>PK in pediatric EE</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Cuancha Serrant,Wendy Hamon</td>
        <td>Data Management</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>113</td>
        <td>72</td>
        <td>84</td>
        <td>93.6</td>
        <td>90.1</td>
        <td>2006-09-11</td>
        <td>2008-03-07</td>
        <td>2009-11-25</td>
        <td>34</td>
    </tr>
    <tr>
        <td>435</td>
        <td>MEE103226</td>
        <td>Adult EE</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Margaret Byrne</td>
        <td>Completed</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>13</td>
        <td>10</td>
        <td>11</td>
        <td>22.1</td>
        <td>23.1</td>
        <td>2005-12-27</td>
        <td>2006-05-16</td>
        <td>2009-11-25</td>
        <td>1</td>
    </tr>
    <tr>
        <td>436</td>
        <td>MEE105872</td>
        <td>Adult EE study- Mepolizumab</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>75</td>
        <td>0</td>
        <td>50.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>437</td>
        <td>MET111645</td>
        <td>XL880 phase I/II HCC</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Start-Up</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>40</td>
        <td>0</td>
        <td>61.7</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>438</td>
        <td>MKC101614</td>
        <td>SB-681323 28d study in COPD patients</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Eva Gomez</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>173</td>
        <td>82</td>
        <td>71</td>
        <td>28.3</td>
        <td>32.4</td>
        <td>2005-07-12</td>
        <td>2006-01-18</td>
        <td>2009-11-25</td>
        <td>17</td>
    </tr>
    <tr>
        <td>439</td>
        <td>MKC106954</td>
        <td>SB-681323 12 week COPD patient study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Paul Russell</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>200</td>
        <td>0</td>
        <td>45.3</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>440</td>
        <td>MKI102428</td>
        <td>GW856553X 12 week RD study in COPD</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Anfal Ibrahim,Dilini Reynold,Eva Gomez,Faye
            Jamali</td>
        <td>Recruitment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>254</td>
        <td>315</td>
        <td>145</td>
        <td>68.1</td>
        <td>97.9</td>
        <td>2008-02-14</td>
        <td>2009-11-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>441</td>
        <td>MKI110007</td>
        <td>GW856553 Severe COPD exercise tolerance study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Eva Gomez</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>200</td>
        <td>0</td>
        <td>38.1</td>
        <td>2009-11-25</td>
        <td>4</td>
    </tr>
    <tr>
        <td>442</td>
        <td>MKN109419</td>
        <td>R, DB, PBO-controlled study of SB681323</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>500</td>
        <td>0</td>
        <td>31.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>443</td>
        <td>MMY106755</td>
        <td>GW856553 in multiple myeloma</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Ross Harding</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>40</td>
        <td>0</td>
        <td>16.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>444</td>
        <td>MPX111349</td>
        <td>XP13512 LTS IN MIGRAINE PROPHYLAXIS</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Joanne Cedrone</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>600</td>
        <td>0</td>
        <td>18.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>445</td>
        <td>MPX111368</td>
        <td>XP13512 Pivotal Efficacy Study</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>840</td>
        <td>0</td>
        <td>20.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>446</td>
        <td>MPX111369</td>
        <td>XP13512 Pivotal Efficacy Study</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Karen Ryan</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>840</td>
        <td>0</td>
        <td>20.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>447</td>
        <td>MPX111381</td>
        <td>XP in migraine prophylaxis Phase 2B</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Alison Wentz,Gema Gomez,Joanne Cedrone,Sookti
            Bhangu</td>
        <td>Recruitment</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>436</td>
        <td>528</td>
        <td>45</td>
        <td>23.6</td>
        <td>66.4</td>
        <td>2008-08-28</td>
        <td>2009-11-25</td>
        <td>68</td>
    </tr>
    <tr>
        <td>448</td>
        <td>NAA104606</td>
        <td>SB773812 POC</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Kimberly Sue-Ling,Lewis Millen,Mary Bevivino,Mary
            Elkins</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>379</td>
        <td>338</td>
        <td>319</td>
        <td>80.0</td>
        <td>80.0</td>
        <td>2005-09-20</td>
        <td>2007-03-29</td>
        <td>2009-11-25</td>
        <td>53</td>
    </tr>
    <tr>
        <td>449</td>
        <td>NAA108434</td>
        <td>Efficacy in Acute Schizophrenia vs OLZ</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Connie Orander,Elena Shvartsman,Heinz Richter,Lewis
            Millen,Petra Hermanova,Tina Blajeva,Troy Longley</td>
        <td>Start-Up</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>690</td>
        <td>0</td>
        <td>57.4</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>450</td>
        <td>NAA108444</td>
        <td>Efficacy in Acute Mania</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>560</td>
        <td>0</td>
        <td>106.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>451</td>
        <td>NAA108506</td>
        <td>Fixed Dose Continuation Study in Schizophrenia</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>510</td>
        <td>0</td>
        <td>58.6</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>452</td>
        <td>NAA110902</td>
        <td>Efficacy in Acute Schizophrenia vs OLZ</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Connie Orander,Elena Shvartsman,Irena
            Bartosova,Laetitia Roustand,Lewis Millen,Marcin
            Budzinski,Troy Longley</td>
        <td>Start-Up</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>635</td>
        <td>0</td>
        <td>57.4</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>453</td>
        <td>NAA110905</td>
        <td>Twelve Month Long Term Safety and Tolerability</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>480</td>
        <td>0</td>
        <td>50.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>454</td>
        <td>NAA110906</td>
        <td>Effect on Treatment Resistance</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>240</td>
        <td>0</td>
        <td>67.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>456</td>
        <td>NAI107871</td>
        <td>IV Relenza in Hospitalized Patients</td>
        <td>Infectious Disease- Anti Viral</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>100</td>
        <td>0</td>
        <td>50.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>457</td>
        <td>NAI107873</td>
        <td>IV Relenza in Nursing Home Patients</td>
        <td>Infectious Disease- Anti Viral</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>375</td>
        <td>0</td>
        <td>50.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>458</td>
        <td>NAI107934</td>
        <td>IV Relenza in Immunocompromised Patients</td>
        <td>Infectious Disease- Anti Viral</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>50</td>
        <td>0</td>
        <td>50.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>540</td>
        <td>PKI111353</td>
        <td>GW856553X in Patients with MDD and inflammation
            US</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Start-Up</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>80</td>
        <td>0</td>
        <td>38.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>541</td>
        <td>PM1111138</td>
        <td>FDG-PET/CT QD/BID study</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Angela Harter,Karen Chalk</td>
        <td>Start-Up</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>90</td>
        <td>0</td>
        <td>21.0</td>
        <td>2009-11-25</td>
        <td>4</td>
    </tr>
    <tr>
        <td>542</td>
        <td>PM111138</td>
        <td>PM111138</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>Source Unavailable</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>0</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>543</td>
        <td>PMK103349</td>
        <td>6-month dosing in CHD patients</td>
        <td>Cardio &amp; Urology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Rachel James</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>350</td>
        <td>0</td>
        <td>41.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>544</td>
        <td>PMK103351</td>
        <td>3-wk dosing in patients undergoing planned PCI</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Rachel James</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>161</td>
        <td>90</td>
        <td>93</td>
        <td>71.1</td>
        <td>70.9</td>
        <td>2006-03-28</td>
        <td>2007-06-25</td>
        <td>2009-11-25</td>
        <td>19</td>
    </tr>
    <tr>
        <td>545</td>
        <td>PMK105588</td>
        <td>GW856553 POC study</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>120</td>
        <td>0</td>
        <td>48.3</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>546</td>
        <td>PMK108274</td>
        <td>Non-invasive imaging study of SB-68132</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>50</td>
        <td>0</td>
        <td>42.3</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>547</td>
        <td>PMK108301</td>
        <td>Bilateral CEA study of SB-681323 vs placebo</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>50</td>
        <td>0</td>
        <td>56.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>548</td>
        <td>PXN110448</td>
        <td>PDN DRF</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Carrie Taylor,Dawn Rogers,Doris Cooper,Kathleen
            Harding,Rochelle Suffern,Samantha Warren</td>
        <td>Treatment</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1013</td>
        <td>392</td>
        <td>422</td>
        <td>33.6</td>
        <td>29.0</td>
        <td>2008-03-18</td>
        <td>2008-09-24</td>
        <td>2009-11-25</td>
        <td>168</td>
    </tr>
    <tr>
        <td>549</td>
        <td>PXN110527</td>
        <td>PHN-DIFF</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Carrie Taylor,Dawn Rogers,Kathleen Harding,Rochelle
            Suffern,Samantha Warren</td>
        <td>Recruitment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>165</td>
        <td>164</td>
        <td>48</td>
        <td>54.3</td>
        <td>94.8</td>
        <td>2008-03-20</td>
        <td>2009-11-25</td>
        <td>86</td>
    </tr>
    <tr>
        <td>550</td>
        <td>PXN110748</td>
        <td>PHN DRF</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Carrie McClung,Carrie Taylor,Kathleen
            Harding,Rochelle Suffern,Samantha Warren</td>
        <td>Recruitment</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>622</td>
        <td>368</td>
        <td>236</td>
        <td>51.1</td>
        <td>95.2</td>
        <td>2008-02-06</td>
        <td>2009-11-25</td>
        <td>104</td>
    </tr>
    <tr>
        <td>551</td>
        <td>RA1100849</td>
        <td>SB-681323 28d RD study in RA patients</td>
        <td>Inflammation - RA</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Kjellaug Melvik</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>204</td>
        <td>84</td>
        <td>78</td>
        <td>51.1</td>
        <td>50.7</td>
        <td>2005-11-14</td>
        <td>2006-09-08</td>
        <td>2009-11-25</td>
        <td>41</td>
    </tr>
    <tr>
        <td>552</td>
        <td>RA1100854</td>
        <td>SB-681323 12 week RD study in RA</td>
        <td>Inflammation - RA</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Fiona O'Neill</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>150</td>
        <td>0</td>
        <td>31.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>553</td>
        <td>RA1104046</td>
        <td>SB-681323 SD PD study in RA patients</td>
        <td>Inflammation - RA</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Kjellaug Melvik</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>213</td>
        <td>77</td>
        <td>77</td>
        <td>60.0</td>
        <td>62.7</td>
        <td>2005-06-21</td>
        <td>2006-08-01</td>
        <td>2009-11-25</td>
        <td>28</td>
    </tr>
    <tr>
        <td>554</td>
        <td>RAD104394</td>
        <td>GW353162 Dose Range study in obese subjects</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Jessica Jolly,Samantha Wright</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>375</td>
        <td>0</td>
        <td>25.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>555</td>
        <td>RES111453</td>
        <td>Circulating tumor cells in NSCLC</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>50</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>556</td>
        <td>ROF102100</td>
        <td>Fibromyalgia Ropinirole CR</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Sarah Jarman,Ursula Unvericht</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>209</td>
        <td>160</td>
        <td>183</td>
        <td>18.1</td>
        <td>20.1</td>
        <td>2004-02-02</td>
        <td>2005-03-10</td>
        <td>2009-11-25</td>
        <td>22</td>
    </tr>
    <tr>
        <td>557</td>
        <td>ROP105323</td>
        <td>Requip CR Phase IIIb</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Sixolelwe Belgrave</td>
        <td>Completed</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>405</td>
        <td>344</td>
        <td>349</td>
        <td>41.6</td>
        <td>42.7</td>
        <td>2006-07-03</td>
        <td>2007-02-23</td>
        <td>2009-11-25</td>
        <td>83</td>
    </tr>
    <tr>
        <td>558</td>
        <td>ROP106064</td>
        <td>Japan ReQuip Open Parkinson's Disease</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Yoshifumi Gotoh</td>
        <td>Treatment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>66</td>
        <td>60</td>
        <td>62</td>
        <td>51.4</td>
        <td>48.6</td>
        <td>2007-04-09</td>
        <td>2008-02-21</td>
        <td>2009-11-25</td>
        <td>16</td>
    </tr>
    <tr>
        <td>559</td>
        <td>ROR104836</td>
        <td>D-B, P-C, P-G (26 weeks) + O- L (40 wks): rop</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Dagmar Theis,Elena Garcia Mendez,Julian Lopez
            Espada,Maddy Kelly,Raihana Ehsanullah,Setrina
            Hunter</td>
        <td>Statistical Analysis</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>536</td>
        <td>400</td>
        <td>404</td>
        <td>74.6</td>
        <td>61.3</td>
        <td>2006-03-20</td>
        <td>2007-05-16</td>
        <td>2009-11-25</td>
        <td>39</td>
    </tr>
    <tr>
        <td>560</td>
        <td>ROX104805</td>
        <td>Ropinirole XR Switch Study</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Christopher Henry,Sylvia White</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>164</td>
        <td>156</td>
        <td>135</td>
        <td>58.1</td>
        <td>40.0</td>
        <td>2005-11-14</td>
        <td>2006-08-10</td>
        <td>2009-11-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>561</td>
        <td>ROX107846</td>
        <td>ReQuip XR RLS Phase ll study</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Atsuyo Kurata,Erika Mitsuyama,Kaoru
            Fujikura,Masanari Yazawa,Masumi Matsueda,Nobuhiko Okuda,Yuka
            Kunitomi</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>37</td>
        <td>30</td>
        <td>35</td>
        <td>17.6</td>
        <td>13.6</td>
        <td>2007-08-23</td>
        <td>2007-10-26</td>
        <td>2009-11-25</td>
        <td>16</td>
    </tr>
    <tr>
        <td>563</td>
        <td>RPD105837</td>
        <td>Nighttime dosing in PD patients with morning
            sympt</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Christopher Henry,Setrina Hunter</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>200</td>
        <td>0</td>
        <td>28.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>564</td>
        <td>RPD106504</td>
        <td>Requip PD Monotherapy</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Christopher Henry</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>140</td>
        <td>0</td>
        <td>28.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>565</td>
        <td>RRL103660</td>
        <td>RLS PSG Latency</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Ashley Hall,Jeffery Ellis,Keri Klontz,Shannon
            Ivey-Morgan,Sheila Alvarez-Marsh</td>
        <td>Completed</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>312</td>
        <td>216</td>
        <td>39</td>
        <td>27.0</td>
        <td>21.9</td>
        <td>2006-10-17</td>
        <td>2007-03-05</td>
        <td>2009-11-25</td>
        <td>53</td>
    </tr>
    <tr>
        <td>566</td>
        <td>RRL103663</td>
        <td>RLS Polysomnography Study</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Jeffery Ellis</td>
        <td>Start-Up</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>216</td>
        <td>0</td>
        <td>28.1</td>
        <td>2009-11-25</td>
        <td>5</td>
    </tr>
    <tr>
        <td>675</td>
        <td>TRX109011</td>
        <td>Trexima vs butalbital</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Melissa Jewett</td>
        <td>Recruitment</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>294</td>
        <td>500</td>
        <td>167</td>
        <td>59.6</td>
        <td>102.8</td>
        <td>2008-02-07</td>
        <td>2009-11-25</td>
        <td>174</td>
    </tr>
    <tr>
        <td>676</td>
        <td>TRX109013</td>
        <td>Trexima vs butalbitol</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Melissa Jewett</td>
        <td>Recruitment</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>308</td>
        <td>500</td>
        <td>166</td>
        <td>60.7</td>
        <td>103.2</td>
        <td>2007-12-19</td>
        <td>2009-11-25</td>
        <td>55</td>
    </tr>
    <tr>
        <td>677</td>
        <td>TXA107563</td>
        <td>Trexima in treatment of probable migraine w/o
            aura</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>David Goodman,Kerrick Wilson,Patti Owen</td>
        <td>Completed</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>5134</td>
        <td>680</td>
        <td>687</td>
        <td>61.3</td>
        <td>58.1</td>
        <td>2006-09-14</td>
        <td>2007-10-29</td>
        <td>2009-11-25</td>
        <td>72</td>
    </tr>
    <tr>
        <td>678</td>
        <td>TXA107977</td>
        <td>Suma/Naprox Long Term Safety</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Janice Royall</td>
        <td>Treatment</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>48</td>
        <td>650</td>
        <td>656</td>
        <td>64.6</td>
        <td>62.0</td>
        <td>2007-01-18</td>
        <td>2008-08-25</td>
        <td>2009-11-25</td>
        <td>81</td>
    </tr>
    <tr>
        <td>679</td>
        <td>TXA107979</td>
        <td>Suma/Naprox Efficacy in Adolescents</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Janette Daves,Nicole Cecil</td>
        <td>Recruitment</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>3</td>
        <td>765</td>
        <td>0</td>
        <td>52.1</td>
        <td>56.5</td>
        <td>2008-12-01</td>
        <td>2009-11-25</td>
        <td>415</td>
    </tr>
    <tr>
        <td>680</td>
        <td>TXA107997</td>
        <td>TXA107997</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>Source Unavailable</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>0</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>681</td>
        <td>TXA110948</td>
        <td>Chronic Blood Pressure Effects of Trexima</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>David Goodman</td>
        <td>Recruitment</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1</td>
        <td>420</td>
        <td>1</td>
        <td>21.0</td>
        <td>54.8</td>
        <td>2008-11-20</td>
        <td>2009-11-25</td>
        <td>63</td>
    </tr>
    <tr>
        <td>682</td>
        <td>VEG102616</td>
        <td>VEGF -GW786034 In Renal Cancer Patients (Phase
            II)</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Katherine Baker</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>295</td>
        <td>225</td>
        <td>0</td>
        <td>102.7</td>
        <td>54.0</td>
        <td>2005-10-24</td>
        <td>2006-10-17</td>
        <td>2009-11-25</td>
        <td>85</td>
    </tr>
    <tr>
        <td>683</td>
        <td>VEG104642</td>
        <td>016 + 034 in Renal</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Katherine Baker,Poul Nielsen</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>50</td>
        <td>0</td>
        <td>67.6</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>684</td>
        <td>VEG105192</td>
        <td>Pazopanib (GW786034) in metastatic RCC</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Angel Uriol,Dilini Reynold,Fiona Shields,Harini
            Ramakrishnan,Jackie Gilbert,Laurie Baylor Curtis,Nadia
            Romano</td>
        <td>Treatment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>550</td>
        <td>400</td>
        <td>434</td>
        <td>83.7</td>
        <td>51.4</td>
        <td>2003-12-05</td>
        <td>2007-03-28</td>
        <td>2009-11-25</td>
        <td>109</td>
    </tr>
    <tr>
        <td>685</td>
        <td>VEG105276</td>
        <td>Phase III 1L ErbB2 over-expressing open-label,
            mul</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Amy McLaren</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>605</td>
        <td>0</td>
        <td>136.1</td>
        <td>2009-11-25</td>
        <td>1</td>
    </tr>
    <tr>
        <td>686</td>
        <td>VEG105277</td>
        <td>GW786034 plus Lapatinib in Meta Gastric Cancer</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>100</td>
        <td>0</td>
        <td>71.7</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>687</td>
        <td>VEG105279</td>
        <td>GW786034 plus Lapatinib in Head and Neck Cancer</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>100</td>
        <td>0</td>
        <td>65.4</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>688</td>
        <td>VEG105281</td>
        <td>GW786034 plus Lapatinib in Meta Cervical Cancer</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Angela Gibson-White,Barbara Ibarguchi,Claire
            Marsden,Hema Raval,Jacquelyn Alber,Laurie Baylor
            Curtis,Patricia Davies,Stephanie Smith</td>
        <td>Treatment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>335</td>
        <td>210</td>
        <td>228</td>
        <td>89.7</td>
        <td>62.0</td>
        <td>2006-11-23</td>
        <td>2008-01-23</td>
        <td>2009-11-25</td>
        <td>72</td>
    </tr>
    <tr>
        <td>689</td>
        <td>VEG105284</td>
        <td>GW786034 plus Lapatinib in Meta Cholang Cancer</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>100</td>
        <td>0</td>
        <td>65.6</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>690</td>
        <td>VEG105285</td>
        <td>GW786034 plus Lapatinib in Hepato Cancer</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>100</td>
        <td>0</td>
        <td>65.9</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>692</td>
        <td>VEG105292</td>
        <td>Phase III adjuvant French Study</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Start-Up</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>808</td>
        <td>0</td>
        <td>75.7</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>693</td>
        <td>VEG105298</td>
        <td>GW786034 and Lapatinib NeoAd in MBC</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>50</td>
        <td>0</td>
        <td>17.7</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>694</td>
        <td>VEG105302</td>
        <td>GW786034 and Lapatinib NeoAd in MBC</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>50</td>
        <td>0</td>
        <td>17.7</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>695</td>
        <td>VEG105304</td>
        <td>GW786034 as 2L in Ovarian</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>500</td>
        <td>0</td>
        <td>106.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>696</td>
        <td>VEG105440</td>
        <td>MDC</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Michele Sample</td>
        <td>Planned</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>40</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>697</td>
        <td>VEG105524</td>
        <td>Pazo + dual chemotherapy in 1st line NSCLC - US</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>840</td>
        <td>0</td>
        <td>54.3</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>698</td>
        <td>VEG105525</td>
        <td>GW786034 plus Chemo in Meta Breast Cancer</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>324</td>
        <td>0</td>
        <td>54.6</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>700</td>
        <td>VEG107149</td>
        <td>Ph II Pazopanib in Mesothelioma 2L</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>31</td>
        <td>0</td>
        <td>27.4</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>701</td>
        <td>VEG107516</td>
        <td>Mesothelioma and pazopanib</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>35</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>702</td>
        <td>VEG107518</td>
        <td>Bladder and pazopanib</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>80</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>703</td>
        <td>VEG107522</td>
        <td>Breast and fulvestrant and pazopanib</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>200</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>704</td>
        <td>VEG107769</td>
        <td>Pazopanib Renal Extension Study</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Angel Uriol,Harini Ramakrishnan,Jackie
            Gilbert,Laurie Baylor Curtis,Nadia Romano,Zaza
            Ebert</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>75</td>
        <td>170</td>
        <td>74</td>
        <td>99.6</td>
        <td>166.2</td>
        <td>2006-09-29</td>
        <td>2009-11-25</td>
        <td>72</td>
    </tr>
    <tr>
        <td>705</td>
        <td>VEG108838</td>
        <td>Phase 3 Lapatinib +/- Pazopanib in IBC</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Loubaba Belbaraka,Megan Schaeffer,Muhammad
            Shoaib,Patricia Davies,Poul Nielsen,Shonda Little</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>107</td>
        <td>327</td>
        <td>74</td>
        <td>160.7</td>
        <td>109.4</td>
        <td>2007-12-04</td>
        <td>2009-11-25</td>
        <td>153</td>
    </tr>
    <tr>
        <td>706</td>
        <td>VEG108843</td>
        <td>Phase II Exemestane +/- Pazopanib in ER/PR+ MBC</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Christoph Geiger,Ilana Sufaro,Judy He,Lelia
            Pinedo,Lisa Marcello,Sherri Smithson</td>
        <td>Start-Up</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>150</td>
        <td>0</td>
        <td>54.1</td>
        <td>82.1</td>
        <td>2009-11-25</td>
        <td>2</td>
    </tr>
    <tr>
        <td>707</td>
        <td>VEG108844</td>
        <td>Phase III trial pazopanib vs. sunitinib in RCC</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Elena Garcia Mendez,Franklin Pennell,Grainne
            Power,Hema Raval,Karla Denney,Katarina Mel&#233;n,Will
            Williams</td>
        <td>Start-Up</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>876</td>
        <td>0</td>
        <td>76.1</td>
        <td>68.4</td>
        <td>2009-11-25</td>
        <td>208</td>
    </tr>
    <tr>
        <td>708</td>
        <td>VEG108925</td>
        <td>P1 of pazopanib, cetuximab and irinotecan in CRC</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Recruitment</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>17</td>
        <td>40</td>
        <td>15</td>
        <td>76.0</td>
        <td>126.8</td>
        <td>2007-07-13</td>
        <td>2009-11-25</td>
        <td>2</td>
    </tr>
    <tr>
        <td>709</td>
        <td>VEG109599</td>
        <td>Gemcitabine and Pazopanib</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Christine Pence</td>
        <td>Start-Up</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>39</td>
        <td>0</td>
        <td>54.1</td>
        <td>2009-11-25</td>
        <td>2</td>
    </tr>
    <tr>
        <td>710</td>
        <td>VEG109601</td>
        <td>Taxotere and pazopanib</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Christine Pence</td>
        <td>Start-Up</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>90</td>
        <td>0</td>
        <td>40.7</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>711</td>
        <td>VEG109603</td>
        <td>Doxorubicin and Pazopanib</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Christine Pence</td>
        <td>Start-Up</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>78</td>
        <td>0</td>
        <td>64.4</td>
        <td>2009-11-25</td>
        <td>4</td>
    </tr>
    <tr>
        <td>712</td>
        <td>VEG109605</td>
        <td>MTOR and pazopanib</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Start-Up</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>30</td>
        <td>0</td>
        <td>43.3</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>713</td>
        <td>VEG109607</td>
        <td>Alimta and Tarceva and Pazopanib</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Recruitment</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>44</td>
        <td>55</td>
        <td>34</td>
        <td>63.1</td>
        <td>106.8</td>
        <td>2007-11-16</td>
        <td>2009-11-25</td>
        <td>4</td>
    </tr>
    <tr>
        <td>714</td>
        <td>VEG109609</td>
        <td>Pazopanib and NSCLC</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Will Williams</td>
        <td>Treatment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>22</td>
        <td>14</td>
        <td>14</td>
        <td>54.4</td>
        <td>27.9</td>
        <td>2008-02-07</td>
        <td>2008-05-07</td>
        <td>2009-11-25</td>
        <td>13</td>
    </tr>
    <tr>
        <td>715</td>
        <td>VEG109611</td>
        <td>Pazopanib and SCLC</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Megan Schaeffer,Poul Nielsen</td>
        <td>Start-Up</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>60</td>
        <td>0</td>
        <td>78.4</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>716</td>
        <td>VEG109693</td>
        <td>Japan Phase I monotherapy and combinationtherapy</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Hirofumi Ogura,Kazuo Nagamatsu,Miki Kikuchi,Yukiko
            Yanagita</td>
        <td>Recruitment</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>17</td>
        <td>23</td>
        <td>17</td>
        <td>77.9</td>
        <td>117.4</td>
        <td>2007-09-14</td>
        <td>2009-11-25</td>
        <td>2</td>
    </tr>
    <tr>
        <td>717</td>
        <td>VEG109975</td>
        <td>chemotherapy +/- pazopanib as neoadjuvant
            therapy</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>3600</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>718</td>
        <td>VEG110190</td>
        <td>Pazopanib Feasibility Study Adv Gynecological
            Can</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Kate Norman,Laetitia Roustand,Laurie Baylor
            Curtis,Silvia Neumeier</td>
        <td>Data Management</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>16</td>
        <td>12</td>
        <td>12</td>
        <td>38.0</td>
        <td>25.1</td>
        <td>2007-09-21</td>
        <td>2008-03-06</td>
        <td>2009-11-25</td>
        <td>8</td>
    </tr>
    <tr>
        <td>719</td>
        <td>VEG110264</td>
        <td>Neo breast with NSABP</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Lisa Marcello</td>
        <td>Start-Up</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>100</td>
        <td>0</td>
        <td>91.4</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>720</td>
        <td>VEG110267</td>
        <td>Pilot of AC followed by Tax + paz</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>120</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>721</td>
        <td>VEG110324</td>
        <td>TKI Failure Study</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Start-Up</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>200</td>
        <td>0</td>
        <td>71.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>722</td>
        <td>VEG110655</td>
        <td>Ph III Conc/ Extend Pazo Combined w/ Chemo in
            Ovar</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Bridgette White,Laurie Baylor Curtis,Vinka
            Ljubimir</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>900</td>
        <td>0</td>
        <td>56.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>724</td>
        <td>VEG110710</td>
        <td>Pazopanib plus erlotinib 2nd line NSCLC</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>800</td>
        <td>0</td>
        <td>66.3</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>725</td>
        <td>VEG110725</td>
        <td>Phase I Pazopanib+Ifosfamide</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Start-Up</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>80</td>
        <td>0</td>
        <td>24.7</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>726</td>
        <td>VEG110727</td>
        <td>Phase III pazopanib sarcoma study</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Christopher Cunnane</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>3</td>
        <td>255</td>
        <td>4</td>
        <td>109.1</td>
        <td>63.4</td>
        <td>2008-10-28</td>
        <td>2009-11-25</td>
        <td>68</td>
    </tr>
    <tr>
        <td>727</td>
        <td>VEG110760</td>
        <td>Ph II Monotherapy Pazo in Res/Refr Ovarian
            Cancer</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>150</td>
        <td>0</td>
        <td>52.4</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>728</td>
        <td>VEG110761</td>
        <td>Ph I Pazo + Doxil MTD Study in Gyn Cancers</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>40</td>
        <td>0</td>
        <td>51.9</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>729</td>
        <td>VEG111019</td>
        <td>Taxol + pazo</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>250</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>730</td>
        <td>VEG111020</td>
        <td>Taxotere + pazo</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>250</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>731</td>
        <td>VEG111048</td>
        <td>Extension study for VEG110324</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Start-Up</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>53</td>
        <td>0</td>
        <td>77.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>732</td>
        <td>VEG111073</td>
        <td>Phase 1 pazopanib+tratsuzumab+lapatinib</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Claire Marsden</td>
        <td>Start-Up</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>136</td>
        <td>0</td>
        <td>76.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>733</td>
        <td>VEG111109</td>
        <td>Phase II pazo+taxol vs carbo+taxol Stage 3/4
            NSCLC</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>150</td>
        <td>0</td>
        <td>56.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>734</td>
        <td>VEG111128</td>
        <td>Phase II pazopanib + Alimta in 1L NSCLC</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>150</td>
        <td>0</td>
        <td>56.7</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>735</td>
        <td>VEG20007</td>
        <td>VEGF - GW786034 in Breast Cancer Patients (Phase
            I</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Allison Jack,Angelique Ditoro,Barbara O
            Connell,Barbara O'Connell,Catherine Barrett,Chad
            Stewart,Charlotte Deane-Bowers,Elaine Orchiston,Iwona
            Chwesiuk,Megan Schaeffer,Merryn Collard,Nicole Walley,Sherri
            Smithson,Titilayo Femi-Ola</td>
        <td>Treatment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>322</td>
        <td>180</td>
        <td>189</td>
        <td>93.0</td>
        <td>98.3</td>
        <td>2006-07-24</td>
        <td>2008-04-23</td>
        <td>2009-11-25</td>
        <td>89</td>
    </tr>
    <tr>
        <td>736</td>
        <td>VLX103596</td>
        <td>Valacyclovir for the Suppression of HSV-2 Viral
            Sh</td>
        <td>Anti Infectives</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Kate Fleeman</td>
        <td>Completed</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>114</td>
        <td>65</td>
        <td>74</td>
        <td>20.7</td>
        <td>25.1</td>
        <td>2005-03-29</td>
        <td>2005-09-02</td>
        <td>2009-11-25</td>
        <td>17</td>
    </tr>
    <tr>
        <td>737</td>
        <td>VLX105832</td>
        <td>Effect of Valtrex on Suppression of HSV-2
            Shedding</td>
        <td>Anti Infectives</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Lee Anne McConville</td>
        <td>Completed</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>129</td>
        <td>66</td>
        <td>70</td>
        <td>23.9</td>
        <td>20.7</td>
        <td>2006-02-20</td>
        <td>2006-07-14</td>
        <td>2009-11-25</td>
        <td>18</td>
    </tr>
    <tr>
        <td>738</td>
        <td>WXL102274</td>
        <td>MDD in Child and Adolescents</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>213</td>
        <td>0</td>
        <td>61.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>739</td>
        <td>WXL108860</td>
        <td>Adolescent SAD study</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>300</td>
        <td>0</td>
        <td>65.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>26</td>
        <td>223412/093</td>
        <td>Schizophrenia Talnetant 400mg BID</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Denise Fontanilla</td>
        <td>Recruitment</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>429</td>
        <td>150</td>
        <td>282</td>
        <td>266.4</td>
        <td>2004-11-09</td>
        <td>2009-11-25</td>
        <td>26</td>
    </tr>
    <tr>
        <td>48</td>
        <td>ABD103820</td>
        <td>Comparative PIII:Alvimopan cOBD Cancer Pain Ph
            III</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>100</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>52</td>
        <td>ABD107202</td>
        <td>Alvimopan for Opioid-related Upper GI Symptoms</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>500</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>75</td>
        <td>ADG107020</td>
        <td>PPARpan plus statin in Hypercholesterolaemia</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Gail Kemp</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>195</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>81</td>
        <td>AK130940</td>
        <td>EU MDD Elderly Study Wellbutrin XL</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Irene Miller,Lewis Millen,Mary Furlow,Michelle
            Gee,Mirjana Zeremski,Monica Lopez</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>860</td>
        <td>364</td>
        <td>420</td>
        <td>292.1</td>
        <td>2004-06-02</td>
        <td>2009-11-25</td>
        <td>113</td>
    </tr>
    <tr>
        <td>99</td>
        <td>ARI105326</td>
        <td>Avolve, Phase III, DB, 0.5mg vs Placebo</td>
        <td>Urogenital</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Satoshi Kase</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>460</td>
        <td>330</td>
        <td>378</td>
        <td>201.1</td>
        <td>2006-02-17</td>
        <td>2009-11-25</td>
        <td>65</td>
    </tr>
    <tr>
        <td>132</td>
        <td>AZ3110865</td>
        <td>SB742457 as monotherapy in AD</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Alison Emsley,Beverly Allen,Darren Blackley,Gareth
            Maher-Edwards,Jeni De'ath,Mark Briggs,Nicola Hall,Sharon
            Sawchak,Sofia Artemenko</td>
        <td>Recruitment</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>208</td>
        <td>576</td>
        <td>48</td>
        <td>54.1</td>
        <td>74.1</td>
        <td>2008-07-04</td>
        <td>2009-11-25</td>
        <td>55</td>
    </tr>
    <tr>
        <td>153</td>
        <td>B3P108803</td>
        <td>MR solabegron dose ranging study</td>
        <td>Urogenital</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>1200</td>
        <td>0</td>
        <td>45.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>185</td>
        <td>CFD109701</td>
        <td>orthostatic hyportension pt study</td>
        <td>Cardiovascular</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Allison Moore,Brendt Stier,Shawn Shearn,Tracy
            Vanderslice</td>
        <td>Reporting</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>60</td>
        <td>0</td>
        <td>36.9</td>
        <td>36.9</td>
        <td>2008-04-01</td>
        <td>2009-11-25</td>
        <td>21</td>
    </tr>
    <tr>
        <td>209</td>
        <td>CXA30009</td>
        <td>Phase 3: Rheumatoid arthritis efficacy and
            safety</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Curtis Owens,Fiona O'Neill,Lisa Howard,Megan
            Vaughan,Neville Harkin</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>3073</td>
        <td>2208</td>
        <td>2254</td>
        <td>54.1</td>
        <td>58.0</td>
        <td>2005-02-08</td>
        <td>2006-05-31</td>
        <td>2009-11-25</td>
        <td>368</td>
    </tr>
    <tr>
        <td>239</td>
        <td>EGF104579</td>
        <td>Ph II, GW572016 w/paclitaxel,gastric cancer</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>200</td>
        <td>0</td>
        <td>106.6</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>261</td>
        <td>EGF110384</td>
        <td>Lapatinib plus Pazopanib in neoadjuvant breast
            can</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Reinhard Sokolowski</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>55</td>
        <td>0</td>
        <td>106.4</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>567</td>
        <td>RRL105839</td>
        <td>Efficacy and Tolerability of Ropinirole Extended
            R</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Christopher Henry,Robin Monteith,Setrina
            Hunter</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>315</td>
        <td>0</td>
        <td>19.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>568</td>
        <td>RRL105841</td>
        <td>Eff &amp; Safety of Ropinirole XL in Depr Mood
            RLS</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Setrina Hunter</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>266</td>
        <td>0</td>
        <td>36.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>569</td>
        <td>RRL105843</td>
        <td>Next Day Alertness in RLS Subjects Ropinirole XR</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Setrina Hunter</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>200</td>
        <td>0</td>
        <td>45.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>570</td>
        <td>RRL105845</td>
        <td>Next Day Alertness in RLS Subjects Ropinirole XR</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Setrina Hunter</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>200</td>
        <td>0</td>
        <td>45.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>571</td>
        <td>RXP110908</td>
        <td>GSK1838262 (XP13512) RLS Polysomnography Study</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Jeffery Ellis,Marlene Jordan</td>
        <td>Recruitment</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>147</td>
        <td>114</td>
        <td>28</td>
        <td>23.1</td>
        <td>61.8</td>
        <td>2008-10-01</td>
        <td>2009-11-25</td>
        <td>38</td>
    </tr>
    <tr>
        <td>572</td>
        <td>RXP110909</td>
        <td>XP13512 RLS Polysomnography Study</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Jeffery Ellis,Marlene Jordan</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>252</td>
        <td>0</td>
        <td>54.3</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>573</td>
        <td>RXP110962</td>
        <td>XP13512 Painful RLS Study</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>220</td>
        <td>0</td>
        <td>39.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>574</td>
        <td>S2W109361</td>
        <td>Naratriptan vs naltrexone for acute migraine</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>500</td>
        <td>0</td>
        <td>14.7</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>575</td>
        <td>S3B105663</td>
        <td>Japan Phae II Dose ranging study</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>315</td>
        <td>0</td>
        <td>34.7</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>576</td>
        <td>S3B105665</td>
        <td>Japan Phase III study</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>210</td>
        <td>0</td>
        <td>21.9</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>577</td>
        <td>S3B40042</td>
        <td>mechanism of action III</td>
        <td>Gastrointestinal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Laurel Watts</td>
        <td>Completed</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>54</td>
        <td>44</td>
        <td>48</td>
        <td>56.7</td>
        <td>53.1</td>
        <td>2006-12-05</td>
        <td>2007-12-11</td>
        <td>2009-11-25</td>
        <td>1</td>
    </tr>
    <tr>
        <td>578</td>
        <td>SAM104926</td>
        <td>Seretide50/100 Diskus bd versus Flixotide Diskus
            2</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Martyn Gilson</td>
        <td>Completed</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>585</td>
        <td>340</td>
        <td>326</td>
        <td>32.7</td>
        <td>30.6</td>
        <td>2005-11-18</td>
        <td>2006-06-10</td>
        <td>2009-11-25</td>
        <td>67</td>
    </tr>
    <tr>
        <td>579</td>
        <td>SAM49071</td>
        <td>AHR in aiming for total control or maintaining
            wel</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Martyn Gilson</td>
        <td>Completed</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>389</td>
        <td>150</td>
        <td>179</td>
        <td>47.7</td>
        <td>44.4</td>
        <td>2005-11-28</td>
        <td>2006-09-29</td>
        <td>2009-11-25</td>
        <td>37</td>
    </tr>
    <tr>
        <td>580</td>
        <td>SAS100686</td>
        <td>Seretide Asthma, Pediatrics, Ph III</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>50</td>
        <td>0</td>
        <td>22.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>581</td>
        <td>SAS107530</td>
        <td>Japan_Seretide HFA MDI 25/50 1 puff for
            paediatric</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Takanori Sadamitsu,Yasuyuki Tokai</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>300</td>
        <td>0</td>
        <td>35.4</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>583</td>
        <td>SAS110101</td>
        <td>Japan ped Adoair 25/50 Long-term safety</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>40</td>
        <td>35</td>
        <td>40</td>
        <td>9.1</td>
        <td>6.4</td>
        <td>2007-03-30</td>
        <td>2007-05-12</td>
        <td>2009-11-25</td>
        <td>3</td>
    </tr>
    <tr>
        <td>584</td>
        <td>SB030001</td>
        <td>Pediatric Exclusivity -safety and efficacy trial
            i</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Emily Badalamenti</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>118</td>
        <td>80</td>
        <td>86</td>
        <td>38.4</td>
        <td>27.6</td>
        <td>2004-07-01</td>
        <td>2005-01-06</td>
        <td>2009-11-25</td>
        <td>40</td>
    </tr>
    <tr>
        <td>585</td>
        <td>SB030002</td>
        <td>Ventolin HFA-MDI Dose Accumulation Study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Completed</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>109</td>
        <td>80</td>
        <td>88</td>
        <td>103.7</td>
        <td>87.1</td>
        <td>2004-09-10</td>
        <td>2006-02-21</td>
        <td>2009-11-25</td>
        <td>30</td>
    </tr>
    <tr>
        <td>586</td>
        <td>SCA102833</td>
        <td>Bipolar Adolescents: adjunctive LTG maintenance
            tx</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Sherrie LaRue</td>
        <td>Recruitment</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>54</td>
        <td>340</td>
        <td>31</td>
        <td>105.1</td>
        <td>70.9</td>
        <td>2008-07-31</td>
        <td>2009-11-25</td>
        <td>78</td>
    </tr>
    <tr>
        <td>588</td>
        <td>SCA104481</td>
        <td>Schizophrenia :Lamotrigine XR Adjunctive Therapy</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>David Morrison,Kimberly Sue-Ling,Tonya
            Peele</td>
        <td>Start-Up</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>220</td>
        <td>0</td>
        <td>42.3</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>589</td>
        <td>SCA104779</td>
        <td>Bipolar disorder Japan</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Midori Shimamura,Sachiko Shinoda,Takao
            Mogi,Terufumi Hara</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>186</td>
        <td>200</td>
        <td>170</td>
        <td>60.4</td>
        <td>107.8</td>
        <td>2007-11-12</td>
        <td>2009-11-25</td>
        <td>64</td>
    </tr>
    <tr>
        <td>590</td>
        <td>SCA106052</td>
        <td>Bipolar Japan Lamictal Ext. Study of SCA104779</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Midori Shimamura,Sachiko Shinoda,Takao
            Mogi,Terufumi Hara</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>63</td>
        <td>15</td>
        <td>105.0</td>
        <td>101.1</td>
        <td>2008-04-22</td>
        <td>2009-11-25</td>
        <td>63</td>
    </tr>
    <tr>
        <td>591</td>
        <td>SCB110690</td>
        <td>GSK1014802 Acute bipolar depression</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Claire Roberts</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>168</td>
        <td>0</td>
        <td>69.3</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>593</td>
        <td>SCO104925</td>
        <td>Seretide COPD Endpoints Trial</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Debbie Dukeman</td>
        <td>Completed</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>210</td>
        <td>140</td>
        <td>163</td>
        <td>34.1</td>
        <td>34.1</td>
        <td>2006-03-07</td>
        <td>2006-10-27</td>
        <td>2009-11-25</td>
        <td>11</td>
    </tr>
    <tr>
        <td>594</td>
        <td>SCO104960</td>
        <td>ECLIPSE</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Eric Lamb,Stephen Tisi</td>
        <td>Treatment</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>3294</td>
        <td>2800</td>
        <td>2677</td>
        <td>54.3</td>
        <td>67.9</td>
        <td>2005-12-19</td>
        <td>2007-04-02</td>
        <td>2009-11-25</td>
        <td>47</td>
    </tr>
    <tr>
        <td>595</td>
        <td>SCO104962</td>
        <td>Seretide plus Tiotropium V individual componants</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Completed</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>52</td>
        <td>48</td>
        <td>41</td>
        <td>28.3</td>
        <td>27.3</td>
        <td>2005-12-21</td>
        <td>2006-06-13</td>
        <td>2009-11-25</td>
        <td>5</td>
    </tr>
    <tr>
        <td>596</td>
        <td>SCO105782</td>
        <td>COPD Dyspnea Questionnaire Validation Study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Deborah Young,Eric Lamb</td>
        <td>Start-Up</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>350</td>
        <td>0</td>
        <td>22.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>597</td>
        <td>SCO109481</td>
        <td>Adviar Hyperinflation and Exercise</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Jennifer Gidley,Robin Fisher</td>
        <td>Start-Up</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>500</td>
        <td>0</td>
        <td>42.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>598</td>
        <td>SCO109483</td>
        <td>Adviar Hyperinflation and Exercise</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Jennifer Gidley</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>500</td>
        <td>0</td>
        <td>42.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>599</td>
        <td>SCO40043</td>
        <td>Advair vs Serevent in pts. previously receiving
            IC</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Amanda Masterman,Chastity Lattanzio,Freddy
            Byrth,Kim Sink,Patti Rouse,Susan Sigmon</td>
        <td>Completed</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1265</td>
        <td>740</td>
        <td>783</td>
        <td>59.4</td>
        <td>53.1</td>
        <td>2004-02-23</td>
        <td>2005-10-07</td>
        <td>2009-11-25</td>
        <td>99</td>
    </tr>
    <tr>
        <td>600</td>
        <td>SFA100062</td>
        <td>Beta-Agonist Response by Genotype Study (Barge
            II)</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Candice Blackley,Jennifer Gidley</td>
        <td>Completed</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>2214</td>
        <td>540</td>
        <td>547</td>
        <td>79.6</td>
        <td>80.6</td>
        <td>2004-02-08</td>
        <td>2006-04-28</td>
        <td>2009-11-25</td>
        <td>104</td>
    </tr>
    <tr>
        <td>601</td>
        <td>SFA105079</td>
        <td>Advair 50/50 pediatric long-term safety study</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>350</td>
        <td>0</td>
        <td>25.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>602</td>
        <td>SFA106484</td>
        <td>Advair HFA MDI 88/42 in children 4-11 years</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Troy Longley,Yvonne Anderson</td>
        <td>Completed</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>429</td>
        <td>300</td>
        <td>351</td>
        <td>41.7</td>
        <td>33.6</td>
        <td>2007-02-27</td>
        <td>2007-10-15</td>
        <td>2009-11-25</td>
        <td>60</td>
    </tr>
    <tr>
        <td>603</td>
        <td>SMS30077</td>
        <td>Pediatric Exclusivity--safety and efficacy trial
            i</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Michelle Verhaeghe</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>255</td>
        <td>150</td>
        <td>167</td>
        <td>82.0</td>
        <td>75.7</td>
        <td>2003-11-08</td>
        <td>2005-04-15</td>
        <td>2009-11-25</td>
        <td>98</td>
    </tr>
    <tr>
        <td>604</td>
        <td>SND103285</td>
        <td>MDD POC GSK372475</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Alicia Li,Bob Alexander,David Morrison,Joanne
            Cedrone,Kimberley Hammond,Mary Bevivino,Ole Graff,Sookti
            Bhangu,Zikia Siddique</td>
        <td>Treatment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>690</td>
        <td>399</td>
        <td>398</td>
        <td>73.7</td>
        <td>70.3</td>
        <td>2007-04-24</td>
        <td>2008-07-15</td>
        <td>2009-11-25</td>
        <td>77</td>
    </tr>
    <tr>
        <td>605</td>
        <td>SND103288</td>
        <td>MDD POC Study GSK372475 Subjects Depressive Dis</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Alicia Li,Bob Alexander,Kimberley Hammond,Mary
            Bevivino,Nana Gyambibi,Ole Graff,Ruth Braganza,Sookti
            Bhangu,Zikia Siddique</td>
        <td>Reporting</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>825</td>
        <td>492</td>
        <td>506</td>
        <td>64.0</td>
        <td>60.3</td>
        <td>2006-12-19</td>
        <td>2008-02-12</td>
        <td>2009-11-25</td>
        <td>57</td>
    </tr>
    <tr>
        <td>606</td>
        <td>SND105544</td>
        <td>GSK372475 in Adult ADHD</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>176</td>
        <td>0</td>
        <td>35.4</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>607</td>
        <td>SRM105106</td>
        <td>SERM VMS Phase IIa Study</td>
        <td>Urogenital</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Amy Lee,Hayley Crouch,Lori Hall,Meike
            Winsel,Muhammad Shoaib,Peter Abaci,Phillip Ertel,Terese
            Pfister-Peltola</td>
        <td>Reporting</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>980</td>
        <td>300</td>
        <td>359</td>
        <td>29.4</td>
        <td>26.1</td>
        <td>2007-01-04</td>
        <td>2008-01-14</td>
        <td>2009-11-25</td>
        <td>92</td>
    </tr>
    <tr>
        <td>608</td>
        <td>STA106711</td>
        <td>Imigran STATdose clinical experience study</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Tadashi Urashima</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>76</td>
        <td>60</td>
        <td>75</td>
        <td>23.6</td>
        <td>3.7</td>
        <td>2006-06-20</td>
        <td>2006-07-14</td>
        <td>2009-11-25</td>
        <td>5</td>
    </tr>
    <tr>
        <td>610</td>
        <td>STQ106074</td>
        <td>Efficacy, safety and tolerability of STQ for
            leish</td>
        <td>Anti Infectives</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>1001</td>
        <td>0</td>
        <td>168.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>611</td>
        <td>STQ106075</td>
        <td>Efficacy, safety and tolerability of STQ</td>
        <td>Anti Infectives</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>200</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>612</td>
        <td>STQ110766</td>
        <td>SB252220 Co-infected Study</td>
        <td>Anti Infectives</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Christopher Hair</td>
        <td>Planned</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>20</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>613</td>
        <td>STQ110767</td>
        <td>SB252220 Probe Study</td>
        <td>Anti Infectives</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Christopher Hair</td>
        <td>Planned</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>20</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>614</td>
        <td>SUM108693</td>
        <td>Cluster Headache - 4mg StatDose Sumatriptan</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>146</td>
        <td>0</td>
        <td>26.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>615</td>
        <td>TDC106220</td>
        <td>TDC 28 Day Repeat Dose Ranging</td>
        <td>Metabolic</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Elizabeth Gould,Susan McMullen</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>100</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>10</td>
    </tr>
    <tr>
        <td>616</td>
        <td>TNS103358</td>
        <td>Talnetant - Safety-1</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>200</td>
        <td>0</td>
        <td>71.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>617</td>
        <td>TNS103360</td>
        <td>Talnetant Pivotal-1</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Joanne Cedrone</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>400</td>
        <td>0</td>
        <td>51.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>618</td>
        <td>TNS105144</td>
        <td>Talnetant - Switch</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>300</td>
        <td>0</td>
        <td>44.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>619</td>
        <td>TNS105160</td>
        <td>Talnetant Maintenance of Effect-1</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>1200</td>
        <td>0</td>
        <td>35.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>620</td>
        <td>TNS105164</td>
        <td>Talnetant - Safety-2</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>200</td>
        <td>0</td>
        <td>71.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>621</td>
        <td>TNS105172</td>
        <td>Talnetant Pivotal-2</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>400</td>
        <td>0</td>
        <td>50.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>622</td>
        <td>TNS105174</td>
        <td>Talnetant Pivotal-3</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>400</td>
        <td>0</td>
        <td>50.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>623</td>
        <td>TNS105339</td>
        <td>Talnetant - Mania-PoC</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>150</td>
        <td>0</td>
        <td>49.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>624</td>
        <td>TNS105772</td>
        <td>Relapse Prevention</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>540</td>
        <td>0</td>
        <td>61.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>625</td>
        <td>TNS106860</td>
        <td>6 Week Inpatient Talnetant Study</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Start-Up</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>240</td>
        <td>0</td>
        <td>26.9</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>626</td>
        <td>TOC100224</td>
        <td>SB275833 Impetigo</td>
        <td>Inflammation - Dermatology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Julia Vassiliadou</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>520</td>
        <td>520</td>
        <td>24.9</td>
        <td>18.6</td>
        <td>2005-04-27</td>
        <td>2005-08-25</td>
        <td>2009-11-25</td>
        <td>78</td>
    </tr>
    <tr>
        <td>627</td>
        <td>TOC103469</td>
        <td>Topical pleuromutilin (SB-275833) in the
            treatment</td>
        <td>Anti Infectives</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Julia Vassiliadou</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>210</td>
        <td>211</td>
        <td>37.1</td>
        <td>34.0</td>
        <td>2005-04-27</td>
        <td>2005-12-14</td>
        <td>2009-11-25</td>
        <td>22</td>
    </tr>
    <tr>
        <td>628</td>
        <td>TOC103491</td>
        <td>TOC ECG Study</td>
        <td>Anti Infectives</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>70</td>
        <td>0</td>
        <td>21.4</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>629</td>
        <td>TOC106489</td>
        <td>Retapamulin in Pediatric Subjects with SSTIs</td>
        <td>Anti Infectives</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Binita Patel,Neville Harkin,Sangeeta Sedani,Vinnie
            Lopez</td>
        <td>Reporting</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>60</td>
        <td>87</td>
        <td>117.0</td>
        <td>55.4</td>
        <td>2007-09-25</td>
        <td>2008-07-31</td>
        <td>2009-11-25</td>
        <td>45</td>
    </tr>
    <tr>
        <td>630</td>
        <td>TOC110965</td>
        <td>ABR Epi Study</td>
        <td>Anti Infectives</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>1200</td>
        <td>0</td>
        <td>52.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>631</td>
        <td>TOC110966</td>
        <td>ABR PRO Study - Part One: Focus Groups</td>
        <td>Anti Infectives</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>50</td>
        <td>0</td>
        <td>51.3</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>632</td>
        <td>TOC110977</td>
        <td>Retap SITL Ph IIIb</td>
        <td>Anti Infectives</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Heath Hair</td>
        <td>Recruitment</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE1</td>
        <td>NOSOURCE</td>
        <td>true</td>
        <td>false</td>
        <td>357</td>
        <td>0</td>
        <td>357</td>
        <td>114</td>
        <td>93.0</td>
        <td>80.1</td>
        <td>2008-05-21</td>
        <td>2009-11-25</td>
        <td>42</td>
    </tr>
    <tr>
        <td>633</td>
        <td>TOC110978</td>
        <td>Retap MRSA (open-label)</td>
        <td>Anti Infectives</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Annie Cameron</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>500</td>
        <td>0</td>
        <td>67.3</td>
        <td>2009-11-25</td>
        <td>2</td>
    </tr>
    <tr>
        <td>634</td>
        <td>TPD108213</td>
        <td>Paediatric PK/Safety study</td>
        <td>Inflammation - Dermatology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>40</td>
        <td>0</td>
        <td>27.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>635</td>
        <td>TPL102357</td>
        <td>HCv/ Fibrosis associated thrombocytopenia</td>
        <td>Oncology - Supportive</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Sean Keegan,Souria Hasan</td>
        <td>Completed</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>136</td>
        <td>160</td>
        <td>75</td>
        <td>41.3</td>
        <td>41.0</td>
        <td>2005-04-07</td>
        <td>2005-12-21</td>
        <td>2009-11-25</td>
        <td>93</td>
    </tr>
    <tr>
        <td>636</td>
        <td>TPL103922</td>
        <td>Phase III/ HCV Interferon assoc.
            thrombocytopenia</td>
        <td>Oncology - Supportive</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>James Geib,John Brennan,Neville Harkin,Nicole
            Blackman,Olorunwa Asiru,Reinhard Sokolowski,Ruth
            Braganza,Ruth Friedhoff,Sumita Biswas-Baldwin,Viviana
            Garay</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>710</td>
        <td>750</td>
        <td>326</td>
        <td>119.1</td>
        <td>111.8</td>
        <td>2007-10-30</td>
        <td>2009-11-25</td>
        <td>232</td>
    </tr>
    <tr>
        <td>637</td>
        <td>TPL103924</td>
        <td>Phase III/HCV- Fibrosis Assoc. thrombocytopenia</td>
        <td>Onc, Musc &amp; Inflam</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>300</td>
        <td>0</td>
        <td>3.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>638</td>
        <td>TPL104054</td>
        <td>CLD - Procedures (1)</td>
        <td>Oncology - Supportive</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Denise Hyde,Muhammad Shoaib,Ronny Odegbami,Ruth
            Braganza,Souria Hasan,Viviana Garay</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>151</td>
        <td>500</td>
        <td>94</td>
        <td>54.1</td>
        <td>81.1</td>
        <td>2008-06-02</td>
        <td>2009-11-25</td>
        <td>97</td>
    </tr>
    <tr>
        <td>639</td>
        <td>TPL105523</td>
        <td>Chronic Liver Disease/Thmrombocytopenia</td>
        <td>Oncology - Supportive</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>160</td>
        <td>0</td>
        <td>28.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>640</td>
        <td>TPL108388</td>
        <td>CLD - Procedures (2)</td>
        <td>Oncology - Supportive</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>300</td>
        <td>0</td>
        <td>55.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>641</td>
        <td>TPL108390</td>
        <td>HCV thrombocytopenia (PEG-intron)</td>
        <td>Oncology - Supportive</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>James Geib,John Brennan,Neville Harkin,Nicole
            Blackman,Olorunwa Asiru,Reinhard Sokolowski,Ruth
            Braganza,Ruth Friedhoff,Sumita Biswas-Baldwin,Viviana
            Garay,Zaza Ebert</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>528</td>
        <td>750</td>
        <td>235</td>
        <td>119.1</td>
        <td>111.8</td>
        <td>2007-10-30</td>
        <td>2009-11-25</td>
        <td>178</td>
    </tr>
    <tr>
        <td>642</td>
        <td>TPL108392</td>
        <td>Open label, roll-over study</td>
        <td>Oncology - Supportive</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Sean Keegan</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>340</td>
        <td>0</td>
        <td>83.9</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>644</td>
        <td>TRA102506</td>
        <td>ESCALATE</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>100</td>
        <td>0</td>
        <td>41.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>645</td>
        <td>TRA102508</td>
        <td>Compassionate Use of Eltrombopag</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Nigel Payne</td>
        <td>Start-Up</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>240</td>
        <td>0</td>
        <td>169.7</td>
        <td>2009-11-25</td>
        <td>53</td>
    </tr>
    <tr>
        <td>646</td>
        <td>TRA102510</td>
        <td>Phase III Study of SB497115 in Immune
            Thrombocytop</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>200</td>
        <td>0</td>
        <td>28.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>647</td>
        <td>TRA102537</td>
        <td>RAISE</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Allison Moore,Avi Manic,Blandine Ngo,Debra
            Pearson,Jhangir Irani,Julie Switzky,Martin
            Greensmith,Michelle Beveridge,Souria Hasan</td>
        <td>Data Management</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>287</td>
        <td>189</td>
        <td>197</td>
        <td>48.9</td>
        <td>36.0</td>
        <td>2006-11-22</td>
        <td>2007-07-11</td>
        <td>2009-11-25</td>
        <td>115</td>
    </tr>
    <tr>
        <td>648</td>
        <td>TRA105325</td>
        <td>EXTEND</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Avi Manic,Cairstine Findlay-McDougall,Debra
            Pearson,Jhangir Irani,Martin Greensmith</td>
        <td>Recruitment</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>336</td>
        <td>400</td>
        <td>298</td>
        <td>194.0</td>
        <td>180.1</td>
        <td>2006-07-06</td>
        <td>2009-11-25</td>
        <td>125</td>
    </tr>
    <tr>
        <td>649</td>
        <td>TRA108057</td>
        <td>REPEAT</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Angela Gibson- White,Debra Pearson,Jhangir
            Irani,Julie Switzky,Martin Greensmith,Michelle
            Beveridge,Souria Hasan</td>
        <td>Data Management</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>100</td>
        <td>50</td>
        <td>66</td>
        <td>16.1</td>
        <td>21.3</td>
        <td>2007-03-13</td>
        <td>2007-08-08</td>
        <td>2009-11-25</td>
        <td>42</td>
    </tr>
    <tr>
        <td>650</td>
        <td>TRA108059</td>
        <td>Validation Study - ITP Bleeding Score</td>
        <td>Oncology - Supportive</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>20</td>
        <td>0</td>
        <td>4.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>651</td>
        <td>TRA108062</td>
        <td>Eltrombopag pediatric study</td>
        <td>Oncology - Supportive</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Nigel Payne</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>40</td>
        <td>0</td>
        <td>54.3</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>652</td>
        <td>TRA108109</td>
        <td>Japanese Phase III for ITP</td>
        <td>Oncology - Supportive</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Nobuyuki Koh,Toshihiro Hattori,Yukio
            Makihara</td>
        <td>Treatment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>31</td>
        <td>22</td>
        <td>25</td>
        <td>52.4</td>
        <td>55.6</td>
        <td>2007-09-18</td>
        <td>2008-05-23</td>
        <td>2009-11-25</td>
        <td>7</td>
    </tr>
    <tr>
        <td>653</td>
        <td>TRA108112</td>
        <td>Fatigue assessment of patients with ITP</td>
        <td>Oncology - Supportive</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>180</td>
        <td>0</td>
        <td>9.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>654</td>
        <td>TRA108132</td>
        <td>LENS</td>
        <td>Oncology - Supportive</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Avi Manic,Cairstine Findlay-McDougall,Christine
            Bailey,Jhangir Irani,Mary Maginnis,Nigel Payne</td>
        <td>Recruitment</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>350</td>
        <td>60</td>
        <td>313.7</td>
        <td>146.9</td>
        <td>2007-03-21</td>
        <td>2009-11-25</td>
        <td>43</td>
    </tr>
    <tr>
        <td>655</td>
        <td>TRA111433</td>
        <td>Japan extension study from TRA108109</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Nobuyuki Koh,Toshihiro Hattori,Yukio
            Makihara</td>
        <td>Recruitment</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>19</td>
        <td>22</td>
        <td>19</td>
        <td>44.4</td>
        <td>82.9</td>
        <td>2008-05-07</td>
        <td>2009-11-25</td>
        <td>7</td>
    </tr>
    <tr>
        <td>656</td>
        <td>TRC104803</td>
        <td>SB497115 Gemcitabine + Platinum Study</td>
        <td>Oncology - Supportive</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>24</td>
        <td>0</td>
        <td>27.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>657</td>
        <td>TRC105293</td>
        <td>CIT dose and schedule finding study</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Nigel Payne</td>
        <td>Planned</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>72</td>
        <td>0</td>
        <td>80.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>658</td>
        <td>TRC105295</td>
        <td>Phase III Study of SB497115 in Non-Hodgkin's
            Lymp</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>300</td>
        <td>0</td>
        <td>69.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>659</td>
        <td>TRC105499</td>
        <td>Sarcoma</td>
        <td>Oncology - Supportive</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Christopher Cunnane,Nigel Payne,Sean
            Keegan</td>
        <td>Recruitment</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE1</td>
        <td>NOSOURCE</td>
        <td>true</td>
        <td>false</td>
        <td>38</td>
        <td>16</td>
        <td>38</td>
        <td>16</td>
        <td>204.1</td>
        <td>185.8</td>
        <td>2006-06-05</td>
        <td>2009-11-25</td>
        <td>12</td>
    </tr>
    <tr>
        <td>660</td>
        <td>TRC106811</td>
        <td>SB497115GR in bortezomib induced
            thrombocytopenia</td>
        <td>Oncology - Supportive</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>40</td>
        <td>0</td>
        <td>23.6</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>661</td>
        <td>TRC107927</td>
        <td>Eltrombopag in MDS</td>
        <td>Oncology - Supportive</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>50</td>
        <td>0</td>
        <td>43.7</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>662</td>
        <td>TRX101998</td>
        <td>Trexima in EI</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>David Goodman</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>691</td>
        <td>600</td>
        <td>658</td>
        <td>18.9</td>
        <td>16.0</td>
        <td>2004-01-11</td>
        <td>2005-01-20</td>
        <td>2009-11-25</td>
        <td>56</td>
    </tr>
    <tr>
        <td>663</td>
        <td>TRX101999</td>
        <td>Trexima in EI</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>David Goodman</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>674</td>
        <td>600</td>
        <td>647</td>
        <td>18.9</td>
        <td>16.7</td>
        <td>2004-01-05</td>
        <td>2005-02-01</td>
        <td>2009-11-25</td>
        <td>55</td>
    </tr>
    <tr>
        <td>664</td>
        <td>TRX103629</td>
        <td>Trexima STATDose</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Angela Steel</td>
        <td>Statistical Analysis</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>28</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>2</td>
    </tr>
    <tr>
        <td>665</td>
        <td>TRX103632</td>
        <td>Consistency of Response with Trexima (Study #2)</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>David Goodman</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>691</td>
        <td>600</td>
        <td>646</td>
        <td>18.0</td>
        <td>16.3</td>
        <td>2005-01-05</td>
        <td>2006-02-02</td>
        <td>2009-11-25</td>
        <td>53</td>
    </tr>
    <tr>
        <td>666</td>
        <td>TRX103635</td>
        <td>Consistency of Response with Trexima (Study#1)</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>David Goodman,Yolanda Overton</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>672</td>
        <td>600</td>
        <td>623</td>
        <td>18.1</td>
        <td>16.3</td>
        <td>2005-10-13</td>
        <td>2006-02-03</td>
        <td>2009-11-25</td>
        <td>54</td>
    </tr>
    <tr>
        <td>667</td>
        <td>TRX105848</td>
        <td>A Scintigraphy Study of Gastric Transit Time</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Caryl Schwartzbach,Melissa Jewett,Stacey
            Goode-Sellers</td>
        <td>Completed</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>20</td>
        <td>25</td>
        <td>20</td>
        <td>18.1</td>
        <td>17.4</td>
        <td>2006-09-13</td>
        <td>2006-10-19</td>
        <td>2009-11-25</td>
        <td>1</td>
    </tr>
    <tr>
        <td>668</td>
        <td>TRX105850</td>
        <td>Trexima for Menstrually-Related Migraine</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Janette Daves</td>
        <td>Completed</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>361</td>
        <td>320</td>
        <td>354</td>
        <td>18.6</td>
        <td>17.4</td>
        <td>2006-05-09</td>
        <td>2006-09-01</td>
        <td>2009-11-25</td>
        <td>34</td>
    </tr>
    <tr>
        <td>670</td>
        <td>TRX106362</td>
        <td>Trexima Landmark Study 1 (of 2)</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Sue Neuman</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>390</td>
        <td>0</td>
        <td>14.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>671</td>
        <td>TRX106363</td>
        <td>Trexima Landmark Study 2 (of 2)</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Sue Neuman</td>
        <td>Planned</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>390</td>
        <td>0</td>
        <td>14.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>672</td>
        <td>TRX106396</td>
        <td>Trexima vs sumatriptan 100mg RT PK study</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Melissa Jewett</td>
        <td>Completed</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>32</td>
        <td>32</td>
        <td>31</td>
        <td>2.9</td>
        <td>2.7</td>
        <td>2006-02-13</td>
        <td>2006-03-03</td>
        <td>2009-11-25</td>
        <td>1</td>
    </tr>
    <tr>
        <td>673</td>
        <td>TRX106571</td>
        <td>Combination Product Non-Responders - Study 1 of
            2</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Sue Neuman</td>
        <td>Completed</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>184</td>
        <td>167</td>
        <td>174</td>
        <td>37.7</td>
        <td>36.3</td>
        <td>2006-11-13</td>
        <td>2007-07-20</td>
        <td>2009-11-25</td>
        <td>26</td>
    </tr>
    <tr>
        <td>266</td>
        <td>EGF20014</td>
        <td>Non-Small Cell Lung Cancer-1L GW572016
            Monotherapy</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Frances Spektor,Rose Dickens,Stephanie
            Derbyshire</td>
        <td>Data Management</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>150</td>
        <td>131</td>
        <td>103.6</td>
        <td>110.1</td>
        <td>2003-11-21</td>
        <td>2005-11-29</td>
        <td>2009-11-25</td>
        <td>31</td>
    </tr>
    <tr>
        <td>287</td>
        <td>FFA109685</td>
        <td>GW685698X Dose ranging study in Moderate asthma</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Angela Davis,Candice Blackley,Cindy
            Handelsman,Hilary Medley,Irene Shupe,Jodi Tipper,Lavora
            Mountain,Marie Duggan,Niko Pretorius,Susannah Hammond,Tracie
            Pickler</td>
        <td>Data Management</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1492</td>
        <td>628</td>
        <td>622</td>
        <td>43.0</td>
        <td>37.4</td>
        <td>2007-12-20</td>
        <td>2008-08-28</td>
        <td>2009-11-25</td>
        <td>194</td>
    </tr>
    <tr>
        <td>293</td>
        <td>FFR100012</td>
        <td>Pediatric Six Week HPA axis study, GW6859698X aq
            n</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>158</td>
        <td>105</td>
        <td>113</td>
        <td>18.9</td>
        <td>17.1</td>
        <td>2005-02-04</td>
        <td>2005-05-04</td>
        <td>2009-11-25</td>
        <td>12</td>
    </tr>
    <tr>
        <td>310</td>
        <td>FFR30007</td>
        <td>Adult Vasomotor Rhinitis, GW6859698X AQ Nasal
            Spra</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>901</td>
        <td>350</td>
        <td>350</td>
        <td>29.9</td>
        <td>22.3</td>
        <td>2004-11-03</td>
        <td>2005-12-01</td>
        <td>2009-11-25</td>
        <td>59</td>
    </tr>
    <tr>
        <td>316</td>
        <td>FFU109047</td>
        <td>Fluticasone Furoate vs fexofenadine</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Candice Blackley</td>
        <td>Completed</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1008</td>
        <td>678</td>
        <td>682</td>
        <td>15.1</td>
        <td>12.4</td>
        <td>2006-08-27</td>
        <td>2007-10-24</td>
        <td>2009-11-25</td>
        <td>44</td>
    </tr>
    <tr>
        <td>366</td>
        <td>HZA106836</td>
        <td>Horizon vs GW685698 vs ICS comparator 24 wks -
            EU</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>1000</td>
        <td>0</td>
        <td>28.1</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>373</td>
        <td>HZC111348</td>
        <td>4-week 444/698 combination once-daily in COPD</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Bettie Thomas,Brian Marks</td>
        <td>Recruitment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>61</td>
        <td>60</td>
        <td>48</td>
        <td>17.7</td>
        <td>68.8</td>
        <td>2008-08-12</td>
        <td>2009-11-25</td>
        <td>9</td>
    </tr>
    <tr>
        <td>397</td>
        <td>LAM30055</td>
        <td>Efficacy of Lamotrigine Monotherapy at 200mg
            daily</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Deian Jelev,Ekaterina Zenkova,Kathleen
            Harding,Kerrick Wilson,Soo-Yeon Chung,Zaza Ebert</td>
        <td>Data Management</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>299</td>
        <td>190</td>
        <td>226</td>
        <td>73.1</td>
        <td>73.1</td>
        <td>2006-05-16</td>
        <td>2007-09-13</td>
        <td>2009-11-25</td>
        <td>108</td>
    </tr>
    <tr>
        <td>403</td>
        <td>LEP105974</td>
        <td>Co-Morbid Depression</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Erica Lawson,Robin Monteith</td>
        <td>Start-Up</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>250</td>
        <td>0</td>
        <td>84.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>423</td>
        <td>MAB111475</td>
        <td>Dose-Ranging and Dose-Interval Study for
            GSK961081</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>627</td>
        <td>0</td>
        <td>34.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>431</td>
        <td>MD7108240</td>
        <td>Pazopanib eye drop PoC in AMD patients</td>
        <td>Musculoskeletal</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Apurva Patel,Jocelyne Dewulf</td>
        <td>Recruitment</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE5</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>27</td>
        <td>75</td>
        <td>18</td>
        <td>76.1</td>
        <td>102.8</td>
        <td>2008-05-13</td>
        <td>2009-11-25</td>
        <td>29</td>
    </tr>
    <tr>
        <td>455</td>
        <td>NAI106784</td>
        <td>Relenza IV / Phase I Open-label PK</td>
        <td>Infectious Disease- Anti Viral</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Lori Jones</td>
        <td>Completed</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>42</td>
        <td>0</td>
        <td>2006-07-24</td>
        <td>2009-11-25</td>
        <td>2</td>
    </tr>
    <tr>
        <td>479</td>
        <td>NKT102245</td>
        <td>Phase II Three Day Dosing GW679769 in PONV</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Anna Rhesa Kallam,Leah Lilienfeld</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>454</td>
        <td>441</td>
        <td>435</td>
        <td>24.7</td>
        <td>30.3</td>
        <td>2005-02-15</td>
        <td>2005-08-12</td>
        <td>2009-11-25</td>
        <td>48</td>
    </tr>
    <tr>
        <td>485</td>
        <td>NKV102549</td>
        <td>Phase III GW679769 Study in Moderately
            Emetogenic</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Benoit Bourdon,Erik Peterson,Franklin Pennell,Ina
            Camlett,Maura Watmuff,Muhammad Shoaib,Oliver Wright,Sachin
            Kulkarni</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>2022</td>
        <td>1840</td>
        <td>1933</td>
        <td>46.0</td>
        <td>47.3</td>
        <td>2004-01-31</td>
        <td>2007-06-06</td>
        <td>2009-11-25</td>
        <td>251</td>
    </tr>
    <tr>
        <td>502</td>
        <td>OFA110889</td>
        <td>Ofatumumab dose ranging Sjogren syndrome</td>
        <td>Inflammation - RA</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>200</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>536</td>
        <td>PIR104776</td>
        <td>SAD Double-blind study of Paroxetine Japan</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Yoshinori Suzuki</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>489</td>
        <td>390</td>
        <td>400</td>
        <td>34.9</td>
        <td>30.0</td>
        <td>2005-12-03</td>
        <td>2006-06-28</td>
        <td>2009-11-25</td>
        <td>59</td>
    </tr>
    <tr>
        <td>562</td>
        <td>ROX107850</td>
        <td>ReQuip XR RLS Phase ?/I? study</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Guojun Cai,Hideki Matsushita,Nobuhiko Okuda,Yuka
            Kunitomi</td>
        <td>Planned</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>150</td>
        <td>0</td>
        <td>31.0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>582</td>
        <td>SAS110099</td>
        <td>Japan ped Adoair 25/50 Efficacy and Safety</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Completed</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>52</td>
        <td>45</td>
        <td>51</td>
        <td>9.1</td>
        <td>6.4</td>
        <td>2007-04-02</td>
        <td>2007-05-12</td>
        <td>2009-11-25</td>
        <td>9</td>
    </tr>
    <tr>
        <td>587</td>
        <td>SCA103020</td>
        <td>Schizo Lam XR Adjun Therapy to Atypical Anti</td>
        <td>Psychiatry</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>David Morrison,Kimberly Sue-Ling,Tonya
            Peele</td>
        <td>Start-Up</td>
        <td>IIIA</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>254</td>
        <td>0</td>
        <td>42.3</td>
        <td>2009-11-25</td>
        <td>4</td>
    </tr>
    <tr>
        <td>592</td>
        <td>SCO100250</td>
        <td>COPD Exacerbations in subjects switched from
            Advai</td>
        <td>Respiratory</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Karen Singletary</td>
        <td>Completed</td>
        <td>IV</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>1288</td>
        <td>780</td>
        <td>797</td>
        <td>78.1</td>
        <td>74.4</td>
        <td>2004-02-18</td>
        <td>2006-05-05</td>
        <td>2009-11-25</td>
        <td>110</td>
    </tr>
    <tr>
        <td>609</td>
        <td>STQ105938</td>
        <td>Pharmacokinetics, safety and tolerability of
            oral</td>
        <td>Anti Infectives</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Ana Martin,Anthony Thompson,Cletus
            Ugwuegbulam,Steven Lauder,Susan Dixon</td>
        <td>Completed</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>174</td>
        <td>60</td>
        <td>61</td>
        <td>48.3</td>
        <td>33.1</td>
        <td>2006-08-04</td>
        <td>2007-03-17</td>
        <td>2009-11-25</td>
        <td>3</td>
    </tr>
    <tr>
        <td>643</td>
        <td>TRA100773</td>
        <td>497115 repeat dose in subjects with ITP</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Alison Brandt,Bridgette Volosin,Cairstine
            Findlay-McDougall,Kristen Molina,Souria Hasan</td>
        <td>Completed</td>
        <td>IIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>327</td>
        <td>217</td>
        <td>234</td>
        <td>58.7</td>
        <td>66.6</td>
        <td>2005-02-02</td>
        <td>2006-04-17</td>
        <td>2009-11-25</td>
        <td>217</td>
    </tr>
    <tr>
        <td>669</td>
        <td>TRX105852</td>
        <td>Trexima for Menstrually-Related Migraine</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Janette Daves</td>
        <td>Completed</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>363</td>
        <td>320</td>
        <td>351</td>
        <td>18.6</td>
        <td>17.4</td>
        <td>2006-05-09</td>
        <td>2006-09-01</td>
        <td>2009-11-25</td>
        <td>35</td>
    </tr>
    <tr>
        <td>674</td>
        <td>TRX106573</td>
        <td>Combination Product Non-Responders - Study 2 of
            2</td>
        <td>Neurology</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Sue Neuman</td>
        <td>Completed</td>
        <td>IIIB</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>178</td>
        <td>167</td>
        <td>168</td>
        <td>41.7</td>
        <td>38.7</td>
        <td>2006-12-11</td>
        <td>2007-08-10</td>
        <td>2009-11-25</td>
        <td>28</td>
    </tr>
    <tr>
        <td>691</td>
        <td>VEG105290</td>
        <td>GW786034 as pre-surgical therapy in NSCLC</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>Hema Raval,Poul Nielsen,Susan Laabs</td>
        <td>Completed</td>
        <td>IIA</td>
        <td>PLAN_AVAIL_RULE6</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>48</td>
        <td>33</td>
        <td>35</td>
        <td>86.3</td>
        <td>80.0</td>
        <td>2006-11-21</td>
        <td>2008-02-04</td>
        <td>2009-11-25</td>
        <td>14</td>
    </tr>
    <tr>
        <td>699</td>
        <td>VEG105527</td>
        <td>P2 POC study of paz monotherapy in GI tunours</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE4</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>100</td>
        <td>0</td>
        <td>47.3</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
    <tr>
        <td>723</td>
        <td>VEG110698</td>
        <td>Pazopanib plus chemotherapy Phase I 1st line
            NSCLC</td>
        <td>Oncology - PD</td>
        <td>not available</td>
        <td>Source Unavailable</td>
        <td>not available</td>
        <td>Planned</td>
        <td>I</td>
        <td>PLAN_AVAIL_RULE2</td>
        <td>NOSOURCE</td>
        <td>false</td>
        <td>false</td>
        <td>0</td>
        <td>0</td>
        <td>55</td>
        <td>0</td>
        <td>2009-11-25</td>
        <td>0</td>
    </tr>
</tbody>
        </table>
    </div>
    <!-- /content -->

    <div data-role="footer" data-theme="b" data-id="sitefooter" data-position="fixed">
        <h4>Page Footer E</h4>
    </div>
    <!-- /footer -->
</div>
</body>
</html>